Secukinumab/Pediatric Psoriasis CAIN457A2310

AMNOG Dossier Sensitivity Analysis B

Date: 24.08.2020

Document Status: Final

Author: Monika Schwager, Winicker Norimed GmbH

Table of Contents

Tables

Patient Disposition and Baseline Characteristics

1.1 Patient Disposition and Compliance (RAN, FAS)

	Treatment Groups			
Disposition/Reason	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	Total (N=107)
Randomized (RAN)	**39 (100.0)**	**42 (100.0)**	**26 (100.0)**	**107 (100.0)**
Full Analysis Set (FAS)	**39 (100.0)**	**42 (100.0)**	**26 (100.0)**	**107 (100.0)**
Study discontinuation during induction period	**1 (2.6)**	**0 (0.0)**	**0 (0.0)**	**1 (0.9)**
Reasons for study discontinuation during induction period				
Adverse event	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Lack of efficacy	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Protocol deviation	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Subject/guardian decision	1 (2.6)	0 (0.0)	0 (0.0)	1 (0.9)
Study discontinuation during maintenance period	**0 (0.0)**	**1 (2.4)**	**1 (3.8)**	**2 (1.9)**
Reasons for study discontinuation during maintenance period				
Adverse event	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Lack of efficacy	0 (0.0)	0 (0.0)	1 (3.8)	1 (0.9)
Protocol deviation	0 (0.0)	1 (2.4)	0 (0.0)	1 (0.9)
Subject/guardian decision	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Study drug during induction period				
Received study drug	39 (100.0)	42 (100.0)	26 (100.0)	107 (100.0)
Did not receive study drug	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Completed induction period on double-blind study drug	38 (97.4)	42 (100.0)	26 (100.0)	106 (99.1)
Prematurely discontinued double-blind study drug during induction period	1 (2.6)	0 (0.0)	0 (0.0)	1 (0.9)
Primary reason for premature discontinuation from double-blind study drug during induction period				
Adverse event	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Lack of efficacy	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Pregnancy	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Protocol deviation	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Subject/guardian decision	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Withdrawal of informed consent	1 (2.6)	0 (0.0)	0 (0.0)	1 (0.9)

Disposition/Reason	Treatment Groups			
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	Total (N=107)
Study drug during maintenance period				
Received study drug	38 (97.4)	42 (100.0)	26 (100.0)	106 (99.1)
Did not receive study drug	1 (2.6)	0 (0.0)	0 (0.0)	1 (0.9)
Completed maintenance period on double-blind study drug	37 (94.9)	40 (95.2)	21 (80.8)	98 (91.6)
Prematurely discontinued double-blind study drug during maintenance period	1 (2.6)	2 (4.8)	5 (19.2)	8 (7.5)
<u>Primary reason for premature discontinuation from double-blind study drug during maintenance period</u>				
Adverse event	1 (2.6)	0 (0.0)	1 (3.8)	2 (1.9)
Lack of efficacy	0 (0.0)	1 (2.4)	3 (11.5)	4 (3.7)
Pregnancy	0 (0.0)	0 (0.0)	1 (3.8)	1 (0.9)
Protocol deviation	0 (0.0)	1 (2.4)	0 (0.0)	1 (0.9)
Subject/guardian decision	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Withdrawal of informed consent	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Protocol deviations during induction period				
Subject with at least one protocol deviation	9 (23.1)	9 (21.4)	12 (46.2)	30 (28.0)
Selection criteria not met	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Treatment deviation	1 (2.6)	1 (2.4)	4 (15.4)	6 (5.6)
Prohibited concomitant medication	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Other deviation	8 (20.5)	9 (21.4)	8 (30.8)	25 (23.4)
Protocol deviations during maintenance period				
Subject with at least one protocol deviation	12 (30.8)	17 (40.5)	14 (53.8)	43 (40.2)
Selection criteria not met	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Treatment deviation	8 (20.5)	11 (26.2)	11 (42.3)	30 (28.0)
Prohibited concomitant medication	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Other deviation	6 (15.4)	7 (16.7)	4 (15.4)	17 (15.9)

1.2 Length of Study Participation (FAS)

Subgroups	Treatment Groups			
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	Total (N=107)
Study participation in induction period				
Mean ± SD (in days)	85.0 ± 13.5	86.4 ± 7.3	86.6 ± 5.0	86.0 ± 9.6
Median (in days)	85.0	85.0	85.0	85.0
Range (in days)	9 - 106	78 - 127	81 - 108	9 - 127
Study participation in maintenance period				
Mean ± SD (in days)	277.3 ± 18.6	276.2 ± 36.2	245.9 ± 85.0	269.2 ± 50.3
Median (in days)	281.0	281.0	281.0	281.0
Range (in days)	175 - 309	64 - 316	24 - 304	24 - 316
Study participation in induction+maintenance period				
Mean ± SD (in days)	354.2 ± 59.5	361.6 ± 36.6	331.5 ± 82.5	351.6 ± 59.4
Median (in days)	365.0	365.0	365.0	365.0
Range (in days)	9 - 393	148 - 401	113 - 388	9 - 401
Duration of study participation in each period is defined as the time from the first entry up to the last entry in the respective period.				

1.3 Characterization of Study Population, Demographic Characteristics (FAS)

Patient characteristics	Treatment Groups			
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	Total (N=107)
Age (years)				
Mean ± SD	13.7 ± 3.1	13.5 ± 3.3	13.5 ± 2.9	13.6 ± 3.1
Median	15.0	14.5	14.0	14.0
Range	7 - 17	6 - 17	6 - 17	6 - 17
Age group (years), n(%)				
<12	9 (23.1)	9 (21.4)	6 (23.1)	24 (22.4)
≥12	30 (76.9)	33 (78.6)	20 (76.9)	83 (77.6)
Sex, n(%)				
Male	14 (35.9)	22 (52.4)	10 (38.5)	46 (43.0)
Female	25 (64.1)	20 (47.6)	16 (61.5)	61 (57.0)
Weight (kg)				
Mean ± SD	52.9 ± 16.5	56.1 ± 23.7	52.2 ± 19.9	54.0 ± 20.3
Median	50.5	51.0	50.9	50.7
Range	21 - 88.9	17.6 - 116	20.5 - 105.5	17.6 - 116
Weight group (kg), n(%)				
<25	2 (5.1)	3 (7.1)	3 (11.5)	8 (7.5)
≥25 - <50	17 (43.6)	16 (38.1)	8 (30.8)	41 (38.3)
≥50	20 (51.3)	23 (54.8)	15 (57.7)	58 (54.2)
Height (cm)				
Mean ± SD	158.8 ± 14.8	155.8 ± 19.5	154.4 ± 17.4	156.6 ± 17.3
Median	161.0	159.0	158.0	160.0
Range	121 - 185	115 - 194	118 - 183	115 - 194
BMI (kg/m)				
Mean ± SD	20.5 ± 3.9	22.2 ± 6.1	21.0 ± 4.6	21.3 ± 5.1
Median	19.6	20.8	21.1	20.4
Range	14.1 - 30.7	12.6 - 42.5	14.7 - 31.5	12.6 - 42.5
Child bearing status, n(%)				
Able to bear children	15 (38.5)	14 (33.3)	11 (42.3)	40 (37.4)
Premenarche	10 (25.6)	6 (14.3)	5 (19.2)	21 (19.6)
Race, n(%)				
Caucasian	32 (82.1)	37 (88.1)	20 (76.9)	89 (83.2)
Black	1 (2.6)	1 (2.4)	0 (0.0)	2 (1.9)
Asian	2 (5.1)	1 (2.4)	2 (7.7)	5 (4.7)
Native American	3 (7.7)	2 (4.8)	4 (15.4)	9 (8.4)
Other	1 (2.6)	1 (2.4)	0 (0.0)	2 (1.9)

Patient characteristics	Treatment Groups			
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	Total (N=107)
Ethnicity, n(%)				
Hispanic/Latino	4 (10.3)	4 (9.5)	4 (15.4)	12 (11.2)
Not Hispanic or Latino	29 (74.4)	31 (73.8)	17 (65.4)	77 (72.0)
Unknown	3 (7.7)	3 (7.1)	2 (7.7)	8 (7.5)
Region, n(%)				
Africa	2 (5.1)	2 (4.8)	3 (11.5)	7 (6.5)
America	4 (10.3)	5 (11.9)	4 (15.4)	13 (12.1)
Asia	8 (20.5)	1 (2.4)	3 (11.5)	12 (11.2)
Europe	25 (64.1)	34 (81.0)	16 (61.5)	75 (70.1)

1.4 Disease History and Prior Medication (FAS)

	Treatment Groups			
Disease history	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	Total (N=107)
Diagnosis of plaque-type psoriasis, n(%)				
Yes	39 (100.0)	42 (100.0)	26 (100.0)	107 (100.0)
Time since first diagnosis of plaque-type psoriasis (years)				
Mean ± SD	5.8 ± 4.5	5.3 ± 4.4	5.2 ± 4.3	5.5 ± 4.4
Median	5.0	4.3	4.0	4.4
Range	0.3 - 17.0	0.4 - 17.5	0.5 - 14.0	0.3 - 17.5
Diagnosis of psoriatic arthritis, n(%)				
Yes	4 (10.3)	4 (9.5)	3 (11.5)	11 (10.3)
No	35 (89.7)	38 (90.5)	23 (88.5)	96 (89.7)
Time since first diagnosis of psoriatic arthritis (years)				
Mean ± SD	5.4 ± 3.5	2.0 ± 2.6	1.4 ± 1.1	3.0 ± 3.1
Median	5.1	0.7	1.2	1.6
Range	1.6 - 9.7	0.5 - 5.9	0.3 - 2.6	0.3 - 9.7
Previous psoriasis therapies, n(%)				
Yes	39 (100.0)	42 (100.0)	26 (100.0)	107 (100.0)
Previous systemic therapies, n(%)				
Yes	31 (79.5)	29 (69.0)	16 (61.5)	76 (71.0)
No	8 (20.5)	13 (31.0)	10 (38.5)	31 (29.0)
Failure	30 (76.9)	27 (64.3)	14 (53.8)	71 (66.4)
no failure	1 (2.6)	2 (4.8)	2 (7.7)	5 (4.7)
Previous phototherapy or photochemotherapy, n(%)				
Yes	20 (51.3)	31 (73.8)	19 (73.1)	70 (65.4)
No	19 (48.7)	11 (26.2)	7 (26.9)	37 (34.6)
Failure	18 (46.2)	27 (64.3)	18 (69.2)	63 (58.9)
no failure	2 (5.1)	4 (9.5)	1 (3.8)	7 (6.5)
Previous topical therapy, n(%)				
Yes	30 (76.9)	38 (90.5)	23 (88.5)	91 (85.0)
No	9 (23.1)	4 (9.5)	3 (11.5)	16 (15.0)
Failure	28 (71.8)	34 (81.0)	19 (73.1)	81 (75.7)
no failure	2 (5.1)	4 (9.5)	4 (15.4)	10 (9.3)

	Treatment Groups			
Disease history	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	Total (N=107)
Failure of at least one systemic therapy or phototherapy or photochemotherapy, n(%)				
Yes	39 (100.0)	42 (100.0)	26 (100.0)	107 (100.0)

1.5 Baseline Disease Characteristics (FAS)

Baseline disease characteristics	Treatment Groups			
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	Total (N=107)
Baseline PASI score				
Mean ± SD	27.9 ± 7.1	28.1 ± 8.5	29.3 ± 10.4	28.3 ± 8.5
Median	25.2	25.8	25.3	25.8
Range	20.2 - 48	20.2 - 58.8	20.1 - 59.8	20.1 - 59.8
Baseline PASI, n(%)				
>20	39 (100.0)	42 (100.0)	26 (100.0)	107 (100.0)
Baseline total BSA				
Mean ± SD	37.4 ± 15.8	39.2 ± 17.5	44.2 ± 23.0	39.7 ± 18.4
Median	36.1	35.3	34.0	35.0
Range	12 - 72.5	16 - 94	13.1 - 90.5	12 - 94
Baseline IGA mod 2011 score, n(%)				
4 = Severe disease	39 (100.0)	42 (100.0)	26 (100.0)	107 (100.0)

1.6 Subgroups (FAS)

Subgroups	Treatment Groups			
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	Total (N=107)
Subgroup Age, n (%)				
< 12 years	9 (23.1)	9 (21.4)	6 (23.1)	24 (22.4)
≥ 12 years	30 (76.9)	33 (78.6)	20 (76.9)	83 (77.6)
Subgroup Gender, n (%)				
Male	14 (35.9)	22 (52.4)	10 (38.5)	46 (43.0)
Female	25 (64.1)	20 (47.6)	16 (61.5)	61 (57.0)
Subgroup Disease Severity, n (%)				
Baseline PASI ≤ median	20 (51.3)	19 (45.2)	13 (50.0)	52 (48.6)
Baseline PASI > median	19 (48.7)	23 (54.8)	13 (50.0)	55 (51.4)
Subgroup Region, n (%)				
Africa	2 (5.1)	2 (4.8)	3 (11.5)	7 (6.5)
America	4 (10.3)	5 (11.9)	4 (15.4)	13 (12.1)
Asia	8 (20.5)	1 (2.4)	3 (11.5)	12 (11.2)
Europe	25 (64.1)	34 (81.0)	16 (61.5)	75 (70.1)
Subgroup Region - Europe vs. Others, n (%)				
Europe	25 (64.1)	34 (81.0)	16 (61.5)	75 (70.1)
Others	14 (35.9)	8 (19.0)	10 (38.5)	32 (29.9)
Subgroup Weight, n (%)				
< 25 kg	2 (5.1)	3 (7.1)	3 (11.5)	8 (7.5)
≥ 25 kg - < 50 kg	17 (43.6)	16 (38.1)	8 (30.8)	41 (38.3)
≥ 50 kg	20 (51.3)	23 (54.8)	15 (57.7)	58 (54.2)
Subgroup Weight - < 50kg vs. ≥ 50 kg, n (%)				
< 50 kg	19 (48.7)	19 (45.2)	11 (42.3)	49 (45.8)
≥ 50 kg	20 (51.3)	23 (54.8)	15 (57.7)	58 (54.2)
Subgroup Previous Systemic Therapy, n (%)				
No	8 (20.5)	13 (31.0)	10 (38.5)	31 (29.0)
Yes	31 (79.5)	29 (69.0)	16 (61.5)	76 (71.0)
Efficacy and safety subgroup analysis is displayed for all subgrouping factors with at least 10 patients in each subgroup.				

Efficacy Analysis

2.1 All-Cause Mortality (FAS)

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
All-cause Mortality						
N'	**39**	**42**	**26**			
n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

N': Number of patients with available response value
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR (with CI and p-value) from exact logistic regression model with treatment as predictor.
RR and RD calculated directly (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups.

3.0 BSA (Percent), Return Rates (FAS)

	Treatment Groups			
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	Total (N=107)
Number of patients with valid data n (%)				
Baseline Returns	39 (100.0)	42 (100.0)	26 (100.0)	107 (100.0)
Week 1 Returns	37 (94.9)	40 (95.2)	26 (100.0)	103 (96.3)
Week 2 Returns	35 (89.7)	41 (97.6)	25 (96.2)	101 (94.4)
Week 3 Returns	38 (97.4)	40 (95.2)	26 (100.0)	104 (97.2)
Week 4 Returns	37 (94.9)	42 (100.0)	25 (96.2)	104 (97.2)
Week 8 Returns	38 (97.4)	41 (97.6)	26 (100.0)	105 (98.1)
Week 12 Returns	31 (79.5)	40 (95.2)	23 (88.5)	94 (87.9)
Week 13 Returns	30 (76.9)	39 (92.9)	21 (80.8)	90 (84.1)
Week 14 Returns	34 (87.2)	39 (92.9)	24 (92.3)	97 (90.7)
Week 15 Returns	37 (94.9)	37 (88.1)	23 (88.5)	97 (90.7)
Week 16 Returns	38 (97.4)	41 (97.6)	24 (92.3)	103 (96.3)
Week 20 Returns	38 (97.4)	42 (100.0)	26 (100.0)	106 (99.1)
Week 24 Returns	38 (97.4)	41 (97.6)	23 (88.5)	102 (95.3)
Week 28 Returns	37 (94.9)	40 (95.2)	23 (88.5)	100 (93.5)
Week 32 Returns	38 (97.4)	39 (92.9)	23 (88.5)	100 (93.5)
Week 36 Returns	37 (94.9)	41 (97.6)	23 (88.5)	101 (94.4)
Week 40 Returns	37 (94.9)	41 (97.6)	22 (84.6)	100 (93.5)
Week 44 Returns	38 (97.4)	41 (97.6)	21 (80.8)	100 (93.5)
Week 48 Returns	37 (94.9)	38 (90.5)	22 (84.6)	97 (90.7)
Week 52 Returns	38 (97.4)	41 (97.6)	21 (80.8)	100 (93.5)

3.1 BSA (Percent), Change from Baseline (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=39)	**SEC high (N=42)**	**ETA (N=26)**	**SEC low-ETA Mean Diff [95% CI] p-value**	**SEC high-ETA Mean Diff [95% CI] p-value**
N'	38	42	26		
Baseline Mean (SD)	37.38 (15.76)	39.19 (17.47)	44.16 (22.95)		
Week 52 Adjusted Mean Change (SE)	-34.15 (2.23)	-34.17 (2.13)	-28.44 (2.86)	-5.71 [-12.85; 1.43] 0.117	-5.73 [-12.72; 1.27] 0.109

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, treatment x visit
Covariance structure: compound symmetry (cs)

3.2 BSA (Percent), Change from Baseline by Age (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Interaction test: p=0.730					
Age < 12 years, N	**9**	**9**	**6**		
N'	9	9	6		
Baseline Mean (SD)	38.54 (16.90)	41.49 (17.96)	52.27 (22.40)		
Week 52 Adjusted Mean Change (SE)	-34.43 (4.61)	-31.81 (4.61)	-28.96 (5.96)	-5.47 [-20.26; 9.32] 0.468	-2.85 [-17.60; 11.90] 0.705
Age ≥ 12 years, N	**30**	**33**	**20**		
N'	29	33	20		
Baseline Mean (SD)	37.03 (15.69)	38.56 (17.56)	41.73 (23.11)		
Week 52 Adjusted Mean Change (SE)	-34.07 (2.57)	-34.83 (2.42)	-28.27 (3.27)	-5.80 [-13.98; 2.37] 0.164	-6.56 [-14.55; 1.42] 0.107

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

3.3 BSA (Percent), Change from Baseline by Gender (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Interaction test: p=0.397					
Male, N	**14**	**22**	**10**		
N'	14	22	10		
Baseline Mean (SD)	37.53 (20.05)	36.33 (17.20)	40.70 (22.44)		
Week 52 Adjusted Mean Change (SE)	-33.26 (3.69)	-34.63 (2.98)	-24.79 (4.99)	-8.47 [-20.65; 3.71] 0.173	-9.84 [-21.25; 1.57] 0.091
Female, N	**25**	**20**	**16**		
N'	24	20	16		
Baseline Mean (SD)	37.30 (13.25)	42.33 (17.66)	46.32 (23.72)		
Week 52 Adjusted Mean Change (SE)	-34.68 (2.82)	-33.62 (3.09)	-30.04 (3.53)	-4.64 [-13.54; 4.26] 0.307	-3.58 [-12.75; 5.59] 0.444

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

3.4 BSA (Percent), Change from Baseline by Disease Severity (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Interaction test: p=0.650					
Baseline PASI ≤ Median, N	20	19	13		
N'	20	19	13		
Baseline Mean (SD)	26.93 (8.79)	33.74 (13.64)	30.21 (14.23)		
Week 52 Adjusted Mean Change (SE)	-29.87 (3.14)	-31.88 (3.13)	-27.66 (3.88)	-2.21 [-11.81; 7.39] 0.651	-4.22 [-13.92; 5.48] 0.394
Baseline PASI > Median, N	19	23	13		
N'	18	23	13		
Baseline Mean (SD)	48.39 (13.91)	43.69 (19.23)	58.11 (21.75)		
Week 52 Adjusted Mean Change (SE)	-38.77 (3.25)	-36.07 (2.88)	-30.15 (4.33)	-8.62 [-18.97; 1.73] 0.102	-5.92 [-15.96; 4.12] 0.247

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

3.5 BSA (Percent), Change from Baseline by Region (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Interaction test: p=0.074					
Europe, N	**25**	**34**	**16**		
N'	25	34	16		
Baseline Mean (SD)	35.61 (14.58)	38.40 (17.45)	33.89 (16.86)		
Week 52 Adjusted Mean Change (SE)	-34.73 (2.71)	-34.94 (2.33)	-32.68 (3.50)	-2.05 [-10.70; 6.61] 0.643	-2.26 [-10.51; 5.99] 0.591
Others, N	**14**	**8**	**10**		
N'	13	8	10		
Baseline Mean (SD)	40.55 (17.80)	42.54 (18.34)	60.58 (22.42)		
Week 52 Adjusted Mean Change (SE)	-33.52 (3.74)	-30.77 (4.78)	-20.78 (4.87)	-12.74 [-24.81; -0.68] 0.038	-9.99 [-23.28; 3.31] 0.141

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

3.6 BSA (Percent), Change from Baseline by Weight (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Interaction test: p=0.838					
Weight < 50 kg, N	**19**	**19**	**11**		
N'	19	19	11		
Baseline Mean (SD)	38.26 (15.29)	40.55 (19.90)	49.98 (21.44)		
Week 52 Adjusted Mean Change (SE)	-34.08 (3.12)	-31.75 (3.12)	-25.22 (4.36)	-8.85 [-19.37; 1.66] 0.099	-6.53 [-17.01; 3.96] 0.222
Weight ≥ 50 kg, N	**20**	**23**	**15**		
N'	19	23	15		
Baseline Mean (SD)	36.55 (16.54)	38.06 (15.55)	39.89 (23.79)		
Week 52 Adjusted Mean Change (SE)	-34.33 (3.13)	-36.14 (2.86)	-30.56 (3.71)	-3.77 [-13.29; 5.75] 0.438	-5.58 [-14.77; 3.62] 0.234

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

3.7 BSA (Percent), Change from Baseline by Previous Systemic Therapy (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Interaction test: p=0.966					
No previous systemic therapy, N	8	13	10		
N'	7	13	10		
Baseline Mean (SD)	38.99 (24.30)	29.52 (9.72)	41.49 (22.88)		
Week 52 Adjusted Mean Change (SE)	-33.19 (5.26)	-33.32 (3.90)	-28.92 (4.65)	-4.27 [-18.06; 9.52] 0.544	-4.40 [-16.33; 7.53] 0.469
Previous systemic therapy, N	31	29	16		
N'	31	29	16		
Baseline Mean (SD)	36.97 (13.26)	43.52 (18.54)	45.83 (23.58)		
Week 52 Adjusted Mean Change (SE)	-34.39 (2.50)	-34.58 (2.62)	-28.09 (3.68)	-6.30 [-15.05; 2.45] 0.158	-6.50 [-15.31; 2.32] 0.149

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

4.1 BSA 0% (FAS)

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Total BSA Involvement 0% Week 52						
N'	38	41	21			
n (%)	15.25 (39.10)	24.13 (57.45)	4.01 (15.42)			
SEC low vs. ETA				3.46 [1.00; 11.94] 0.050	2.54 [0.95; 6.79] 0.064	0.24 [0.03; 0.44] 0.026
SEC high vs. ETA				7.18 [2.12; 24.35] 0.002	3.73 [1.46; 9.53] 0.006	0.42 [0.22; 0.63] <.001

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR from exact logistic regression model with treatment as predictor.
RR and RD calculated directly.

All results are combined over MI:
n and % are averaged of all imputations.
Estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back-transformation. All CIs and p-values are Wald-type.

OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

4.2 BSA 0% by Age (FAS)

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Total BSA Involvement 0% Week 52						
Interaction Test	**p=0.028**					
Age < 12 years, N / N'	**9 / 9**	**9 / 9**	**6 / 5**			
n (%)	6.00 (66.67)	3.00 (33.33)	2.01 (33.50)			
SEC low vs. ETA				3.60 [0.44; 29.43] 0.233	1.99 [0.59; 6.76] 0.269	0.33 [-0.16; 0.82] 0.183
SEC high vs. ETA				0.99 [0.12; 8.28] 0.995	1.00 [0.23; 4.29] 0.996	-0.00 [-0.49; 0.49] 0.995
Age ≥ 12 years, N / N'	**30 / 29**	**33 / 32**	**20 / 16**			
n (%)	9.25 (30.83)	21.13 (64.03)	2.00 (10.00)			
SEC low vs. ETA				3.91 [0.75; 20.27] 0.105	3.08 [0.74; 12.78] 0.121	0.21 [-0.00; 0.42] 0.055
SEC high vs. ETA				15.14 [3.03; 75.72] <.001	6.40 [1.68; 24.45] 0.007	0.54 [0.33; 0.75] <.001

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

4.3 BSA 0% by Gender (FAS)

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Total BSA Involvement 0% Week 52						
Interaction Test	**p=0.842**					
Male, N / N'	**14 / 14**	**22 / 21**	**10 / 6**			
n (%)	4.00 (28.57)	12.13 (55.14)	1.01 (10.10)			
SEC low vs. ETA				3.40 [0.33; 34.97] 0.303	2.84 [0.37; 21.72] 0.315	0.18 [-0.12; 0.49] 0.231
SEC high vs. ETA				10.23 [1.12; 93.13] 0.039	5.47 [0.82; 36.52] 0.079	0.45 [0.17; 0.73] 0.002
Female, N / N'	**25 / 24**	**20 / 20**	**16 / 15**			
n (%)	11.25 (45.00)	12.00 (60.00)	3.00 (18.75)			
SEC low vs. ETA				3.44 [0.79; 14.97] 0.100	2.40 [0.79; 7.28] 0.123	0.26 [-0.01; 0.54] 0.062
SEC high vs. ETA				N.E.	3.20 [1.09; 9.43] 0.035	0.41 [0.12; 0.70] 0.005

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

4.4 BSA 0% by Disease Severity (FAS)

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Total BSA Involvement 0% Week 52						
Interaction Test	p=0.694					
Baseline PASI ≤ Median, N / N'	20 / 20	19 / 19	13 / 12			
n (%)	7.00 (35.00)	12.00 (63.16)	2.00 (15.38)			
SEC low vs. ETA				N.E.	2.28 [0.56; 9.30] 0.252	0.20 [-0.09; 0.48] 0.180
SEC high vs. ETA				N.E.	4.11 [1.10; 15.37] 0.036	0.48 [0.19; 0.77] 0.001
Baseline PASI > Median, N / N'	19 / 18	23 / 22	13 / 9			
n (%)	8.25 (43.42)	12.13 (52.74)	2.01 (15.46)			
SEC low vs. ETA				4.02 [0.70; 22.97] 0.118	2.81 [0.71; 11.14] 0.142	0.28 [-0.02; 0.58] 0.069
SEC high vs. ETA				5.81 [1.07; 31.69] 0.042	3.41 [0.90; 12.95] 0.071	0.37 [0.09; 0.66] 0.010

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

4.5 BSA 0% by Region (FAS)

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Total BSA Involvement 0% Week 52						
Interaction Test	**p=0.503**					
Europe, N / N'	**25 / 25**	**34 / 33**	**16 / 14**			
n (%)	13.00 (52.00)	23.13 (68.03)	3.00 (18.75)			
SEC low vs. ETA				N.E.	2.77 [0.93; 8.23] 0.066	0.33 [0.06; 0.61] 0.017
SEC high vs. ETA				8.78 [2.10; 36.73] 0.003	3.63 [1.27; 10.33] 0.016	0.49 [0.24; 0.74] <.001
Others, N / N'	**14 / 13**	**8 / 8**	**10 / 7**			
n (%)	2.25 (16.07)	1.00 (12.50)	1.01 (10.10)			
SEC low vs. ETA				1.65 [0.13; 20.25] 0.696	1.57 [0.17; 14.92] 0.695	0.06 [-0.22; 0.34] 0.671
SEC high vs. ETA				1.26 [0.07; 21.95] 0.875	1.24 [0.09; 16.90] 0.871	0.02 [-0.27; 0.32] 0.874

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

4.6 BSA 0% by Weight (FAS)

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Total BSA Involvement 0% Week 52						
Interaction Test	**p=0.015**					
Weight < 50 kg, N / N'	**19 / 19**	**19 / 19**	**11 / 9**			
n (%)	10.00 (52.63)	7.00 (36.84)	2.01 (18.27)			
SEC low vs. ETA				4.71 [0.82; 27.08] 0.082	2.88 [0.77; 10.84] 0.117	0.34 [0.02; 0.66] 0.036
SEC high vs. ETA				2.53 [0.43; 14.83] 0.303	2.02 [0.51; 8.06] 0.320	0.19 [-0.13; 0.50] 0.249
Weight ≥ 50 kg, N / N'	**20 / 19**	**23 / 22**	**15 / 12**			
n (%)	5.25 (26.25)	17.13 (74.48)	2.00 (13.33)			
SEC low vs. ETA				2.25 [0.38; 13.39] 0.371	1.96 [0.44; 8.75] 0.377	0.13 [-0.13; 0.39] 0.333
SEC high vs. ETA				17.20 [3.06; 96.59] 0.001	5.58 [1.50; 20.76] 0.010	0.61 [0.36; 0.86] <.001

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

4.7 BSA 0% by Previous Systemic Therapy (FAS)

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Total BSA Involvement 0% Week 52						
Interaction Test	**p=0.740**					
No previous systemic therapy, N / N'	**8 / 7**	**13 / 13**	**10 / 8**			
n (%)	4.25 (53.13)	10.00 (76.92)	3.00 (30.00)			
SEC low vs. ETA				2.50 [0.36; 17.19] 0.350	1.76 [0.55; 5.67] 0.342	0.23 [-0.23; 0.69] 0.323
SEC high vs. ETA				N.E.	2.56 [0.95; 6.92] 0.063	0.47 [0.10; 0.83] 0.012
Previous systemic therapy, N / N'	**31 / 31**	**29 / 28**	**16 / 13**			
n (%)	11.00 (35.48)	14.13 (48.72)	1.01 (6.31)			
SEC low vs. ETA				7.90 [0.93; 67.27] 0.059	5.64 [0.80; 39.87] 0.083	0.29 [0.09; 0.50] 0.006
SEC high vs. ETA				13.44 [1.58; 114.18] 0.017	7.74 [1.12; 53.57] 0.038	0.42 [0.21; 0.64] <.001

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

5.0 PASI, Return Rates (FAS)

	Treatment Groups			
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	Total (N=107)
Number of patients with valid data n (%)				
Baseline Returns	39 (100.0)	42 (100.0)	26 (100.0)	107 (100.0)
Week 1 Returns	37 (94.9)	40 (95.2)	26 (100.0)	103 (96.3)
Week 2 Returns	35 (89.7)	41 (97.6)	25 (96.2)	101 (94.4)
Week 3 Returns	38 (97.4)	40 (95.2)	26 (100.0)	104 (97.2)
Week 4 Returns	37 (94.9)	42 (100.0)	25 (96.2)	104 (97.2)
Week 8 Returns	38 (97.4)	41 (97.6)	26 (100.0)	105 (98.1)
Week 12 Returns	31 (79.5)	40 (95.2)	23 (88.5)	94 (87.9)
Week 13 Returns	30 (76.9)	39 (92.9)	21 (80.8)	90 (84.1)
Week 14 Returns	34 (87.2)	39 (92.9)	24 (92.3)	97 (90.7)
Week 15 Returns	37 (94.9)	37 (88.1)	23 (88.5)	97 (90.7)
Week 16 Returns	38 (97.4)	41 (97.6)	24 (92.3)	103 (96.3)
Week 20 Returns	38 (97.4)	42 (100.0)	26 (100.0)	106 (99.1)
Week 24 Returns	38 (97.4)	41 (97.6)	23 (88.5)	102 (95.3)
Week 28 Returns	37 (94.9)	40 (95.2)	23 (88.5)	100 (93.5)
Week 32 Returns	38 (97.4)	39 (92.9)	23 (88.5)	100 (93.5)
Week 36 Returns	37 (94.9)	41 (97.6)	23 (88.5)	101 (94.4)
Week 40 Returns	37 (94.9)	41 (97.6)	22 (84.6)	100 (93.5)
Week 44 Returns	38 (97.4)	41 (97.6)	21 (80.8)	100 (93.5)
Week 48 Returns	37 (94.9)	38 (90.5)	22 (84.6)	97 (90.7)
Week 52 Returns	38 (97.4)	41 (97.6)	21 (80.8)	100 (93.5)

5.1 PASI, Change from Baseline (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
N'	38	42	26		
Baseline Mean (SD)	27.87 (7.10)	28.08 (8.48)	29.31 (10.36)		
Week 52 Adjusted Mean Change (SE)	-25.81 (1.33)	-26.14 (1.28)	-20.36 (1.70)	-5.46 [-9.70; -1.21] 0.012	-5.79 [-9.96; -1.62] 0.007

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, treatment x visit
Covariance structure: compound symmetry (cs)

5.2 PASI, Change from Baseline by Age (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Interaction test: p=0.969					
Age < 12 years, N	**9**	**9**	**6**		
N'	9	9	6		
Baseline Mean (SD)	29.47 (9.15)	27.43 (6.29)	28.97 (8.68)		
Week 52 Adjusted Mean Change (SE)	-26.47 (2.73)	-23.45 (2.73)	-16.17 (3.50)	-10.31 [-19.01; -1.61] 0.020	-7.28 [-15.98; 1.42] 0.101
Age ≥ 12 years, N	**30**	**33**	**20**		
N'	29	33	20		
Baseline Mean (SD)	27.39 (6.47)	28.26 (9.06)	29.42 (11.02)		
Week 52 Adjusted Mean Change (SE)	-25.61 (1.52)	-26.89 (1.43)	-21.57 (1.93)	-4.04 [-8.87; 0.79] 0.101	-5.32 [-10.05; -0.60] 0.027

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

5.2 PASI, Change from Baseline by Age (FAS)

5.3 PASI, Change from Baseline by Gender (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Interaction test: p=0.546					
Male, N	**14**	**22**	**10**		
N'	14	22	10		
Baseline Mean (SD)	27.41 (8.02)	27.91 (8.37)	30.67 (10.69)		
Week 52 Adjusted Mean Change (SE)	-24.95 (2.21)	-26.87 (1.78)	-20.52 (2.99)	-4.42 [-11.72; 2.87] 0.235	-6.35 [-13.18; 0.48] 0.069
Female, N	**25**	**20**	**16**		
N'	24	20	16		
Baseline Mean (SD)	28.12 (6.68)	28.28 (8.82)	28.46 (10.41)		
Week 52 Adjusted Mean Change (SE)	-26.32 (1.69)	-25.37 (1.85)	-20.50 (2.10)	-5.82 [-11.10; -0.55] 0.031	-4.87 [-10.35; 0.61] 0.081

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

5.4 PASI, Change from Baseline by Disease Severity (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Interaction test: p=0.126					
Baseline PASI ≤ Median, N	**20**	**19**	**13**		
N'	20	19	13		
Baseline Mean (SD)	22.51 (1.68)	22.95 (1.34)	22.32 (1.61)		
Week 52 Adjusted Mean Change (SE)	-24.39 (1.90)	-24.34 (1.93)	-22.15 (2.36)	-2.24 [-7.99; 3.51] 0.444	-2.19 [-8.00; 3.62] 0.459
Baseline PASI > Median, N	**19**	**23**	**13**		
N'	18	23	13		
Baseline Mean (SD)	33.51 (6.15)	32.32 (9.54)	36.30 (10.73)		
Week 52 Adjusted Mean Change (SE)	-27.38 (1.99)	-27.64 (1.76)	-18.49 (2.60)	-8.89 [-15.05; -2.73] 0.005	-9.14 [-15.10; -3.19] 0.003

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

5.4 PASI, Change from Baseline by Disease Severity (FAS)

5.5 PASI, Change from Baseline by Region (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Interaction test: p=0.032					
Europe, N	**25**	**34**	**16**		
N'	25	34	16		
Baseline Mean (SD)	27.81 (7.91)	28.50 (9.30)	27.08 (9.51)		
Week 52 Adjusted Mean Change (SE)	-25.96 (1.60)	-27.04 (1.38)	-24.24 (2.07)	-1.72 [-6.84; 3.41] 0.511	-2.80 [-7.68; 2.08] 0.260
Others, N	**14**	**8**	**10**		
N'	13	8	10		
Baseline Mean (SD)	27.98 (5.62)	26.33 (3.08)	32.89 (11.15)		
Week 52 Adjusted Mean Change (SE)	-25.56 (2.22)	-22.34 (2.83)	-13.35 (2.80)	-12.21 [-19.22; -5.20] <.001	-8.99 [-16.82; -1.17] 0.024

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

5.6 PASI, Change from Baseline by Weight (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Interaction test: p=0.310					
Weight < 50 kg, N	**19**	**19**	**11**		
N'	19	19	11		
Baseline Mean (SD)	28.47 (7.51)	27.43 (9.01)	30.01 (10.07)		
Week 52 Adjusted Mean Change (SE)	-26.00 (1.83)	-24.33 (1.83)	-15.99 (2.54)	-10.02 [-16.16; -3.88] 0.001	-8.34 [-14.49; -2.20] 0.008
Weight ≥ 50 kg, N	**20**	**23**	**15**		
N'	19	23	15		
Baseline Mean (SD)	27.30 (6.83)	28.63 (8.18)	28.80 (10.89)		
Week 52 Adjusted Mean Change (SE)	-25.63 (1.83)	-27.62 (1.68)	-23.49 (2.18)	-2.14 [-7.73; 3.46] 0.454	-4.13 [-9.54; 1.27] 0.134

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

5.7 PASI, Change from Baseline by Previous Systemic Therapy (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Interaction test: p=0.759					
No previous systemic therapy, N	**8**	**13**	**10**		
N'	7	13	10		
Baseline Mean (SD)	25.80 (6.28)	24.23 (3.10)	27.63 (7.37)		
Week 52 Adjusted Mean Change (SE)	-25.30 (3.15)	-26.38 (2.32)	-21.74 (2.77)	-3.55 [-11.77; 4.67] 0.396	-4.63 [-11.72; 2.45] 0.199
Previous systemic therapy, N	**31**	**29**	**16**		
N'	31	29	16		
Baseline Mean (SD)	28.40 (7.29)	29.81 (9.55)	30.36 (11.97)		
Week 52 Adjusted Mean Change (SE)	-25.93 (1.49)	-26.04 (1.56)	-19.47 (2.19)	-6.46 [-11.66; -1.27] 0.015	-6.57 [-11.83; -1.32] 0.014

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

6.1 PASI Response (FAS)

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
PASI50 Response Week 52						
N'	**38**	**41**	**21**			
n (%)	39.00 (100.00)	40.97 (97.55)	21.62 (83.15)			
SEC low vs. ETA				9.68 [N.E.; N.E.] N.E.	1.20 [0.99; 1.46] 0.057	0.17 [0.01; 0.33] 0.036
SEC high vs. ETA				7.74 [0.79; 75.91] 0.079	1.17 [0.96; 1.43] 0.111	0.14 [-0.02; 0.31] 0.087
PASI75 Response Week 52						
N'	**38**	**41**	**21**			
n (%)	33.91 (86.95)	38.70 (92.14)	17.23 (66.27)			
SEC low vs. ETA				3.31 [0.93; 11.86] 0.066	1.31 [0.95; 1.81] 0.094	0.21 [-0.01; 0.43] 0.068
SEC high vs. ETA				5.83 [1.38; 24.63] 0.017	1.39 [1.02; 1.89] 0.035	0.26 [0.05; 0.47] 0.016
PASI90 Response Week 52						
N'	**38**	**41**	**21**			
n (%)	30.61 (78.49)	36.27 (86.36)	13.52 (52.00)			
SEC low vs. ETA				3.30 [1.10; 9.94] 0.033	1.51 [1.00; 2.29] 0.052	0.26 [0.03; 0.50] 0.029
SEC high vs. ETA				5.69 [1.73; 18.65] 0.004	1.66 [1.11; 2.48] 0.013	0.34 [0.12; 0.57] 0.003
PASI100 Response Week 52						
N'	**38**	**41**	**21**			
n (%)	15.29 (39.21)	24.10 (57.38)	4.28 (16.46)			
SEC low vs. ETA				3.23 [0.93; 11.23] 0.065	2.39 [0.90; 6.38] 0.081	0.23 [0.01; 0.44] 0.037

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
SEC high vs. ETA				6.67 [1.96; 22.69] 0.002	3.51 [1.38; 8.91] 0.008	0.41 [0.20; 0.62] <.001
PASI Rebound Week 52						
N'	38	41	21			
n (%)	0.00 (0.00)	0.00 (0.00)	2.04 (7.85)			
SEC low vs. ETA				0.26 [N.E.; N.E.] N.E.	0.13 [0.01; 2.67] 0.187	-0.08 [-0.18; 0.03] 0.141
SEC high vs. ETA				0.24 [N.E.; N.E.] N.E.	0.12 [0.01; 2.48] 0.172	-0.08 [-0.18; 0.03] 0.141

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR from exact logistic regression model with treatment as predictor.
RR and RD calculated directly.

All results are combined over MI:
n and % are averaged of all imputations.
Estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back-transformation. All CIs and p-values are Wald-type.

OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

6.2 PASI Response by Age (FAS)

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
PASI50 Response Week 52						
Interaction Test	N.E.					
Age < 12 years, N / N'	9 / 9	9 / 9	6 / 5			
n (%)	9.00 (100.00)	8.00 (88.89)	4.53 (75.50)			
SEC low vs. ETA				2.43 [N.E.; N.E.] N.E.	1.33 [0.79; 2.23] 0.276	0.25 [-0.13; 0.62] 0.201
SEC high vs. ETA				2.31 [0.13; 40.74] 0.568	1.18 [0.67; 2.09] 0.557	0.13 [-0.29; 0.56] 0.540
Age ≥ 12 years, N / N'	30 / 29	33 / 32	20 / 16			
n (%)	30.00 (100.00)	32.97 (99.91)	17.09 (85.45)			
SEC low vs. ETA				5.91 [N.E.; N.E.] N.E.	1.17 [0.96; 1.42] 0.111	0.15 [-0.02; 0.31] 0.083
SEC high vs. ETA				6.46 [N.E.; N.E.] N.E.	1.17 [0.96; 1.42] 0.114	0.14 [-0.02; 0.31] 0.087
PASI75 Response Week 52						
Interaction Test	p=0.368					
Age < 12 years, N / N'	9 / 9	9 / 9	6 / 5			
n (%)	7.00 (77.78)	7.00 (77.78)	4.31 (71.83)			
SEC low vs. ETA				1.29 [0.11; 15.27] 0.839	1.09 [0.57; 2.09] 0.798	0.06 [-0.41; 0.53] 0.805
SEC high vs. ETA				1.29 [0.11; 15.27] 0.839	1.09 [0.57; 2.09] 0.798	0.06 [-0.41; 0.53] 0.805
Age ≥ 12 years, N / N'	30 / 29	33 / 32	20 / 16			
n (%)	26.91 (89.70)	31.70 (96.06)	12.92 (64.60)			
SEC low vs. ETA				4.61 [0.99; 21.37] 0.051	1.39 [0.96; 2.01] 0.079	0.25 [0.00; 0.50] 0.048
SEC high vs. ETA				13.31 [1.54; 114.73] 0.018	1.49 [1.05; 2.12] 0.027	0.31 [0.08; 0.55] 0.008

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
PASI90 Response Week 52						
Interaction Test	**p=0.470**					
Age < 12 years, N / N'	**9 / 9**	**9 / 9**	**6 / 5**			
n (%)	7.00 (77.78)	7.00 (77.78)	4.14 (69.00)			
SEC low vs. ETA				1.49 [0.14; 15.75] 0.738	1.13 [0.58; 2.19] 0.716	0.09 [-0.38; 0.56] 0.715
SEC high vs. ETA				1.49 [0.14; 15.75] 0.738	1.13 [0.58; 2.19] 0.716	0.09 [-0.38; 0.56] 0.715
Age ≥ 12 years, N / N'	**30 / 29**	**33 / 32**	**20 / 16**			
n (%)	23.61 (78.70)	29.27 (88.70)	9.38 (46.90)			
SEC low vs. ETA				4.06 [1.15; 14.30] 0.029	1.68 [1.00; 2.82] 0.049	0.32 [0.05; 0.59] 0.021
SEC high vs. ETA				8.51 [2.07; 35.06] 0.003	1.89 [1.15; 3.11] 0.012	0.42 [0.17; 0.67] 0.001
PASI100 Response Week 52						
Interaction Test	**p=0.031**					
Age < 12 years, N / N'	**9 / 9**	**9 / 9**	**6 / 5**			
n (%)	6.00 (66.67)	3.00 (33.33)	2.07 (34.50)			
SEC low vs. ETA				3.46 [0.42; 28.82] 0.251	1.94 [0.57; 6.59] 0.286	0.32 [-0.17; 0.82] 0.203
SEC high vs. ETA				0.96 [0.11; 8.10] 0.967	0.97 [0.23; 4.19] 0.970	-0.01 [-0.51; 0.48] 0.963
Age ≥ 12 years, N / N'	**30 / 29**	**33 / 32**	**20 / 16**			
n (%)	9.29 (30.97)	21.10 (63.94)	2.21 (11.05)			
SEC low vs. ETA				3.57 [0.68; 18.68] 0.131	2.84 [0.69; 11.73] 0.149	0.20 [-0.02; 0.42] 0.078
SEC high vs. ETA				13.71 [2.74; 68.63] 0.001	5.87 [1.55; 22.19] 0.009	0.53 [0.31; 0.75] <.001

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

6.3 PASI Response by Gender (FAS)

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
PASI50 Response Week 52						
Interaction Test	N.E.					
Male, N / N'	14 / 14	22 / 21	10 / 6			
n (%)	14.00 (100.00)	21.97 (99.86)	7.36 (73.60)			
SEC low vs. ETA				5.18 [N.E.; N.E.] N.E.	1.37 [0.89; 2.10] 0.156	0.26 [-0.04; 0.57] 0.091
SEC high vs. ETA				8.14 [N.E.; N.E.] N.E.	1.36 [0.89; 2.10] 0.159	0.26 [-0.05; 0.57] 0.094
Female, N / N'	25 / 24	20 / 20	16 / 15			
n (%)	25.00 (100.00)	19.00 (95.00)	14.26 (89.13)			
SEC low vs. ETA				3.11 [N.E.; N.E.] N.E.	1.12 [0.94; 1.35] 0.213	0.11 [-0.05; 0.27] 0.187
SEC high vs. ETA				2.18 [0.16; 30.50] 0.563	1.07 [0.87; 1.31] 0.544	0.06 [-0.13; 0.25] 0.539
PASI75 Response Week 52						
Interaction Test	p=0.826					
Male, N / N'	14 / 14	22 / 21	10 / 6			
n (%)	12.00 (85.71)	20.70 (94.09)	6.18 (61.80)			
SEC low vs. ETA				3.43 [0.43; 27.25] 0.244	1.40 [0.76; 2.58] 0.280	0.24 [-0.15; 0.63] 0.229
SEC high vs. ETA				9.30 [0.83; 104.17] 0.070	1.54 [0.86; 2.76] 0.149	0.32 [-0.04; 0.68] 0.077
Female, N / N'	25 / 24	20 / 20	16 / 15			
n (%)	21.91 (87.64)	18.00 (90.00)	11.05 (69.06)			
SEC low vs. ETA				3.09 [0.63; 15.15] 0.164	1.27 [0.88; 1.82] 0.197	0.19 [-0.08; 0.45] 0.166
SEC high vs. ETA				3.87 [0.65; 23.04] 0.137	1.30 [0.91; 1.87] 0.150	0.21 [-0.05; 0.47] 0.119

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
PASI90 Response Week 52						
Interaction Test	**p=0.413**					
Male, N / N'	**14 / 14**	**22 / 21**	**10 / 6**			
n (%)	10.00 (71.43)	20.27 (92.14)	5.52 (55.20)			
SEC low vs. ETA				1.96 [0.34; 11.18] 0.449	1.30 [0.65; 2.60] 0.454	0.16 [-0.24; 0.57] 0.433
SEC high vs. ETA				9.00 [1.05; 77.09] 0.045	1.68 [0.90; 3.12] 0.101	0.37 [0.02; 0.72] 0.039
Female, N / N'	**25 / 24**	**20 / 20**	**16 / 15**			
n (%)	20.61 (82.44)	16.00 (80.00)	8.00 (50.00)			
SEC low vs. ETA				4.52 [1.09; 18.81] 0.038	1.65 [0.98; 2.79] 0.062	0.32 [0.04; 0.61] 0.028
SEC high vs. ETA				N.E.	1.60 [0.94; 2.74] 0.086	0.30 [-0.00; 0.60] 0.051
PASI100 Response Week 52						
Interaction Test	**p=0.867**					
Male, N / N'	**14 / 14**	**22 / 21**	**10 / 6**			
n (%)	4.00 (28.57)	12.10 (55.00)	1.28 (12.80)			
SEC low vs. ETA				2.76 [0.27; 28.40] 0.393	2.36 [0.32; 17.49] 0.401	0.16 [-0.17; 0.48] 0.344
SEC high vs. ETA				8.25 [0.90; 75.26] 0.061	4.54 [0.70; 29.30] 0.112	0.42 [0.11; 0.73] 0.007
Female, N / N'	**25 / 24**	**20 / 20**	**16 / 15**			
n (%)	11.29 (45.16)	12.00 (60.00)	3.00 (18.75)			
SEC low vs. ETA				3.46 [0.79; 15.07] 0.098	2.41 [0.79; 7.31] 0.121	0.26 [-0.01; 0.54] 0.060
SEC high vs. ETA				N.E.	3.20 [1.09; 9.43] 0.035	0.41 [0.12; 0.70] 0.005

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

6.4 PASI Response by Disease Severity (FAS)

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
PASI50 Response Week 52						
Interaction Test	N.E.					
Baseline PASI ≤ Median, N / N'	20 / 20	19 / 19	13 / 12			
n (%)	20.00 (100.00)	18.00 (94.74)	11.86 (91.23)			
SEC low vs. ETA				1.76 [N.E.; N.E.] N.E.	1.10 [0.92; 1.31] 0.314	0.09 [-0.07; 0.25] 0.289
SEC high vs. ETA				1.65 [0.10; 27.66] 0.729	1.04 [0.84; 1.28] 0.720	0.04 [-0.16; 0.23] 0.718
Baseline PASI > Median, N / N'	19 / 18	23 / 22	13 / 9			
n (%)	19.00 (100.00)	22.97 (99.87)	9.76 (75.08)			
SEC low vs. ETA				6.98 [N.E.; N.E.] N.E.	1.34 [0.94; 1.89] 0.105	0.25 [-0.01; 0.51] 0.058
SEC high vs. ETA				8.41 [N.E.; N.E.] N.E.	1.33 [0.94; 1.90] 0.108	0.25 [-0.01; 0.51] 0.061
PASI75 Response Week 52						
Interaction Test	p=0.778					
Baseline PASI ≤ Median, N / N'	20 / 20	19 / 19	13 / 12			
n (%)	19.00 (95.00)	18.00 (94.74)	9.56 (73.54)			
SEC low vs. ETA				6.38 [0.60; 67.42] 0.124	1.29 [0.90; 1.85] 0.159	0.21 [-0.05; 0.48] 0.117
SEC high vs. ETA				6.04 [0.57; 64.03] 0.135	1.29 [0.90; 1.85] 0.165	0.21 [-0.06; 0.48] 0.124
Baseline PASI > Median, N / N'	19 / 18	23 / 22	13 / 9			
n (%)	14.91 (78.47)	20.70 (90.00)	7.67 (59.00)			

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
SEC low vs. ETA				2.45 [0.50; 12.11] 0.272	1.33 [0.78; 2.30] 0.298	0.19 [-0.15; 0.54] 0.263
SEC high vs. ETA				5.97 [0.96; 37.12] 0.055	1.53 [0.92; 2.54] 0.100	0.31 [-0.00; 0.62] 0.051
PASI90 Response Week 52						
Interaction Test	**p=0.968**					
Baseline PASI ≤ Median, N / N'	**20 / 20**	**19 / 19**	**13 / 12**			
n (%)	16.00 (80.00)	17.00 (89.47)	7.34 (56.46)			
SEC low vs. ETA				2.97 [0.63; 13.99] 0.169	1.42 [0.83; 2.44] 0.205	0.24 [-0.09; 0.56] 0.161
SEC high vs. ETA				6.13 [0.99; 37.73] 0.051	1.59 [0.94; 2.67] 0.081	0.33 [0.02; 0.64] 0.037
Baseline PASI > Median, N / N'	**19 / 18**	**23 / 22**	**13 / 9**			
n (%)	14.61 (76.89)	19.27 (83.78)	6.18 (47.54)			
SEC low vs. ETA				3.53 [0.76; 16.47] 0.108	1.62 [0.85; 3.07] 0.139	0.29 [-0.05; 0.63] 0.090
SEC high vs. ETA				5.42 [1.12; 26.23] 0.035	1.77 [0.95; 3.27] 0.070	0.36 [0.04; 0.68] 0.026
PASI100 Response Week 52						
Interaction Test	**p=0.691**					
Baseline PASI ≤ Median, N / N'	**20 / 20**	**19 / 19**	**13 / 12**			
n (%)	7.00 (35.00)	12.00 (63.16)	2.21 (17.00)			
SEC low vs. ETA				2.59 [0.45; 14.90] 0.286	2.09 [0.52; 8.46] 0.302	0.18 [-0.12; 0.48] 0.237
SEC high vs. ETA				7.88 [1.38; 45.13] 0.020	3.77 [1.02; 13.97] 0.047	0.46 [0.16; 0.77] 0.003
Baseline PASI > Median, N / N'	**19 / 18**	**23 / 22**	**13 / 9**			
n (%)	8.29 (43.63)	12.10 (52.61)	2.07 (15.92)			

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
SEC low vs. ETA				3.94 [0.69; 22.55] 0.124	2.75 [0.70; 10.89] 0.149	0.28 [-0.03; 0.58] 0.074
SEC high vs. ETA				5.61 [1.02; 30.77] 0.047	3.32 [0.88; 12.60] 0.077	0.37 [0.08; 0.66] 0.013

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

6.5 PASI Response by Region (FAS)

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
PASI50 Response Week 52						
Interaction Test	N.E.					
Europe, N / N'	25 / 25	34 / 33	16 / 14			
n (%)	25.00 (100.00)	33.97 (99.91)	14.12 (88.25)			
SEC low vs. ETA				3.42 [N.E.; N.E.] N.E.	1.13 [0.93; 1.38] 0.206	0.12 [-0.05; 0.29] 0.176
SEC high vs. ETA				4.64 [N.E.; N.E.] N.E.	1.13 [0.93; 1.38] 0.211	0.12 [-0.05; 0.29] 0.182
Others, N / N'	14 / 13	8 / 8	10 / 7			
n (%)	14.00 (100.00)	7.00 (87.50)	7.50 (75.00)			
SEC low vs. ETA				4.86 [N.E.; N.E.] N.E.	1.34 [0.90; 1.98] 0.146	0.25 [-0.04; 0.54] 0.089
SEC high vs. ETA				2.19 [0.17; 27.90] 0.547	1.17 [0.73; 1.87] 0.514	0.13 [-0.24; 0.49] 0.506
PASI75 Response Week 52						
Interaction Test	p=0.455					
Europe, N / N'	25 / 25	34 / 33	16 / 14			
n (%)	22.00 (88.00)	32.70 (96.18)	12.61 (78.81)			
SEC low vs. ETA				1.92 [0.34; 10.81] 0.461	1.12 [0.82; 1.52] 0.475	0.09 [-0.15; 0.34] 0.463
SEC high vs. ETA				6.75 [0.67; 67.84] 0.105	1.22 [0.92; 1.61] 0.159	0.17 [-0.05; 0.40] 0.124
Others, N / N'	14 / 13	8 / 8	10 / 7			
n (%)	11.91 (85.07)	6.00 (75.00)	4.62 (46.20)			
SEC low vs. ETA				6.11 [0.86; 43.44] 0.071	1.86 [0.86; 3.99] 0.113	0.39 [0.01; 0.77] 0.047
SEC high vs. ETA				3.25 [0.43; 24.62] 0.253	1.64 [0.71; 3.76] 0.245	0.29 [-0.16; 0.73] 0.206

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
PASI90 Response Week 52						
Interaction Test	**p=0.312**					
Europe, N / N'	**25 / 25**	**34 / 33**	**16 / 14**			
n (%)	19.00 (76.00)	30.27 (89.03)	10.34 (64.63)			
SEC low vs. ETA				1.71 [0.43; 6.80] 0.450	1.18 [0.76; 1.82] 0.462	0.11 [-0.18; 0.41] 0.447
SEC high vs. ETA				4.31 [0.95; 19.62] 0.059	1.38 [0.93; 2.04] 0.109	0.24 [-0.02; 0.51] 0.070
Others, N / N'	**14 / 13**	**8 / 8**	**10 / 7**			
n (%)	11.61 (82.93)	6.00 (75.00)	3.18 (31.80)			
SEC low vs. ETA				9.41 [1.34; 66.04] 0.024	2.62 [0.99; 6.97] 0.053	0.51 [0.15; 0.87] 0.006
SEC high vs. ETA				5.74 [0.76; 43.64] 0.091	2.38 [0.85; 6.62] 0.098	0.43 [0.01; 0.86] 0.046
PASI100 Response Week 52						
Interaction Test	**p=0.513**					
Europe, N / N'	**25 / 25**	**34 / 33**	**16 / 14**			
n (%)	13.00 (52.00)	23.10 (67.94)	3.21 (20.06)			
SEC low vs. ETA				4.19 [0.96; 18.21] 0.056	2.61 [0.89; 7.70] 0.082	0.32 [0.04; 0.60] 0.026
SEC high vs. ETA				8.11 [1.92; 34.18] 0.004	3.41 [1.21; 9.65] 0.021	0.48 [0.22; 0.74] <.001
Others, N / N'	**14 / 13**	**8 / 8**	**10 / 7**			
n (%)	2.29 (16.36)	1.00 (12.50)	1.07 (10.70)			
SEC low vs. ETA				1.60 [0.13; 19.62] 0.712	1.53 [0.16; 14.38] 0.710	0.06 [-0.23; 0.34] 0.695
SEC high vs. ETA				1.20 [0.07; 21.05] 0.900	1.19 [0.09; 16.18] 0.896	0.02 [-0.28; 0.32] 0.907

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

6.6 PASI Response by Weight (FAS)

	Treatment Groups			Comparison		
	SEC low (N=39)	**SEC high (N=42)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
PASI50 Response Week 52						
Interaction Test	**N.E.**					
Weight < 50 kg, N / N'	**19 / 19**	**19 / 19**	**11 / 9**			
n (%)	19.00 (100.00)	18.00 (94.74)	8.54 (77.64)			
SEC low vs. ETA				5.82 [N.E.; N.E.] N.E.	1.29 [0.92; 1.81] 0.142	0.22 [-0.04; 0.48] 0.093
SEC high vs. ETA				4.80 [0.40; 57.43] 0.216	1.22 [0.86; 1.75] 0.269	0.17 [-0.11; 0.45] 0.230
Weight ≥ 50 kg, N / N'	**20 / 19**	**23 / 22**	**15 / 12**			
n (%)	20.00 (100.00)	22.97 (99.87)	13.08 (87.20)			
SEC low vs. ETA				2.98 [N.E.; N.E.] N.E.	1.15 [0.93; 1.42] 0.210	0.13 [-0.06; 0.31] 0.176
SEC high vs. ETA				3.42 [N.E.; N.E.] N.E.	1.15 [0.92; 1.42] 0.217	0.13 [-0.06; 0.31] 0.184
PASI75 Response Week 52						
Interaction Test	**N.E.**					
Weight < 50 kg, N / N'	**19 / 19**	**19 / 19**	**11 / 9**			
n (%)	16.00 (84.21)	16.00 (84.21)	6.31 (57.36)			
SEC low vs. ETA				3.76 [0.68; 20.88] 0.131	1.47 [0.84; 2.59] 0.181	0.27 [-0.08; 0.61] 0.127
SEC high vs. ETA				3.76 [0.68; 20.88] 0.131	1.47 [0.84; 2.59] 0.181	0.27 [-0.08; 0.61] 0.127
Weight ≥ 50 kg, N / N'	**20 / 19**	**23 / 22**	**15 / 12**			
n (%)	17.91 (89.55)	22.70 (98.70)	10.92 (72.80)			
SEC low vs. ETA				3.07 [0.45; 20.93] 0.253	1.23 [0.85; 1.80] 0.275	0.17 [-0.12; 0.45] 0.246
SEC high vs. ETA				9.17 [N.E.; N.E.] N.E.	1.36 [0.96; 1.92] 0.081	0.26 [0.01; 0.51] 0.043

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
PASI90 Response Week 52						
Interaction Test	**p=0.803**					
Weight < 50 kg, N / N'	**19 / 19**	**19 / 19**	**11 / 9**			
n (%)	14.00 (73.68)	15.00 (78.95)	5.14 (46.73)			
SEC low vs. ETA				3.06 [0.65; 14.45] 0.158	1.58 [0.79; 3.18] 0.200	0.27 [-0.09; 0.63] 0.142
SEC high vs. ETA				4.05 [0.82; 20.08] 0.087	1.69 [0.85; 3.36] 0.133	0.32 [-0.03; 0.67] 0.073
Weight ≥ 50 kg, N / N'	**20 / 19**	**23 / 22**	**15 / 12**			
n (%)	16.61 (83.05)	21.27 (92.48)	8.38 (55.87)			
SEC low vs. ETA				3.74 [0.76; 18.45] 0.105	1.49 [0.89; 2.49] 0.128	0.27 [-0.04; 0.58] 0.088
SEC high vs. ETA				9.44 [1.28; 69.73] 0.028	1.66 [1.02; 2.69] 0.040	0.37 [0.08; 0.65] 0.011
PASI100 Response Week 52						
Interaction Test	**p=0.018**					
Weight < 50 kg, N / N'	**19 / 19**	**19 / 19**	**11 / 9**			
n (%)	10.00 (52.63)	7.00 (36.84)	2.07 (18.82)			
SEC low vs. ETA				4.57 [0.79; 26.43] 0.089	2.81 [0.75; 10.57] 0.125	0.34 [0.01; 0.66] 0.041
SEC high vs. ETA				2.46 [0.42; 14.47] 0.320	1.97 [0.49; 7.86] 0.337	0.18 [-0.14; 0.50] 0.269
Weight ≥ 50 kg, N / N'	**20 / 19**	**23 / 22**	**15 / 12**			
n (%)	5.29 (26.45)	17.10 (74.35)	2.21 (14.73)			
SEC low vs. ETA				2.06 [0.34; 12.44] 0.430	1.82 [0.41; 8.07] 0.433	0.12 [-0.16; 0.39] 0.402
SEC high vs. ETA				15.49 [2.75; 87.31] 0.002	5.12 [1.39; 18.83] 0.014	0.60 [0.34; 0.86] <.001

	Treatment Groups			Comparison		
	SEC low (N=39)	**SEC high (N=42)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

6.7 PASI Response by Previous Systemic Therapy (FAS)

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
PASI50 Response Week 52						
Interaction Test	N.E.					
No previous systemic therapy, N / N'	**8 / 7**	**13 / 13**	**10 / 8**			
n (%)	8.00 (100.00)	13.00 (100.00)	8.22 (82.20)			
SEC low vs. ETA				1.66 [N.E.; N.E.] N.E.	1.22 [0.89; 1.67] 0.219	0.18 [-0.08; 0.43] 0.172
SEC high vs. ETA				2.71 [N.E.; N.E.] N.E.	1.22 [0.89; 1.67] 0.219	0.18 [-0.08; 0.43] 0.172
Previous systemic therapy, N / N'	**31 / 31**	**29 / 28**	**16 / 13**			
n (%)	31.00 (100.00)	27.97 (96.45)	13.40 (83.75)			
SEC low vs. ETA				6.65 [N.E.; N.E.] N.E.	1.20 [0.94; 1.52] 0.145	0.16 [-0.04; 0.36] 0.108
SEC high vs. ETA				4.96 [0.42; 58.48] 0.204	1.15 [0.90; 1.48] 0.267	0.13 [-0.08; 0.34] 0.237
PASI75 Response Week 52						
Interaction Test	N.E.					
No previous systemic therapy, N / N'	**8 / 7**	**13 / 13**	**10 / 8**			
n (%)	6.91 (86.38)	13.00 (100.00)	6.36 (63.60)			
SEC low vs. ETA				3.44 [0.29; 40.13] 0.325	1.36 [0.76; 2.43] 0.296	0.23 [-0.17; 0.63] 0.265
SEC high vs. ETA				7.98 [N.E.; N.E.] N.E.	1.58 [0.96; 2.59] 0.072	0.36 [0.05; 0.68] 0.023
Previous systemic therapy, N / N'	**31 / 31**	**29 / 28**	**16 / 13**			
n (%)	27.00 (87.10)	25.70 (88.62)	10.87 (67.94)			

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
SEC low vs. ETA				3.08 [0.67; 14.11] 0.148	1.28 [0.87; 1.89] 0.204	0.19 [-0.08; 0.46] 0.166
SEC high vs. ETA				3.56 [0.70; 18.09] 0.125	1.31 [0.89; 1.92] 0.175	0.21 [-0.07; 0.48] 0.136
PASI90 Response Week 52						
Interaction Test	N.E.					
No previous systemic therapy, N / N'	8 / 7	13 / 13	10 / 8			
n (%)	6.61 (82.63)	13.00 (100.00)	6.04 (60.40)			
SEC low vs. ETA				3.09 [0.29; 33.28] 0.352	1.36 [0.73; 2.53] 0.325	0.22 [-0.20; 0.64] 0.298
SEC high vs. ETA				9.21 [N.E.; N.E.] N.E.	1.66 [1.00; 2.75] 0.051	0.40 [0.09; 0.70] 0.011
Previous systemic therapy, N / N'	31 / 31	29 / 28	16 / 13			
n (%)	24.00 (77.42)	23.27 (80.24)	7.48 (46.75)			
SEC low vs. ETA				3.78 [1.02; 13.97] 0.046	1.66 [0.93; 2.96] 0.086	0.31 [0.01; 0.60] 0.041
SEC high vs. ETA				4.46 [1.14; 17.48] 0.032	1.72 [0.97; 3.06] 0.065	0.33 [0.04; 0.63] 0.025
PASI100 Response Week 52						
Interaction Test	p=0.810					
No previous systemic therapy, N / N'	8 / 7	13 / 13	10 / 8			
n (%)	4.29 (53.63)	10.00 (76.92)	3.00 (30.00)			
SEC low vs. ETA				2.55 [0.37; 17.61] 0.342	1.78 [0.55; 5.71] 0.334	0.24 [-0.22; 0.70] 0.314
SEC high vs. ETA				N.E.	2.56 [0.95; 6.92] 0.063	0.47 [0.10; 0.83] 0.012
Previous systemic therapy, N / N'	31 / 31	29 / 28	16 / 13			
n (%)	11.00 (35.48)	14.10 (48.62)	1.28 (8.00)			

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
SEC low vs. ETA				6.47 [0.77; 54.38] 0.086	4.69 [0.69; 32.07] 0.115	0.27 [0.05; 0.50] 0.015
SEC high vs. ETA				10.96 [1.31; 92.01] 0.027	6.42 [0.96; 43.01] 0.055	0.41 [0.17; 0.64] <.001

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

7.1 IGA mod 2011 Response (FAS)

	Treatment Groups			Comparison		
	SEC low (N=39)	**SEC high (N=42)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
IGA mod 2011 Response Week 52						
N'	**38**	**41**	**21**			
n (%)	29.79 (76.38)	35.69 (84.98)	12.62 (48.54)			
SEC low vs. ETA				3.36 [1.14; 9.96] 0.029	1.58 [1.01; 2.47] 0.047	0.28 [0.04; 0.52] 0.024
SEC high vs. ETA				5.83 [1.82; 18.72] 0.003	1.75 [1.14; 2.70] 0.011	0.36 [0.14; 0.59] 0.002

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR from exact logistic regression model with treatment as predictor.
RR and RD calculated directly.

All results are combined over MI:
n and % are averaged of all imputations.
Estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back-transformation. All CIs and p-values are Wald-type.

OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

7.2 IGA mod 2011 Response by Age (FAS)

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
IGA mod 2011 Response Week 52						
Interaction Test	**p=0.472**					
Age < 12 years, N / N'	**9 / 9**	**9 / 9**	**6 / 5**			
n (%)	7.00 (77.78)	6.00 (66.67)	2.18 (36.33)			
SEC low vs. ETA				5.36 [0.57; 50.01] 0.141	2.17 [0.67; 7.03] 0.197	0.41 [-0.07; 0.90] 0.094
SEC high vs. ETA				3.23 [0.38; 27.53] 0.285	1.86 [0.55; 6.26] 0.317	0.30 [-0.20; 0.81] 0.240
Age ≥ 12 years, N / N'	**30 / 29**	**33 / 32**	**20 / 16**			
n (%)	22.79 (75.97)	29.69 (89.97)	10.44 (52.20)			
SEC low vs. ETA				2.83 [0.83; 9.66] 0.096	1.46 [0.90; 2.35] 0.124	0.24 [-0.04; 0.51] 0.089
SEC high vs. ETA				7.90 [1.82; 34.24] 0.006	1.73 [1.10; 2.70] 0.017	0.38 [0.13; 0.63] 0.003

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

7.3 IGA mod 2011 Response by Gender (FAS)

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
IGA mod 2011 Response Week 52						
Interaction Test	p=0.607					
Male, N / N'	**14 / 14**	**22 / 21**	**10 / 6**			
n (%)	10.00 (71.43)	19.69 (89.50)	4.62 (46.20)			
SEC low vs. ETA				2.78 [0.48; 16.22] 0.256	1.56 [0.69; 3.54] 0.283	0.25 [-0.16; 0.67] 0.232
SEC high vs. ETA				9.18 [1.31; 64.17] 0.025	1.96 [0.91; 4.20] 0.083	0.43 [0.07; 0.80] 0.020
Female, N / N'	**25 / 24**	**20 / 20**	**16 / 15**			
n (%)	19.79 (79.16)	16.00 (80.00)	8.00 (50.00)			
SEC low vs. ETA				3.67 [0.94; 14.43] 0.062	1.58 [0.93; 2.69] 0.090	0.29 [-0.00; 0.59] 0.052
SEC high vs. ETA				N.E.	1.60 [0.94; 2.74] 0.086	0.30 [-0.00; 0.60] 0.051

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

7.4 IGA mod 2011 Response by Disease Severity (FAS)

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
IGA mod 2011 Response Week 52						
Interaction Test	p=0.414					
Baseline PASI ≤ Median, N / N'	20 / 20	19 / 19	13 / 12			
n (%)	15.00 (75.00)	18.00 (94.74)	7.12 (54.77)			
SEC low vs. ETA				2.40 [0.55; 10.54] 0.244	1.37 [0.78; 2.41] 0.272	0.20 [-0.13; 0.54] 0.235
SEC high vs. ETA				13.52 [1.41; 129.70] 0.024	1.73 [1.04; 2.89] 0.036	0.40 [0.11; 0.69] 0.007
Baseline PASI > Median, N / N'	19 / 18	23 / 22	13 / 9			
n (%)	14.79 (77.84)	17.69 (76.91)	5.50 (42.31)			
SEC low vs. ETA				4.56 [0.94; 22.18] 0.060	1.85 [0.90; 3.81] 0.095	0.36 [0.01; 0.70] 0.042
SEC high vs. ETA				4.35 [0.96; 19.70] 0.056	1.83 [0.89; 3.75] 0.099	0.35 [0.01; 0.68] 0.043

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

7.5 IGA mod 2011 Response by Region (FAS)

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
IGA mod 2011 Response Week 52						
Interaction Test	**p=0.095**					
Europe, N / N'	**25 / 25**	**34 / 33**	**16 / 14**			
n (%)	18.00 (72.00)	30.69 (90.26)	10.12 (63.25)			
SEC low vs. ETA				1.48 [0.39; 5.61] 0.567	1.14 [0.73; 1.79] 0.572	0.09 [-0.21; 0.38] 0.564
SEC high vs. ETA				5.21 [1.11; 24.52] 0.037	1.43 [0.96; 2.12] 0.078	0.27 [0.01; 0.53] 0.043
Others, N / N'	**14 / 13**	**8 / 8**	**10 / 7**			
n (%)	11.79 (84.21)	5.00 (62.50)	2.50 (25.00)			
SEC low vs. ETA				14.13 [1.76; 113.38] 0.013	3.47 [1.01; 11.93] 0.048	0.59 [0.24; 0.95] 0.001
SEC high vs. ETA				4.63 [0.59; 36.35] 0.145	2.58 [0.68; 9.71] 0.162	0.38 [-0.07; 0.82] 0.100

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

7.6 IGA mod 2011 Response by Weight (FAS)

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
IGA mod 2011 Response Week 52						
Interaction Test	**p=0.632**					
Weight < 50 kg, N / N'	**19 / 19**	**19 / 19**	**11 / 9**			
n (%)	14.00 (73.68)	15.00 (78.95)	3.22 (29.27)			
SEC low vs. ETA				6.32 [1.21; 33.00] 0.029	2.54 [0.94; 6.88] 0.067	0.44 [0.10; 0.79] 0.011
SEC high vs. ETA				8.32 [1.53; 45.31] 0.014	2.72 [1.01; 7.30] 0.047	0.50 [0.16; 0.83] 0.004
Weight ≥ 50 kg, N / N'	**20 / 19**	**23 / 22**	**15 / 12**			
n (%)	15.79 (78.95)	20.69 (89.96)	9.40 (62.67)			
SEC low vs. ETA				2.18 [0.47; 10.03] 0.316	1.26 [0.79; 2.02] 0.331	0.16 [-0.15; 0.48] 0.307
SEC high vs. ETA				5.16 [0.87; 30.51] 0.071	1.44 [0.93; 2.21] 0.100	0.27 [-0.01; 0.56] 0.060

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

7.7 IGA mod 2011 Response by Previous Systemic Therapy (FAS)

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
IGA mod 2011 Response Week 52						
Interaction Test	N.E.					
No previous systemic therapy, N / N'	**8 / 7**	**13 / 13**	**10 / 8**			
n (%)	6.79 (84.88)	13.00 (100.00)	5.28 (52.80)			
SEC low vs. ETA				4.77 [0.43; 52.38] 0.201	1.61 [0.81; 3.20] 0.175	0.32 [-0.09; 0.74] 0.129
SEC high vs. ETA				12.38 [N.E.; N.E.] N.E.	1.90 [1.03; 3.50] 0.040	0.47 [0.15; 0.79] 0.004
Previous systemic therapy, N / N'	**31 / 31**	**29 / 28**	**16 / 13**			
n (%)	23.00 (74.19)	22.69 (78.24)	7.34 (45.88)			
SEC low vs. ETA				3.30 [0.91; 11.93] 0.069	1.62 [0.90; 2.93] 0.109	0.28 [-0.01; 0.58] 0.061
SEC high vs. ETA				4.10 [1.07; 15.79] 0.040	1.71 [0.95; 3.08] 0.074	0.32 [0.03; 0.62] 0.033

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

8.0 CDLQI, Return Rates (FAS)

	Treatment Groups			
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	Total (N=107)
Number of patients with valid data n (%)				
Baseline Returns	39 (100.0)	42 (100.0)	26 (100.0)	107 (100.0)
Week 4 Returns	37 (94.9)	40 (95.2)	26 (100.0)	103 (96.3)
Week 8 Returns	37 (94.9)	41 (97.6)	26 (100.0)	104 (97.2)
Week 12 Returns	31 (79.5)	40 (95.2)	23 (88.5)	94 (87.9)
Week 24 Returns	37 (94.9)	42 (100.0)	25 (96.2)	104 (97.2)
Week 36 Returns	38 (97.4)	39 (92.9)	21 (80.8)	98 (91.6)
Week 52 Returns	36 (92.3)	40 (95.2)	22 (84.6)	98 (91.6)
Note: Baseline value was imputed for 1 patient(s) in arm SEC low, 2 patient(s) in arm SEC high, and 1 patient(s) in arm ETA.				

8.1 CDLQI, Change from Baseline (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
N'	38	42	26		
Baseline Mean (SD)	12.56 (7.13)	11.83 (6.76)	11.12 (7.70)		
Week 4 Adjusted Mean Change (SE)	-5.38 (0.83)	-4.93 (0.80)	-5.38 (1.00)		
Week 8 Adjusted Mean Change (SE)	-5.94 (0.83)	-7.19 (0.79)	-5.96 (1.00)		
Week 12 Adjusted Mean Change (SE)	-6.85 (0.88)	-6.76 (0.80)	-8.00 (1.04)		
Week 24 Adjusted Mean Change (SE)	-9.39 (0.83)	-8.77 (0.78)	-6.32 (1.01)		
Week 36 Adjusted Mean Change (SE)	-9.36 (0.83)	-8.12 (0.80)	-6.32 (1.07)		
Week 52 Adjusted Mean Change (SE)	-9.61 (0.84)	-9.51 (0.80)	-8.00 (1.05)	-1.61 [-4.25; 1.04] 0.233	-1.51 [-4.10; 1.08] 0.254

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, treatment x visit
Covariance structure: compound symmetry (cs)

Note: Baseline value was imputed for 1 patient(s) in arm SEC low, 2 patient(s) in arm SEC high, and 1 patient(s) in arm ETA.

8.2 CDLQI, Change from Baseline by Age (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Interaction test: p=0.157					
Age < 12 years, N	9	9	6		
N'	9	9	6		
Baseline Mean (SD)	9.11 (6.85)	13.67 (7.31)	14.67 (3.83)		
Week 4 Adjusted Mean Change (SE)	-6.18 (1.75)	-1.67 (1.74)	-3.92 (2.06)		
Week 8 Adjusted Mean Change (SE)	-7.17 (1.69)	-8.45 (1.68)	0.25 (2.06)		
Week 12 Adjusted Mean Change (SE)	-7.30 (2.04)	-8.17 (1.74)	-3.51 (2.34)		
Week 24 Adjusted Mean Change (SE)	-9.28 (1.69)	-10.11 (1.68)	-4.58 (2.06)		
Week 36 Adjusted Mean Change (SE)	-9.72 (1.69)	-9.33 (1.68)	-2.99 (2.18)		
Week 52 Adjusted Mean Change (SE)	-9.61 (1.69)	-8.89 (1.68)	-8.39 (2.18)	-1.22 [-6.65; 4.22] 0.660	-0.50 [-5.90; 4.91] 0.857
Age ≥ 12 years, N	30	33	20		
N'	29	33	20		
Baseline Mean (SD)	13.60 (6.99)	11.33 (6.64)	10.05 (8.31)		
Week 4 Adjusted Mean Change (SE)	-5.13 (0.94)	-5.73 (0.89)	-5.84 (1.13)		
Week 8 Adjusted Mean Change (SE)	-5.53 (0.95)	-6.83 (0.89)	-7.84 (1.13)		
Week 12 Adjusted Mean Change (SE)	-6.70 (0.97)	-6.39 (0.89)	-9.14 (1.15)		
Week 24 Adjusted Mean Change (SE)	-9.41 (0.95)	-8.40 (0.88)	-6.84 (1.15)		
Week 36 Adjusted Mean Change (SE)	-9.23 (0.94)	-7.75 (0.90)	-7.38 (1.21)		

	Treatment Groups			Comparisons	
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Week 52 Adjusted Mean Change (SE)	-9.60 (0.96)	-9.69 (0.89)	-7.93 (1.19)	-1.67 [-4.69; 1.35] 0.278	-1.76 [-4.68; 1.16] 0.236

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

Note: Baseline value was imputed for 1 patient(s) in arm SEC low, 2 patient(s) in arm SEC high, and 1 patient(s) in arm ETA.

8.3 CDLQI, Change from Baseline by Gender (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Interaction test: p=0.001					
Male, N	**14**	**22**	**10**		
N'	14	22	10		
Baseline Mean (SD)	12.29 (7.17)	11.36 (6.04)	6.60 (6.38)		
Week 4 Adjusted Mean Change (SE)	-2.18 (1.31)	-5.24 (1.08)	-5.56 (1.57)		
Week 8 Adjusted Mean Change (SE)	-1.89 (1.31)	-8.13 (1.06)	-7.16 (1.57)		
Week 12 Adjusted Mean Change (SE)	-3.53 (1.42)	-8.23 (1.08)	-8.36 (1.63)		
Week 24 Adjusted Mean Change (SE)	-7.96 (1.31)	-10.27 (1.05)	-4.19 (1.63)		
Week 36 Adjusted Mean Change (SE)	-8.18 (1.31)	-10.33 (1.10)	-5.39 (1.77)		
Week 52 Adjusted Mean Change (SE)	-8.35 (1.34)	-10.26 (1.08)	-5.64 (1.77)	-2.71 [-7.09; 1.66] 0.224	-4.62 [-8.69; -0.55] 0.026
Female, N	**25**	**20**	**16**		
N'	24	20	16		
Baseline Mean (SD)	12.72 (7.25)	12.35 (7.60)	13.94 (7.23)		
Week 4 Adjusted Mean Change (SE)	-7.29 (1.02)	-4.50 (1.10)	-5.27 (1.23)		
Week 8 Adjusted Mean Change (SE)	-8.37 (1.02)	-6.15 (1.10)	-5.20 (1.23)		
Week 12 Adjusted Mean Change (SE)	-8.73 (1.06)	-5.20 (1.10)	-7.78 (1.28)		
Week 24 Adjusted Mean Change (SE)	-10.21 (1.02)	-7.10 (1.10)	-7.52 (1.23)		
Week 36 Adjusted Mean Change (SE)	-10.06 (1.00)	-5.90 (1.10)	-6.80 (1.28)		

	Treatment Groups			Comparisons	
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Week 52 Adjusted Mean Change (SE)	-10.36 (1.01)	-8.65 (1.10)	-9.11 (1.26)	-1.25 [-4.42; 1.92] 0.438	0.46 [-2.82; 3.73] 0.783

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

Note: Baseline value was imputed for 1 patient(s) in arm SEC low, 2 patient(s) in arm SEC high, and 1 patient(s) in arm ETA.

8.4 CDLQI, Change from Baseline by Disease Severity (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Interaction test: p=0.892					
Baseline PASI ≤ Median, N	**20**	**19**	**13**		
N'	20	19	13		
Baseline Mean (SD)	11.50 (6.96)	11.26 (4.47)	10.15 (6.11)		
Week 4 Adjusted Mean Change (SE)	-4.52 (1.16)	-5.64 (1.17)	-5.79 (1.42)		
Week 8 Adjusted Mean Change (SE)	-4.92 (1.16)	-6.59 (1.17)	-4.87 (1.42)		
Week 12 Adjusted Mean Change (SE)	-7.01 (1.16)	-5.43 (1.17)	-7.18 (1.42)		
Week 24 Adjusted Mean Change (SE)	-9.32 (1.14)	-8.49 (1.17)	-6.31 (1.45)		
Week 36 Adjusted Mean Change (SE)	-9.97 (1.14)	-6.85 (1.17)	-5.87 (1.42)		
Week 52 Adjusted Mean Change (SE)	-9.93 (1.16)	-8.84 (1.19)	-7.26 (1.45)	-2.67 [-6.32; 0.98] 0.151	-1.58 [-5.26; 2.11] 0.401
Baseline PASI > Median, N	**19**	**23**	**13**		
N'	18	23	13		
Baseline Mean (SD)	13.68 (7.32)	12.30 (8.27)	12.08 (9.18)		
Week 4 Adjusted Mean Change (SE)	-6.30 (1.21)	-4.23 (1.09)	-4.96 (1.42)		
Week 8 Adjusted Mean Change (SE)	-7.02 (1.21)	-7.69 (1.08)	-7.04 (1.42)		
Week 12 Adjusted Mean Change (SE)	-6.53 (1.37)	-7.93 (1.09)	-8.96 (1.54)		
Week 24 Adjusted Mean Change (SE)	-9.46 (1.23)	-9.00 (1.06)	-6.35 (1.42)		
Week 36 Adjusted Mean Change (SE)	-8.69 (1.21)	-9.29 (1.11)	-6.83 (1.66)		

	Treatment Groups			Comparisons	
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Week 52 Adjusted Mean Change (SE)	-9.25 (1.23)	-10.06 (1.08)	-8.82 (1.54)	-0.43 [-4.30; 3.44] 0.826	-1.24 [-4.94; 2.45] 0.509

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

Note: Baseline value was imputed for 1 patient(s) in arm SEC low, 2 patient(s) in arm SEC high, and 1 patient(s) in arm ETA.

8.5 CDLQI, Change from Baseline by Region (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Interaction test: p=0.307					
Europe, N	25	34	16		
N'	25	34	16		
Baseline Mean (SD)	12.92 (6.83)	11.21 (6.57)	10.69 (8.39)		
Week 4 Adjusted Mean Change (SE)	-5.53 (1.03)	-5.07 (0.88)	-5.77 (1.27)		
Week 8 Adjusted Mean Change (SE)	-6.27 (1.03)	-7.24 (0.88)	-7.96 (1.27)		
Week 12 Adjusted Mean Change (SE)	-7.41 (1.06)	-6.47 (0.88)	-9.06 (1.33)		
Week 24 Adjusted Mean Change (SE)	-9.47 (1.02)	-8.60 (0.87)	-7.68 (1.29)		
Week 36 Adjusted Mean Change (SE)	-9.99 (1.02)	-8.25 (0.90)	-8.05 (1.33)		
Week 52 Adjusted Mean Change (SE)	-9.63 (1.02)	-9.64 (0.89)	-8.81 (1.33)	-0.82 [-4.11; 2.47] 0.624	-0.83 [-3.96; 2.30] 0.603
Others, N	14	8	10		
N'	13	8	10		
Baseline Mean (SD)	11.93 (7.86)	14.50 (7.37)	11.80 (6.83)		
Week 4 Adjusted Mean Change (SE)	-5.06 (1.41)	-4.28 (1.88)	-4.77 (1.60)		
Week 8 Adjusted Mean Change (SE)	-5.29 (1.41)	-6.99 (1.80)	-2.77 (1.60)		
Week 12 Adjusted Mean Change (SE)	-5.57 (1.59)	-8.14 (1.88)	-6.33 (1.66)		
Week 24 Adjusted Mean Change (SE)	-9.24 (1.44)	-9.49 (1.80)	-4.17 (1.60)		
Week 36 Adjusted Mean Change (SE)	-8.14 (1.41)	-7.61 (1.80)	-3.24 (1.80)		

	Treatment Groups			Comparisons	
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Week 52 Adjusted Mean Change (SE)	-9.65 (1.48)	-8.99 (1.80)	-6.72 (1.72)	-2.93 [-7.40; 1.53] 0.198	-2.27 [-7.16; 2.63] 0.364

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

Note: Baseline value was imputed for 1 patient(s) in arm SEC low, 2 patient(s) in arm SEC high, and 1 patient(s) in arm ETA.

8.6 CDLQI, Change from Baseline by Weight (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Interaction test: p=0.059					
Weight < 50 kg, N	**19**	**19**	**11**		
N'	19	19	11		
Baseline Mean (SD)	12.63 (7.28)	13.95 (7.31)	12.82 (4.85)		
Week 4 Adjusted Mean Change (SE)	-6.26 (1.18)	-4.00 (1.18)	-3.92 (1.52)		
Week 8 Adjusted Mean Change (SE)	-6.36 (1.18)	-7.97 (1.16)	-3.10 (1.52)		
Week 12 Adjusted Mean Change (SE)	-7.29 (1.31)	-7.61 (1.18)	-6.23 (1.62)		
Week 24 Adjusted Mean Change (SE)	-9.72 (1.18)	-9.66 (1.16)	-4.01 (1.52)		
Week 36 Adjusted Mean Change (SE)	-8.93 (1.16)	-8.50 (1.16)	-2.94 (1.62)		
Week 52 Adjusted Mean Change (SE)	-9.92 (1.18)	-9.81 (1.16)	-7.61 (1.62)	-2.31 [-6.24; 1.63] 0.250	-2.21 [-6.12; 1.71] 0.269
Weight ≥ 50 kg, N	**20**	**23**	**15**		
N'	19	23	15		
Baseline Mean (SD)	12.50 (7.17)	10.09 (5.88)	9.87 (9.23)		
Week 4 Adjusted Mean Change (SE)	-4.52 (1.16)	-5.69 (1.07)	-6.46 (1.31)		
Week 8 Adjusted Mean Change (SE)	-5.52 (1.16)	-6.52 (1.07)	-8.06 (1.31)		
Week 12 Adjusted Mean Change (SE)	-6.44 (1.18)	-6.05 (1.07)	-9.31 (1.34)		
Week 24 Adjusted Mean Change (SE)	-9.05 (1.16)	-8.03 (1.06)	-8.05 (1.33)		
Week 36 Adjusted Mean Change (SE)	-9.78 (1.16)	-7.79 (1.10)	-8.86 (1.40)		

	Treatment Groups			Comparisons	
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Week 52 Adjusted Mean Change (SE)	-9.29 (1.18)	-9.26 (1.09)	-8.34 (1.37)	-0.95 [-4.50; 2.60] 0.598	-0.92 [-4.34; 2.50] 0.597

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

Note: Baseline value was imputed for 1 patient(s) in arm SEC low, 2 patient(s) in arm SEC high, and 1 patient(s) in arm ETA.

8.7 CDLQI, Change from Baseline by Previous Systemic Therapy (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Interaction test: p=0.950					
No previous systemic therapy, N	8	13	10		
N'	7	13	10		
Baseline Mean (SD)	8.88 (8.56)	11.00 (6.57)	9.40 (6.95)		
Week 4 Adjusted Mean Change (SE)	-7.24 (1.94)	-4.93 (1.42)	-6.52 (1.63)		
Week 8 Adjusted Mean Change (SE)	-8.24 (1.94)	-7.47 (1.42)	-6.02 (1.63)		
Week 12 Adjusted Mean Change (SE)	-8.17 (2.03)	-7.24 (1.42)	-7.85 (1.75)		
Week 24 Adjusted Mean Change (SE)	-8.81 (1.94)	-9.32 (1.42)	-6.16 (1.68)		
Week 36 Adjusted Mean Change (SE)	-10.38 (1.94)	-9.01 (1.42)	-8.59 (1.74)		
Week 52 Adjusted Mean Change (SE)	-9.09 (1.94)	-9.55 (1.42)	-8.84 (1.68)	-0.26 [-5.29; 4.77] 0.919	-0.71 [-5.03; 3.61] 0.746
Previous systemic therapy, N	31	29	16		
N'	31	29	16		
Baseline Mean (SD)	13.52 (6.54)	12.21 (6.93)	12.19 (8.17)		
Week 4 Adjusted Mean Change (SE)	-4.94 (0.93)	-4.94 (0.97)	-4.68 (1.28)		
Week 8 Adjusted Mean Change (SE)	-5.40 (0.93)	-7.06 (0.96)	-5.93 (1.28)		
Week 12 Adjusted Mean Change (SE)	-6.53 (0.99)	-6.54 (0.97)	-8.06 (1.31)		
Week 24 Adjusted Mean Change (SE)	-9.52 (0.93)	-8.52 (0.95)	-6.37 (1.28)		
Week 36 Adjusted Mean Change (SE)	-9.12 (0.92)	-7.69 (0.98)	-4.93 (1.37)		

	Treatment Groups			Comparisons	
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Week 52 Adjusted Mean Change (SE)	-9.74 (0.94)	-9.50 (0.97)	-7.46 (1.37)	-2.28 [-5.54; 0.98] 0.171	-2.04 [-5.33; 1.26] 0.225

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

Note: Baseline value was imputed for 1 patient(s) in arm SEC low, 2 patient(s) in arm SEC high, and 1 patient(s) in arm ETA.

9.0 CDLQI (Age ≤ 16), Return Rates (FAS)

	Treatment Groups			
	SEC low (N=33)	**SEC high (N=34)**	**ETA (N=23)**	**Total (N=90)**
Number of patients with valid data n (%)				
Baseline Returns	33 (100.0)	34 (100.0)	23 (100.0)	90 (100.0)
Week 4 Returns	31 (93.9)	32 (94.1)	23 (100.0)	86 (95.6)
Week 8 Returns	31 (93.9)	33 (97.1)	23 (100.0)	87 (96.7)
Week 12 Returns	25 (75.8)	32 (94.1)	21 (91.3)	78 (86.7)
Week 24 Returns	27 (81.8)	30 (88.2)	18 (78.3)	75 (83.3)
Week 36 Returns	22 (66.7)	26 (76.5)	14 (60.9)	62 (68.9)
Week 52 Returns	21 (63.6)	27 (79.4)	14 (60.9)	62 (68.9)

Note: Baseline value was imputed for 1 patient(s) in arm SEC low, 2 patient(s) in arm SEC high, and 1 patient(s) in arm ETA.

Note: Only responses of patients ≤ 16 years at time of assessment were considered. The table is based on all patients who were ≤ 16 years at Baseline.

9.1 CDLQI (Age ≤ 16), Change from Baseline (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=33)	SEC high (N=34)	ETA (N=23)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
N'	32	34	23		
Baseline Mean (SD)	11.79 (7.18)	12.09 (7.23)	10.48 (6.99)		
Week 4 Adjusted Mean Change (SE)	-5.84 (0.88)	-4.56 (0.86)	-5.14 (1.03)		
Week 8 Adjusted Mean Change (SE)	-6.23 (0.88)	-7.63 (0.85)	-5.19 (1.03)		
Week 12 Adjusted Mean Change (SE)	-7.57 (0.94)	-7.05 (0.86)	-7.39 (1.05)		
Week 24 Adjusted Mean Change (SE)	-9.52 (0.92)	-8.78 (0.88)	-5.88 (1.11)		
Week 36 Adjusted Mean Change (SE)	-8.20 (0.98)	-7.96 (0.92)	-5.69 (1.21)		
Week 52 Adjusted Mean Change (SE)	-8.93 (1.00)	-9.02 (0.91)	-8.56 (1.21)	-0.37 [-3.45; 2.71] 0.812	-0.46 [-3.43; 2.51] 0.762

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, treatment x visit
Covariance structure: compound symmetry (cs)

Note: Baseline value was imputed for 1 patient(s) in arm SEC low, 2 patient(s) in arm SEC high, and 1 patient(s) in arm ETA.

Note: Only responses of patients ≤ 16 years at time of assessment were considered. The table is based on all patients who were ≤ 16 years at Baseline.

9.2 CDLQI (Age ≤ 16), Change from Baseline by Age (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=33)	SEC high (N=34)	ETA (N=23)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Interaction test: p=0.179					
Age < 12 years, N	9	9	6		
N'	9	9	6		
Baseline Mean (SD)	9.11 (6.85)	13.67 (7.31)	14.67 (3.83)		
Week 4 Adjusted Mean Change (SE)	-6.01 (1.68)	-1.36 (1.68)	-3.57 (1.99)		
Week 8 Adjusted Mean Change (SE)	-6.99 (1.62)	-8.13 (1.62)	0.60 (1.99)		
Week 12 Adjusted Mean Change (SE)	-7.15 (1.96)	-7.86 (1.68)	-3.16 (2.25)		
Week 24 Adjusted Mean Change (SE)	-9.10 (1.62)	-9.79 (1.62)	-4.23 (1.99)		
Week 36 Adjusted Mean Change (SE)	-9.55 (1.62)	-9.02 (1.62)	-2.66 (2.10)		
Week 52 Adjusted Mean Change (SE)	-9.44 (1.62)	-8.57 (1.62)	-8.06 (2.10)	-1.38 [-6.62; 3.86] 0.605	-0.52 [-5.72; 4.69] 0.846
Age ≥ 12 years, N	24	25	17		
N'	23	25	17		
Baseline Mean (SD)	12.79 (7.19)	11.52 (7.27)	9.00 (7.33)		
Week 4 Adjusted Mean Change (SE)	-5.76 (1.01)	-5.60 (0.98)	-5.73 (1.19)		
Week 8 Adjusted Mean Change (SE)	-5.90 (1.03)	-7.43 (0.98)	-7.26 (1.19)		
Week 12 Adjusted Mean Change (SE)	-7.63 (1.06)	-6.74 (0.98)	-8.68 (1.19)		
Week 24 Adjusted Mean Change (SE)	-9.76 (1.10)	-8.30 (1.02)	-6.33 (1.32)		
Week 36 Adjusted Mean Change (SE)	-7.30 (1.22)	-7.35 (1.10)	-6.90 (1.46)		

	Treatment Groups			Comparisons	
	SEC low (N=33)	SEC high (N=34)	ETA (N=23)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Week 52 Adjusted Mean Change (SE)	-8.60 (1.26)	-9.21 (1.08)	-8.34 (1.46)	-0.26 [-4.06; 3.54] 0.893	-0.86 [-4.43; 2.70] 0.634

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

Note: Baseline value was imputed for 1 patient(s) in arm SEC low, 2 patient(s) in arm SEC high, and 1 patient(s) in arm ETA.

Note: Only responses of patients ≤ 16 years at time of assessment were considered. The table is based on all patients who were ≤ 16 years at Baseline.

9.3 CDLQI (Age ≤ 16), Change from Baseline by Gender (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=33)	SEC high (N=34)	ETA (N=23)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Interaction test: p=0.024					
Male, N	9	18	9		
N'	9	18	9		
Baseline Mean (SD)	9.11 (6.17)	12.00 (6.49)	7.11 (6.55)		
Week 4 Adjusted Mean Change (SE)	-3.11 (1.61)	-4.45 (1.17)	-5.03 (1.62)		
Week 8 Adjusted Mean Change (SE)	-1.88 (1.61)	-8.26 (1.15)	-6.80 (1.62)		
Week 12 Adjusted Mean Change (SE)	-5.50 (1.83)	-8.25 (1.17)	-8.16 (1.68)		
Week 24 Adjusted Mean Change (SE)	-8.84 (1.74)	-10.48 (1.17)	-2.70 (1.84)		
Week 36 Adjusted Mean Change (SE)	-6.73 (1.95)	-10.85 (1.29)	-4.24 (2.38)		
Week 52 Adjusted Mean Change (SE)	-7.53 (1.95)	-10.00 (1.25)	-6.61 (2.38)	-0.92 [-6.95; 5.11] 0.765	-3.38 [-8.68; 1.91] 0.210
Female, N	24	16	14		
N'	23	16	14		
Baseline Mean (SD)	12.79 (7.40)	12.19 (8.21)	12.64 (6.59)		
Week 4 Adjusted Mean Change (SE)	-6.94 (1.02)	-4.56 (1.20)	-5.18 (1.28)		
Week 8 Adjusted Mean Change (SE)	-7.99 (1.02)	-6.94 (1.20)	-4.11 (1.28)		
Week 12 Adjusted Mean Change (SE)	-8.39 (1.06)	-5.75 (1.20)	-6.93 (1.31)		
Week 24 Adjusted Mean Change (SE)	-9.86 (1.05)	-6.89 (1.25)	-7.36 (1.35)		
Week 36 Adjusted Mean Change (SE)	-8.87 (1.10)	-5.31 (1.25)	-6.03 (1.38)		

	Treatment Groups			Comparisons	
	SEC low (N=33)	SEC high (N=34)	ETA (N=23)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Week 52 Adjusted Mean Change (SE)	-9.56 (1.12)	-7.96 (1.25)	-9.03 (1.38)	-0.53 [-4.03; 2.98] 0.767	1.08 [-2.59; 4.74] 0.564

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

Note: Baseline value was imputed for 1 patient(s) in arm SEC low, 2 patient(s) in arm SEC high, and 1 patient(s) in arm ETA.

Note: Only responses of patients $\leq$ 16 years at time of assessment were considered. The table is based on all patients who were $\leq$ 16 years at Baseline.

9.4 CDLQI (Age ≤ 16), Change from Baseline by Disease Severity (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=33)	SEC high (N=34)	ETA (N=23)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Interaction test: p=0.850					
Baseline PASI ≤ Median, N	16	15	12		
N'	16	15	12		
Baseline Mean (SD)	10.25 (6.98)	10.87 (4.76)	10.83 (5.84)		
Week 4 Adjusted Mean Change (SE)	-4.81 (1.26)	-5.40 (1.27)	-5.33 (1.42)		
Week 8 Adjusted Mean Change (SE)	-4.94 (1.26)	-6.60 (1.27)	-4.33 (1.42)		
Week 12 Adjusted Mean Change (SE)	-7.77 (1.26)	-5.27 (1.27)	-6.83 (1.42)		
Week 24 Adjusted Mean Change (SE)	-8.82 (1.32)	-8.15 (1.30)	-5.94 (1.62)		
Week 36 Adjusted Mean Change (SE)	-8.33 (1.44)	-6.44 (1.30)	-5.57 (1.62)		
Week 52 Adjusted Mean Change (SE)	-8.43 (1.44)	-8.25 (1.33)	-8.96 (1.70)	0.53 [-3.85; 4.90] 0.813	0.71 [-3.53; 4.95] 0.743
Baseline PASI > Median, N	17	19	11		
N'	16	19	11		
Baseline Mean (SD)	13.24 (7.28)	13.05 (8.72)	10.09 (8.35)		
Week 4 Adjusted Mean Change (SE)	-6.85 (1.24)	-3.75 (1.17)	-4.91 (1.49)		
Week 8 Adjusted Mean Change (SE)	-7.47 (1.24)	-8.49 (1.15)	-6.09 (1.49)		
Week 12 Adjusted Mean Change (SE)	-6.99 (1.44)	-8.58 (1.17)	-8.09 (1.58)		
Week 24 Adjusted Mean Change (SE)	-10.20 (1.29)	-9.31 (1.20)	-5.90 (1.53)		
Week 36 Adjusted Mean Change (SE)	-8.18 (1.35)	-9.57 (1.31)	-5.79 (1.81)		

	Treatment Groups			Comparisons	
	SEC low (N=33)	SEC high (N=34)	ETA (N=23)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Week 52 Adjusted Mean Change (SE)	-9.44 (1.39)	-9.67 (1.25)	-8.16 (1.72)	-1.27 [-5.64; 3.09] 0.566	-1.50 [-5.70; 2.69] 0.481

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

Note: Baseline value was imputed for 1 patient(s) in arm SEC low, 2 patient(s) in arm SEC high, and 1 patient(s) in arm ETA.

Note: Only responses of patients ≤ 16 years at time of assessment were considered. The table is based on all patients who were ≤ 16 years at Baseline.

9.5 CDLQI (Age ≤ 16), Change from Baseline by Region (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=33)	SEC high (N=34)	ETA (N=23)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Interaction test: p=0.265					
Europe, N	**20**	**26**	**13**		
N'	20	26	13		
Baseline Mean (SD)	11.85 (6.72)	11.35 (7.17)	9.46 (7.22)		
Week 4 Adjusted Mean Change (SE)	-6.81 (1.10)	-4.74 (0.96)	-5.64 (1.35)		
Week 8 Adjusted Mean Change (SE)	-7.18 (1.10)	-7.94 (0.96)	-7.25 (1.35)		
Week 12 Adjusted Mean Change (SE)	-8.79 (1.14)	-6.84 (0.96)	-8.44 (1.38)		
Week 24 Adjusted Mean Change (SE)	-9.69 (1.17)	-8.45 (0.99)	-7.82 (1.53)		
Week 36 Adjusted Mean Change (SE)	-9.96 (1.25)	-7.78 (1.05)	-8.04 (1.59)		
Week 52 Adjusted Mean Change (SE)	-9.88 (1.25)	-9.22 (1.04)	-9.57 (1.67)	-0.32 [-4.42; 3.78] 0.879	0.35 [-3.51; 4.21] 0.858
Others, N	**13**	**8**	**10**		
N'	12	8	10		
Baseline Mean (SD)	11.69 (8.13)	14.50 (7.37)	11.80 (6.83)		
Week 4 Adjusted Mean Change (SE)	-4.24 (1.40)	-3.90 (1.80)	-4.52 (1.53)		
Week 8 Adjusted Mean Change (SE)	-4.66 (1.40)	-6.65 (1.72)	-2.52 (1.53)		
Week 12 Adjusted Mean Change (SE)	-5.36 (1.60)	-7.76 (1.80)	-6.07 (1.58)		
Week 24 Adjusted Mean Change (SE)	-9.12 (1.44)	-9.86 (1.80)	-3.67 (1.59)		
Week 36 Adjusted Mean Change (SE)	-5.50 (1.54)	-8.43 (1.80)	-2.64 (1.82)		

	Treatment Groups			Comparisons	
	SEC low (N=33)	SEC high (N=34)	ETA (N=23)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Week 52 Adjusted Mean Change (SE)	-7.39 (1.60)	-8.43 (1.80)	-7.25 (1.72)	-0.14 [-4.76; 4.49] 0.953	-1.17 [-6.08; 3.73] 0.638

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

Note: Baseline value was imputed for 1 patient(s) in arm SEC low, 2 patient(s) in arm SEC high, and 1 patient(s) in arm ETA.

Note: Only responses of patients ≤ 16 years at time of assessment were considered. The table is based on all patients who were ≤ 16 years at Baseline.

9.6 CDLQI (Age ≤ 16), Change from Baseline by Weight (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=33)	SEC high (N=34)	ETA (N=23)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Interaction test: p=0.064					
Weight < 50 kg, N	**19**	**19**	**11**		
N'	19	19	11		
Baseline Mean (SD)	12.63 (7.28)	13.95 (7.31)	12.82 (4.85)		
Week 4 Adjusted Mean Change (SE)	-5.99 (1.14)	-3.66 (1.14)	-3.63 (1.47)		
Week 8 Adjusted Mean Change (SE)	-6.09 (1.14)	-7.64 (1.12)	-2.81 (1.47)		
Week 12 Adjusted Mean Change (SE)	-7.10 (1.26)	-7.27 (1.14)	-5.94 (1.56)		
Week 24 Adjusted Mean Change (SE)	-9.45 (1.14)	-9.60 (1.14)	-3.72 (1.47)		
Week 36 Adjusted Mean Change (SE)	-7.93 (1.18)	-8.66 (1.14)	-2.66 (1.56)		
Week 52 Adjusted Mean Change (SE)	-9.14 (1.20)	-9.44 (1.14)	-7.32 (1.56)	-1.82 [-5.69; 2.06] 0.357	-2.11 [-5.91; 1.69] 0.275
Weight ≥ 50 kg, N	**14**	**15**	**12**		
N'	13	15	12		
Baseline Mean (SD)	10.64 (7.15)	9.73 (6.64)	8.33 (8.12)		
Week 4 Adjusted Mean Change (SE)	-5.64 (1.35)	-5.69 (1.29)	-6.57 (1.42)		
Week 8 Adjusted Mean Change (SE)	-6.41 (1.35)	-7.62 (1.29)	-7.40 (1.42)		
Week 12 Adjusted Mean Change (SE)	-8.08 (1.39)	-6.72 (1.29)	-8.82 (1.42)		
Week 24 Adjusted Mean Change (SE)	-9.59 (1.53)	-7.48 (1.35)	-8.41 (1.70)		
Week 36 Adjusted Mean Change (SE)	-8.87 (1.77)	-6.41 (1.56)	-9.94 (1.92)		

	Treatment Groups			Comparisons	
	SEC low (N=33)	SEC high (N=34)	ETA (N=23)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Week 52 Adjusted Mean Change (SE)	-8.37 (1.77)	-8.17 (1.49)	-9.47 (1.92)	1.10 [-4.02; 6.22] 0.673	1.30 [-3.47; 6.07] 0.591

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

Note: Baseline value was imputed for 1 patient(s) in arm SEC low, 2 patient(s) in arm SEC high, and 1 patient(s) in arm ETA.

Note: Only responses of patients ≤ 16 years at time of assessment were considered. The table is based on all patients who were ≤ 16 years at Baseline.

9.7 CDLQI (Age ≤ 16), Change from Baseline by Previous Systemic Therapy (FAS)

	Treatment Groups			Comparisons	
	SEC low (N=33)	SEC high (N=34)	ETA (N=23)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Interaction test: p=0.837					
No previous systemic therapy, N	**6**	**10**	**8**		
N'	5	10	8		
Baseline Mean (SD)	7.00 (8.99)	11.20 (7.11)	9.13 (6.40)		
Week 4 Adjusted Mean Change (SE)	-8.29 (2.23)	-4.05 (1.56)	-5.71 (1.75)		
Week 8 Adjusted Mean Change (SE)	-8.29 (2.23)	-7.15 (1.56)	-5.09 (1.75)		
Week 12 Adjusted Mean Change (SE)	-8.50 (2.37)	-6.45 (1.56)	-7.55 (1.82)		
Week 24 Adjusted Mean Change (SE)	-8.17 (2.40)	-9.74 (1.61)	-6.87 (1.92)		
Week 36 Adjusted Mean Change (SE)	-9.67 (2.40)	-9.07 (1.61)	-9.08 (2.03)		
Week 52 Adjusted Mean Change (SE)	-8.17 (2.40)	-9.96 (1.61)	-10.03 (1.92)	1.86 [-4.15; 7.87] 0.543	0.08 [-4.85; 5.01] 0.976
Previous systemic therapy, N	**27**	**24**	**15**		
N'	27	24	15		
Baseline Mean (SD)	12.85 (6.44)	12.46 (7.40)	11.20 (7.40)		
Week 4 Adjusted Mean Change (SE)	-5.37 (0.96)	-4.80 (1.04)	-4.85 (1.27)		
Week 8 Adjusted Mean Change (SE)	-5.83 (0.96)	-7.84 (1.02)	-5.25 (1.27)		
Week 12 Adjusted Mean Change (SE)	-7.41 (1.03)	-7.34 (1.04)	-7.29 (1.30)		
Week 24 Adjusted Mean Change (SE)	-9.74 (1.00)	-8.36 (1.05)	-5.39 (1.37)		
Week 36 Adjusted Mean Change (SE)	-7.90 (1.08)	-7.37 (1.12)	-3.80 (1.51)		

	Treatment Groups			Comparisons	
	SEC low (N=33)	SEC high (N=34)	ETA (N=23)	SEC low-ETA Mean Diff [95% CI] p-value	SEC high-ETA Mean Diff [95% CI] p-value
Week 52 Adjusted Mean Change (SE)	-9.14 (1.11)	-8.53 (1.10)	-7.58 (1.57)	-1.56 [-5.34; 2.21] 0.416	-0.95 [-4.73; 2.82] 0.619

N': Number of patients in the analysis
CI: Confidence interval
MMRM: Mixed effects repeated measures model
N.E.: Not estimable
SD: Standard deviation
SE: Standard error

Interaction test, adjusted mean change, mean difference and p-value from MMRM with fixed effects:
treatment, visit, baseline value, subgroup, treatment x visit, subgroup x visit, treatment x subgroup, treatment x subgroup x visit
Covariance structure: compound symmetry (cs)

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for continuous parameters, subgroup analysis is displayed only if the number of patients used in the analysis is at least 10 in each subgroup.

Note: Baseline value was imputed for 1 patient(s) in arm SEC low, 2 patient(s) in arm SEC high, and 1 patient(s) in arm ETA.

Note: Only responses of patients ≤ 16 years at time of assessment were considered. The table is based on all patients who were ≤ 16 years at Baseline.

10.1 CDLQI Response (FAS)

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
CDLQI Response Week 52						
N'	36	40	22			
n (%)	19.83 (50.85)	28.64 (68.19)	10.41 (40.04)			
SEC low vs. ETA				1.54 [0.55; 4.29] 0.409	1.27 [0.71; 2.27] 0.417	0.11 [-0.14; 0.36] 0.400
SEC high vs. ETA				3.16 [1.11; 8.95] 0.031	1.71 [1.00; 2.90] 0.049	0.28 [0.04; 0.52] 0.023

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR from exact logistic regression model with treatment as predictor.
RR and RD calculated directly.

All results are combined over MI:
n and % are averaged of all imputations.
Estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back-transformation. All CIs and p-values are Wald-type.

OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

10.2 CDLQI Response by Age (FAS)

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
CDLQI Response Week 52						
Interaction Test	**p=0.506**					
Age < 12 years, N / N'	**9 / 9**	**9 / 9**	**6 / 5**			
n (%)	5.00 (55.56)	5.00 (55.56)	1.21 (20.17)			
SEC low vs. ETA				4.61 [0.40; 53.68] 0.222	2.88 [0.45; 18.48] 0.264	0.35 [-0.12; 0.83] 0.142
SEC high vs. ETA				4.61 [0.40; 53.68] 0.222	2.88 [0.45; 18.48] 0.264	0.35 [-0.12; 0.83] 0.142
Age ≥ 12 years, N / N'	**30 / 27**	**33 / 31**	**20 / 17**			
n (%)	14.83 (49.43)	23.64 (71.64)	9.20 (46.00)			
SEC low vs. ETA				1.14 [0.36; 3.60] 0.817	1.07 [0.58; 1.98] 0.817	0.03 [-0.25; 0.32] 0.815
SEC high vs. ETA				2.91 [0.90; 9.43] 0.076	1.56 [0.91; 2.66] 0.103	0.26 [-0.02; 0.53] 0.066

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

10.3 CDLQI Response by Gender (FAS)

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
CDLQI Response Week 52						
Interaction Test	**p=0.102**					
Male, N / N'	**14 / 13**	**22 / 20**	**10 / 7**			
n (%)	5.20 (37.14)	17.64 (80.18)	3.36 (33.60)			
SEC low vs. ETA				1.17 [0.20; 6.67] 0.862	1.12 [0.35; 3.57] 0.854	0.04 [-0.37; 0.44] 0.863
SEC high vs. ETA				7.47 [1.29; 43.17] 0.025	2.41 [0.92; 6.34] 0.074	0.47 [0.11; 0.83] 0.011
Female, N / N'	**25 / 23**	**20 / 20**	**16 / 15**			
n (%)	14.63 (58.52)	11.00 (55.00)	7.05 (44.06)			
SEC low vs. ETA				1.77 [0.50; 6.26] 0.378	1.33 [0.69; 2.54] 0.392	0.14 [-0.17; 0.46] 0.367
SEC high vs. ETA				1.53 [0.41; 5.67] 0.522	1.25 [0.63; 2.47] 0.523	0.11 [-0.22; 0.44] 0.513

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

10.4 CDLQI Response by Disease Severity (FAS)

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
CDLQI Response Week 52						
Interaction Test	p=0.964					
Baseline PASI ≤ Median, N / N'	**20 / 19**	**19 / 18**	**13 / 12**			
n (%)	9.20 (46.00)	11.88 (62.53)	4.15 (31.92)			
SEC low vs. ETA				1.79 [0.41; 7.75] 0.437	1.44 [0.56; 3.71] 0.445	0.14 [-0.20; 0.48] 0.418
SEC high vs. ETA				3.42 [0.77; 15.19] 0.106	1.96 [0.81; 4.77] 0.135	0.31 [-0.03; 0.65] 0.078
Baseline PASI > Median, N / N'	**19 / 17**	**23 / 22**	**13 / 10**			
n (%)	10.63 (55.95)	16.76 (72.87)	6.26 (48.15)			
SEC low vs. ETA				1.35 [0.32; 5.77] 0.682	1.16 [0.57; 2.39] 0.679	0.08 [-0.29; 0.44] 0.675
SEC high vs. ETA				2.81 [0.66; 11.99] 0.164	1.52 [0.80; 2.88] 0.203	0.25 [-0.09; 0.59] 0.152

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

10.5 CDLQI Response by Region (FAS)

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
CDLQI Response Week 52						
Interaction Test	**p=0.540**					
Europe, N / N'	**25 / 25**	**34 / 32**	**16 / 14**			
n (%)	13.00 (52.00)	24.64 (72.47)	8.20 (51.25)			
SEC low vs. ETA				1.03 [0.29; 3.62] 0.964	1.02 [0.55; 1.88] 0.960	0.01 [-0.31; 0.33] 0.963
SEC high vs. ETA				2.46 [0.70; 8.64] 0.161	1.42 [0.83; 2.42] 0.203	0.21 [-0.08; 0.51] 0.159
Others, N / N'	**14 / 11**	**8 / 8**	**10 / 8**			
n (%)	6.83 (48.79)	4.00 (50.00)	2.21 (22.10)			
SEC low vs. ETA				3.23 [0.49; 21.41] 0.224	2.23 [0.57; 8.70] 0.248	0.27 [-0.12; 0.65] 0.177
SEC high vs. ETA				3.31 [0.44; 25.01] 0.246	2.30 [0.56; 9.41] 0.248	0.28 [-0.16; 0.72] 0.212

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

10.6 CDLQI Response by Weight (FAS)

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
CDLQI Response Week 52						
Interaction Test	**p=0.880**					
Weight < 50 kg, N / N'	**19 / 18**	**19 / 19**	**11 / 9**			
n (%)	9.01 (47.42)	12.00 (63.16)	3.21 (29.18)			
SEC low vs. ETA				2.14 [0.43; 10.58] 0.349	1.64 [0.56; 4.77] 0.366	0.18 [-0.17; 0.54] 0.317
SEC high vs. ETA				3.98 [0.80; 19.83] 0.092	2.18 [0.79; 6.03] 0.133	0.34 [-0.01; 0.69] 0.059
Weight ≥ 50 kg, N / N'	**20 / 18**	**23 / 21**	**15 / 13**			
n (%)	10.82 (54.10)	16.64 (72.35)	7.20 (48.00)			
SEC low vs. ETA				1.27 [0.32; 4.96] 0.732	1.13 [0.57; 2.23] 0.732	0.06 [-0.28; 0.40] 0.728
SEC high vs. ETA				2.76 [0.69; 11.11] 0.153	1.51 [0.83; 2.76] 0.182	0.24 [-0.08; 0.57] 0.139

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

10.7 CDLQI Response by Previous Systemic Therapy (FAS)

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
CDLQI Response Week 52						
Interaction Test	**p=0.694**					
No previous systemic therapy, N / N'	**8 / 7**	**13 / 13**	**10 / 9**			
n (%)	3.62 (45.25)	9.00 (69.23)	5.05 (50.50)			
SEC low vs. ETA				0.82 [0.12; 5.36] 0.833	0.89 [0.32; 2.49] 0.821	-0.05 [-0.53; 0.43] 0.830
SEC high vs. ETA				2.13 [0.40; 11.39] 0.378	1.37 [0.67; 2.81] 0.388	0.19 [-0.21; 0.59] 0.360
Previous systemic therapy, N / N'	**31 / 29**	**29 / 27**	**16 / 13**			
n (%)	16.21 (52.29)	19.64 (67.72)	5.36 (33.50)			
SEC low vs. ETA				2.15 [0.60; 7.71] 0.241	1.57 [0.71; 3.47] 0.268	0.19 [-0.11; 0.49] 0.217
SEC high vs. ETA				4.04 [1.06; 15.39] 0.041	2.03 [0.94; 4.39] 0.072	0.34 [0.04; 0.64] 0.025

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

11.1 CDLQI Response (Age ≤ 16) (FAS)

	Treatment Groups			Comparison		
	SEC low (N=22)	SEC high (N=28)	ETA (N=17)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
CDLQI Response (Age ≤ 16) Week 52						
N'	21	27	14			
n (%)	13.14 (59.73)	17.91 (63.96)	6.60 (38.82)			
SEC low vs. ETA				2.29 [0.61; 8.60] 0.219	1.54 [0.75; 3.17] 0.236	0.21 [-0.11; 0.53] 0.200
SEC high vs. ETA				2.74 [0.77; 9.75] 0.120	1.65 [0.83; 3.29] 0.152	0.25 [-0.05; 0.55] 0.102

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR from exact logistic regression model with treatment as predictor.
RR and RD calculated directly.

All results are combined over MI:
n and % are averaged of all imputations.
Estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back-transformation. All CIs and p-values are Wald-type.

OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

Note: Only responses of patients ≤ 16 years at time of assessment were considered. The table is based on all patients who were ≤ 16 years in Week 52. Missing values with respect to this population were imputed.

11.2 CDLQI Response (Age ≤ 16) by Age (FAS)

	Treatment Groups			Comparison		
	SEC low (N=22)	SEC high (N=28)	ETA (N=17)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
CDLQI Response (Age ≤ 16) Week 52						
Interaction Test	**p=0.808**					
Age < 12 years, N / N'	**9 / 9**	**9 / 9**	**6 / 5**			
n (%)	5.00 (55.56)	5.00 (55.56)	1.28 (21.33)			
SEC low vs. ETA				4.34 [0.37; 50.46] 0.241	2.75 [0.44; 17.29] 0.282	0.34 [-0.14; 0.82] 0.163
SEC high vs. ETA				4.34 [0.37; 50.46] 0.241	2.75 [0.44; 17.29] 0.282	0.34 [-0.14; 0.82] 0.163
Age ≥ 12 years, N / N'	**13 / 12**	**19 / 18**	**11 / 9**			
n (%)	8.14 (62.62)	12.91 (67.95)	5.32 (48.36)			
SEC low vs. ETA				1.75 [0.34; 9.07] 0.506	1.30 [0.60; 2.80] 0.505	0.14 [-0.26; 0.55] 0.492
SEC high vs. ETA				2.20 [0.47; 10.31] 0.317	1.41 [0.69; 2.87] 0.344	0.20 [-0.18; 0.57] 0.303

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

Note: Only responses of patients ≤ 16 years at time of assessment were considered. The table is based on all patients who were ≤ 16 years in Week 52. Missing values with respect to this population were imputed.

11.3 CDLQI Response (Age ≤ 16) by Gender (FAS)

	Treatment Groups			Comparison		
	SEC low (N=22)	SEC high (N=28)	ETA (N=17)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
CDLQI Response (Age ≤ 16) Week 52						
Interaction Test	**p=0.170**					
Male, N / N'	**5 / 5**	**14 / 13**	**6 / 3**			
n (%)	2.00 (40.00)	10.91 (77.93)	1.60 (26.67)			
SEC low vs. ETA				1.83 [0.13; 26.63] 0.657	1.62 [0.23; 11.60] 0.632	0.13 [-0.46; 0.72] 0.657
SEC high vs. ETA				8.96 [0.79; 101.65] 0.077	3.15 [0.59; 16.87] 0.180	0.51 [0.05; 0.97] 0.029
Female, N / N'	**17 / 16**	**14 / 14**	**11 / 11**			
n (%)	11.14 (65.53)	7.00 (50.00)	5.00 (45.45)			
SEC low vs. ETA				2.22 [0.48; 10.26] 0.309	1.44 [0.69; 3.01] 0.331	0.20 [-0.17; 0.57] 0.292
SEC high vs. ETA				N.E.	1.10 [0.48; 2.53] 0.823	0.05 [-0.35; 0.44] 0.821

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

Note: Only responses of patients ≤ 16 years at time of assessment were considered. The table is based on all patients who were ≤ 16 years in Week 52. Missing values with respect to this population were imputed.

11.4 CDLQI Response (Age ≤ 16) by Disease Severity (FAS)

	Treatment Groups			Comparison		
	SEC low (N=22)	SEC high (N=28)	ETA (N=17)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
CDLQI Response (Age ≤ 16) Week 52						
Interaction Test	**p=0.404**					
Baseline PASI ≤ Median, N / N'	**10 / 10**	**14 / 13**	**8 / 7**			
n (%)	7.00 (70.00)	7.91 (56.50)	2.31 (28.88)			
SEC low vs. ETA				5.22 [0.68; 40.00] 0.112	2.47 [0.71; 8.56] 0.154	0.41 [-0.03; 0.85] 0.065
SEC high vs. ETA				3.07 [0.46; 20.71] 0.248	1.99 [0.56; 7.05] 0.286	0.28 [-0.15; 0.70] 0.201
Baseline PASI > Median, N / N'	**12 / 11**	**14 / 14**	**9 / 7**			
n (%)	6.14 (51.17)	10.00 (71.43)	4.29 (47.67)			
SEC low vs. ETA				1.14 [0.20; 6.65] 0.882	1.08 [0.43; 2.70] 0.873	0.03 [-0.41; 0.48] 0.878
SEC high vs. ETA				2.62 [0.45; 15.15] 0.282	1.51 [0.68; 3.34] 0.312	0.24 [-0.18; 0.65] 0.262

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

Note: Only responses of patients ≤ 16 years at time of assessment were considered. The table is based on all patients who were ≤ 16 years in Week 52. Missing values with respect to this population were imputed.

11.5 CDLQI Response (Age ≤ 16) by Region (FAS)

	Treatment Groups			Comparison		
	SEC low (N=22)	SEC high (N=28)	ETA (N=17)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
CDLQI Response (Age ≤ 16) Week 52						
Interaction Test	**p=0.670**					
Europe, N / N'	**13 / 13**	**21 / 20**	**8 / 7**			
n (%)	8.00 (61.54)	14.91 (71.00)	4.31 (53.88)			
SEC low vs. ETA				1.35 [0.22; 8.16] 0.747	1.15 [0.51; 2.57] 0.736	0.08 [-0.37; 0.52] 0.737
SEC high vs. ETA				2.04 [0.36; 11.36] 0.418	1.32 [0.64; 2.76] 0.453	0.17 [-0.24; 0.58] 0.415
Others, N / N'	**9 / 8**	**7 / 7**	**9 / 7**			
n (%)	5.14 (57.11)	3.00 (42.86)	2.29 (25.44)			
SEC low vs. ETA				3.66 [0.48; 28.12] 0.212	2.28 [0.60; 8.75] 0.228	0.32 [-0.13; 0.77] 0.168
SEC high vs. ETA				2.12 [0.26; 17.60] 0.487	1.72 [0.39; 7.52] 0.473	0.17 [-0.30; 0.65] 0.472

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

Note: Only responses of patients ≤ 16 years at time of assessment were considered. The table is based on all patients who were ≤ 16 years in Week 52. Missing values with respect to this population were imputed.

11.6 CDLQI Response (Age ≤ 16) by Weight (FAS)

	Treatment Groups			Comparison		
	SEC low (N=22)	SEC high (N=28)	ETA (N=17)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
CDLQI Response (Age ≤ 16) Week 52						
Interaction Test	**p=0.700**					
Weight < 50 kg, N / N'	**16 / 15**	**18 / 18**	**11 / 9**			
n (%)	8.14 (50.88)	11.00 (61.11)	3.29 (29.91)			
SEC low vs. ETA				2.36 [0.45; 12.36] 0.308	1.72 [0.59; 5.03] 0.325	0.21 [-0.17; 0.59] 0.276
SEC high vs. ETA				3.54 [0.70; 17.89] 0.127	2.06 [0.74; 5.74] 0.165	0.31 [-0.05; 0.67] 0.091
Weight ≥ 50 kg, N / N'	**6 / 6**	**10 / 9**	**6 / 5**			
n (%)	5.00 (83.33)	6.91 (69.10)	3.31 (55.17)			
SEC low vs. ETA				3.57 [0.26; 49.79] 0.343	1.52 [0.65; 3.60] 0.336	0.28 [-0.23; 0.80] 0.285
SEC high vs. ETA				1.74 [0.20; 14.78] 0.612	1.26 [0.52; 3.07] 0.607	0.14 [-0.37; 0.65] 0.594

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

Note: Only responses of patients ≤ 16 years at time of assessment were considered. The table is based on all patients who were ≤ 16 years in Week 52. Missing values with respect to this population were imputed.

11.7 CDLQI Response (Age ≤ 16) by Previous Systemic Therapy (FAS)

	Treatment Groups			Comparison		
	SEC low (N=22)	SEC high (N=28)	ETA (N=17)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
CDLQI Response (Age ≤ 16) Week 52						
Interaction Test	p=0.592					
No previous systemic therapy, N / N'	4 / 4	9 / 9	6 / 6			
n (%)	2.00 (50.00)	7.00 (77.78)	3.00 (50.00)			
SEC low vs. ETA				N.E.	1.00 [0.28; 3.54] 1.000	0.00 [-0.63; 0.63] 1.000
SEC high vs. ETA				N.E.	1.56 [0.65; 3.72] 0.321	0.28 [-0.21; 0.76] 0.260
Previous systemic therapy, N / N'	18 / 17	19 / 18	11 / 8			
n (%)	11.14 (61.89)	10.91 (57.42)	3.60 (32.73)			
SEC low vs. ETA				3.23 [0.62; 16.74] 0.162	1.92 [0.71; 5.21] 0.202	0.29 [-0.08; 0.67] 0.128
SEC high vs. ETA				2.71 [0.54; 13.66] 0.228	1.78 [0.65; 4.88] 0.262	0.25 [-0.13; 0.62] 0.195

N': Number of patients with available response value
n (%): Number and percentage of patients with event
N-N' is the number of values with MI.
CI: Confidence Interval
MI: Multiple Imputation
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from logistic regression model with predictors treatment, subgroup and treatment x subgroup.
OR from exact logistic regression models per subgroup with treatment as predictor.
RR and RD calculated directly per subgroup.

All results are combined over MI:
n and % are averaged of all imputations.
P-value of interaction test, estimates, CIs and p-values of OR, RR and RD are combined using Rubin's rule, OR and RR on log-scale with subsequent back- transformation. All CIs and p-values are Wald-type.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup in at least 90% of imputations.

The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups in more than 10% of imputations.
OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups in more than 10% of imputations.

Note: Only responses of patients ≤ 16 years at time of assessment were considered. The table is based on all patients who were ≤ 16 years in Week 52. Missing values with respect to this population were imputed.

Safety Analysis

S.1.1 Adverse Events, Binary Analysis (SAF)

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	39	42	26			
Any AE, n (%)	32 (82.1)	33 (78.6)	24 (92.3)			
SEC low vs. ETA				0.39 [0.04; 2.28] 0.426	0.89 [0.74; 1.07] 0.296	-0.10 [-0.26; 0.06] 0.204
SEC high vs. ETA				0.31 [0.03; 1.70] 0.245	0.85 [0.70; 1.03] 0.184	-0.14 [-0.30; 0.02] 0.094
Any AE, disease specific events excluded, n (%)	32 (82.1)	32 (76.2)	24 (92.3)			
SEC low vs. ETA				0.39 [0.04; 2.28] 0.426	0.89 [0.74; 1.07] 0.296	-0.10 [-0.26; 0.06] 0.204
SEC high vs. ETA				0.27 [0.03; 1.45] 0.165	0.83 [0.67; 1.01] 0.112	-0.16 [-0.33; 0.00] 0.055
Any SAE, n (%)	3 (7.7)	4 (9.5)	5 (19.2)			
SEC low vs. ETA				0.36 [0.05; 2.04] 0.317	0.40 [0.10; 1.53] 0.250	-0.12 [-0.29; 0.06] 0.191
SEC high vs. ETA				0.45 [0.08; 2.33] 0.432	0.50 [0.15; 1.68] 0.287	-0.10 [-0.27; 0.08] 0.279
Any SAE, disease specific events excluded, n (%)	3 (7.7)	4 (9.5)	5 (19.2)			
SEC low vs. ETA				0.36 [0.05; 2.04] 0.317	0.40 [0.10; 1.53] 0.250	-0.12 [-0.29; 0.06] 0.191
SEC high vs. ETA				0.45 [0.08; 2.33] 0.432	0.50 [0.15; 1.68] 0.287	-0.10 [-0.27; 0.08] 0.279
Any severe AE, n (%)	3 (7.7)	3 (7.1)	4 (15.4)			
SEC low vs. ETA				0.46 [0.06; 3.03] 0.560	0.50 [0.12; 2.05] 0.424	-0.08 [-0.24; 0.09] 0.352
SEC high vs. ETA				0.43 [0.06; 2.79] 0.492	0.46 [0.11; 1.91] 0.415	-0.08 [-0.24; 0.08] 0.310

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Any severe AE, disease specific events excluded, n (%)	3 (7.7)	3 (7.1)	4 (15.4)			
SEC low vs. ETA				0.46 [0.06; 3.03] 0.560	0.50 [0.12; 2.05] 0.424	-0.08 [-0.24; 0.09] 0.352
SEC high vs. ETA				0.43 [0.06; 2.79] 0.492	0.46 [0.11; 1.91] 0.415	-0.08 [-0.24; 0.08] 0.310
Any AE leading to study discontinuation, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Any AE leading to study drug discontinuation, n (%)	1 (2.6)	0 (0.0)	1 (3.8)			
SEC low vs. ETA				0.66 [<0.01; 53.69] 1.000	0.67 [0.04; 10.19] 1.000	-0.01 [-0.10; 0.08] 0.778
SEC high vs. ETA				0.62 [<0.01; 24.14] 0.765	0.21 [0.01; 4.95] 0.382	-0.04 [-0.11; 0.04] 0.308

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR (with CI and p-value) from exact logistic regression model with treatment as predictor.
RR and RD calculated directly (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups.

List of Excluded Disease-Specific SOC/Preferred Terms

Preferred Terms (grouped by disease-specific event category)
General disorders and administration site conditions
Fatigue
Malaise
Musculoskeletal and connective tissue disorders
Arthralgia
Back pain
Joint swelling
Pain in extremity
Skin and subcutaneous tissue disorders
Dry skin
Erythema
Pruritus
Pruritus generalised
Psoriasis
Skin fissures
Skin irritation

S.1.2 Adverse Events by SOC, PT and Severity, Binary Analysis (SAF)

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	39	42	26			
Any adverse event, n (%)	32 (82.1)	33 (78.6)	24 (92.3)			
SEC low vs. ETA				0.39 [0.04; 2.28] 0.426	0.89 [0.74; 1.07] 0.296	-0.10 [-0.26; 0.06] 0.204
SEC high vs. ETA				0.31 [0.03; 1.70] 0.245	0.85 [0.70; 1.03] 0.184	-0.14 [-0.30; 0.02] 0.094
Mild, n (%)	29 (74.4)	31 (73.8)	22 (84.6)			
SEC low vs. ETA				0.53 [0.11; 2.16] 0.504	0.88 [0.69; 1.12] 0.373	-0.10 [-0.30; 0.09] 0.303
SEC high vs. ETA				0.52 [0.11; 2.05] 0.462	0.87 [0.68; 1.11] 0.375	-0.11 [-0.30; 0.08] 0.270
Moderate, n (%)	16 (41.0)	17 (40.5)	16 (61.5)			
SEC low vs. ETA				0.44 [0.14; 1.34] 0.171	0.67 [0.41; 1.08] 0.132	-0.21 [-0.45; 0.04] 0.097
SEC high vs. ETA				0.43 [0.14; 1.29] 0.150	0.66 [0.41; 1.06] 0.134	-0.21 [-0.45; 0.03] 0.084
Severe, n (%)	3 (7.7)	3 (7.1)	4 (15.4)			
SEC low vs. ETA				0.46 [0.06; 3.03] 0.560	0.50 [0.12; 2.05] 0.424	-0.08 [-0.24; 0.09] 0.352
SEC high vs. ETA				0.43 [0.06; 2.79] 0.492	0.46 [0.11; 1.91] 0.415	-0.08 [-0.24; 0.08] 0.310
Infections and infestations, n (%)	27 (69.2)	27 (64.3)	19 (73.1)			
SEC low vs. ETA				0.83 [0.23; 2.81] 0.962	0.95 [0.69; 1.30] 0.787	-0.04 [-0.26; 0.19] 0.736
SEC high vs. ETA				0.67 [0.19; 2.16] 0.632	0.88 [0.64; 1.22] 0.595	-0.09 [-0.31; 0.14] 0.441

S.1.2 Adverse Events by SOC, PT and Severity, Binary Analysis (SAF)

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Mild, n (%)	23 (59.0)	25 (59.5)	17 (65.4)			
SEC low vs. ETA				0.76 [0.24; 2.38] 0.798	0.90 [0.61; 1.32] 0.795	-0.06 [-0.30; 0.18] 0.600
SEC high vs. ETA				0.78 [0.25; 2.39] 0.825	0.91 [0.63; 1.32] 0.798	-0.06 [-0.29; 0.18] 0.626
Moderate, n (%)	12 (30.8)	14 (33.3)	8 (30.8)			
SEC low vs. ETA				1.00 [0.30; 3.43] 1.000	1.00 [0.48; 2.11] 1.000	0.00 [-0.23; 0.23] 1.000
SEC high vs. ETA				1.12 [0.35; 3.76] 1.000	1.08 [0.53; 2.22] 1.000	0.03 [-0.20; 0.25] 0.825
Severe, n (%)	3 (7.7)	3 (7.1)	1 (3.8)			
SEC low vs. ETA				2.06 [0.16; 113.67] 0.945	2.00 [0.22; 18.20] 0.644	0.04 [-0.07; 0.15] 0.499
SEC high vs. ETA				1.91 [0.14; 104.93] 1.000	1.86 [0.20; 16.92] 1.000	0.03 [-0.07; 0.14] 0.547
Nasopharyngitis, n (%)	10 (25.6)	15 (35.7)	8 (30.8)			
SEC low vs. ETA				0.78 [0.23; 2.73] 0.859	0.83 [0.38; 1.83] 0.779	-0.05 [-0.28; 0.17] 0.654
SEC high vs. ETA				1.25 [0.39; 4.14] 0.882	1.16 [0.57; 2.35] 0.794	0.05 [-0.18; 0.28] 0.672
Mild, n (%)	9 (23.1)	13 (31.0)	7 (26.9)			
SEC low vs. ETA				0.82 [0.23; 3.05] 0.945	0.86 [0.36; 2.01] 0.774	-0.04 [-0.25; 0.18] 0.727
SEC high vs. ETA				1.21 [0.37; 4.29] 0.943	1.15 [0.53; 2.50] 0.790	0.04 [-0.18; 0.26] 0.720
Moderate, n (%)	1 (2.6)	3 (7.1)	2 (7.7)			
SEC low vs. ETA				0.32 [<0.01; 6.49] 0.699	0.33 [0.03; 3.49] 0.559	-0.05 [-0.17; 0.06] 0.377
SEC high vs. ETA				0.92 [0.10; 11.81] 1.000	0.93 [0.17; 5.19] 1.000	-0.01 [-0.13; 0.12] 0.933

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Pharyngitis, n (%)	4 (10.3)	5 (11.9)	3 (11.5)			
SEC low vs. ETA				0.88 [0.13; 6.55] 1.000	0.89 [0.22; 3.65] 1.000	-0.01 [-0.17; 0.14] 0.872
SEC high vs. ETA				1.04 [0.18; 7.30] 1.000	1.03 [0.27; 3.96] 1.000	0.00 [-0.15; 0.16] 0.964
Mild, n (%)	2 (5.1)	4 (9.5)	1 (3.8)			
SEC low vs. ETA				1.35 [0.07; 82.87] 1.000	1.33 [0.13; 13.96] 1.000	0.01 [-0.09; 0.11] 0.804
SEC high vs. ETA				2.60 [0.24; 134.70] 0.722	2.48 [0.29; 20.96] 0.642	0.06 [-0.06; 0.17] 0.335
Moderate, n (%)	1 (2.6)	1 (2.4)	1 (3.8)			
SEC low vs. ETA				0.66 [<0.01; 53.69] 1.000	0.67 [0.04; 10.19] 1.000	-0.01 [-0.10; 0.08] 0.778
SEC high vs. ETA				0.61 [<0.01; 49.76] 1.000	0.62 [0.04; 9.48] 1.000	-0.01 [-0.10; 0.07] 0.742
Severe, n (%)	1 (2.6)	0 (0.0)	1 (3.8)			
SEC low vs. ETA				0.66 [<0.01; 53.69] 1.000	0.67 [0.04; 10.19] 1.000	-0.01 [-0.10; 0.08] 0.778
SEC high vs. ETA				0.62 [<0.01; 24.14] 0.765	0.21 [0.01; 4.95] 0.382	-0.04 [-0.11; 0.04] 0.308
Rhinitis, n (%)	3 (7.7)	5 (11.9)	1 (3.8)			
SEC low vs. ETA				2.06 [0.16; 113.67] 0.945	2.00 [0.22; 18.20] 0.644	0.04 [-0.07; 0.15] 0.499
SEC high vs. ETA				3.33 [0.34; 166.07] 0.500	3.10 [0.38; 25.04] 0.395	0.08 [-0.04; 0.20] 0.198
Mild, n (%)	2 (5.1)	5 (11.9)	1 (3.8)			
SEC low vs. ETA				1.35 [0.07; 82.87] 1.000	1.33 [0.13; 13.96] 1.000	0.01 [-0.09; 0.11] 0.804
SEC high vs. ETA				3.33 [0.34; 166.07] 0.500	3.10 [0.38; 25.04] 0.395	0.08 [-0.04; 0.20] 0.198

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Moderate, n (%)	1 (2.6)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				0.67 [0.02; >999.99] 1.000	2.03 [0.09; 47.88] 1.000	0.03 [-0.02; 0.08] 0.311
SEC high vs. ETA				N.E.	N.E.	N.E.
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Upper respiratory tract infection, n (%)	5 (12.8)	2 (4.8)	2 (7.7)			
SEC low vs. ETA				1.75 [0.26; 19.83] 0.825	1.67 [0.35; 7.95] 0.693	0.05 [-0.10; 0.20] 0.493
SEC high vs. ETA				0.60 [0.04; 8.85] 0.992	0.62 [0.09; 4.13] 0.633	-0.03 [-0.15; 0.09] 0.635
Mild, n (%)	3 (7.7)	1 (2.4)	2 (7.7)			
SEC low vs. ETA				1.00 [0.11; 12.81] 1.000	1.00 [0.18; 5.58] 1.000	0.00 [-0.13; 0.13] 1.000
SEC high vs. ETA				0.30 [<0.01; 6.01] 0.648	0.31 [0.03; 3.25] 0.553	-0.05 [-0.17; 0.06] 0.354
Moderate, n (%)	3 (7.7)	1 (2.4)	0 (0.0)			
SEC low vs. ETA				2.67 [0.28; >999.99] 0.418	4.73 [0.25; 87.85] 0.269	0.08 [-0.01; 0.16] 0.071
SEC high vs. ETA				0.62 [0.02; >999.99] 1.000	1.88 [0.08; 44.59] 1.000	0.02 [-0.02; 0.07] 0.311
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Gastroenteritis, n (%)	4 (10.3)	0 (0.0)	1 (3.8)			
SEC low vs. ETA				2.82 [0.26; 146.24] 0.657	2.67 [0.32; 22.54] 0.640	0.06 [-0.06; 0.18] 0.297
SEC high vs. ETA				0.62 [<0.01; 24.14] 0.765	0.21 [0.01; 4.95] 0.382	-0.04 [-0.11; 0.04] 0.308

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Mild, n (%)	3 (7.7)	0 (0.0)	1 (3.8)			
SEC low vs. ETA				2.06 [0.16; 113.67] 0.945	2.00 [0.22; 18.20] 0.644	0.04 [-0.07; 0.15] 0.499
SEC high vs. ETA				0.62 [<0.01; 24.14] 0.765	0.21 [0.01; 4.95] 0.382	-0.04 [-0.11; 0.04] 0.308
Moderate, n (%)	1 (2.6)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				0.67 [0.02; >999.99] 1.000	2.03 [0.09; 47.88] 1.000	0.03 [-0.02; 0.08] 0.311
SEC high vs. ETA				N.E.	N.E.	N.E.
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Oral herpes, n (%)	1 (2.6)	1 (2.4)	3 (11.5)			
SEC low vs. ETA				0.21 [<0.01; 2.75] 0.344	0.22 [0.02; 2.02] 0.293	-0.09 [-0.22; 0.04] 0.184
SEC high vs. ETA				0.19 [<0.01; 2.54] 0.305	0.21 [0.02; 1.88] 0.152	-0.09 [-0.22; 0.04] 0.171
Mild, n (%)	1 (2.6)	1 (2.4)	2 (7.7)			
SEC low vs. ETA				0.32 [<0.01; 6.49] 0.699	0.33 [0.03; 3.49] 0.559	-0.05 [-0.17; 0.06] 0.377
SEC high vs. ETA				0.30 [<0.01; 6.01] 0.648	0.31 [0.03; 3.25] 0.553	-0.05 [-0.17; 0.06] 0.354
Moderate, n (%)	0 (0.0)	1 (2.4)	1 (3.8)			
SEC low vs. ETA				0.67 [<0.01; 26.00] 0.800	0.23 [0.01; 5.32] 0.400	-0.04 [-0.11; 0.04] 0.308
SEC high vs. ETA				0.61 [<0.01; 49.76] 1.000	0.62 [0.04; 9.48] 1.000	-0.01 [-0.10; 0.07] 0.742
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Gastrointestinal disorders, n (%)	11 (28.2)	14 (33.3)	10 (38.5)			
SEC low vs. ETA				0.63 [0.19; 2.07] 0.549	0.73 [0.36; 1.47] 0.426	-0.10 [-0.34; 0.13] 0.391
SEC high vs. ETA				0.80 [0.26; 2.53] 0.861	0.87 [0.45; 1.66] 0.795	-0.05 [-0.29; 0.18] 0.669
Mild, n (%)	10 (25.6)	13 (31.0)	5 (19.2)			
SEC low vs. ETA				1.44 [0.38; 6.20] 0.773	1.33 [0.51; 3.45] 0.765	0.06 [-0.14; 0.27] 0.539
SEC high vs. ETA				1.87 [0.52; 7.74] 0.438	1.61 [0.65; 3.99] 0.399	0.12 [-0.09; 0.32] 0.265
Moderate, n (%)	3 (7.7)	3 (7.1)	5 (19.2)			
SEC low vs. ETA				0.36 [0.05; 2.04] 0.317	0.40 [0.10; 1.53] 0.250	-0.12 [-0.29; 0.06] 0.191
SEC high vs. ETA				0.33 [0.05; 1.88] 0.266	0.37 [0.10; 1.43] 0.244	-0.12 [-0.29; 0.05] 0.164
Severe, n (%)	0 (0.0)	0 (0.0)	1 (3.8)			
SEC low vs. ETA				0.67 [<0.01; 26.00] 0.800	0.23 [0.01; 5.32] 0.400	-0.04 [-0.11; 0.04] 0.308
SEC high vs. ETA				0.62 [<0.01; 24.14] 0.765	0.21 [0.01; 4.95] 0.382	-0.04 [-0.11; 0.04] 0.308
Abdominal pain, n (%)	3 (7.7)	4 (9.5)	5 (19.2)			
SEC low vs. ETA				0.36 [0.05; 2.04] 0.317	0.40 [0.10; 1.53] 0.250	-0.12 [-0.29; 0.06] 0.191
SEC high vs. ETA				0.45 [0.08; 2.33] 0.432	0.50 [0.15; 1.68] 0.287	-0.10 [-0.27; 0.08] 0.279
Mild, n (%)	2 (5.1)	4 (9.5)	3 (11.5)			
SEC low vs. ETA				0.42 [0.03; 3.96] 0.624	0.44 [0.08; 2.48] 0.382	-0.06 [-0.21; 0.08] 0.373
SEC high vs. ETA				0.81 [0.12; 6.03] 1.000	0.83 [0.20; 3.40] 1.000	-0.02 [-0.17; 0.13] 0.794

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Moderate, n (%)	1 (2.6)	0 (0.0)	1 (3.8)			
SEC low vs. ETA				0.66 [<0.01; 53.69] 1.000	0.67 [0.04; 10.19] 1.000	-0.01 [-0.10; 0.08] 0.778
SEC high vs. ETA				0.62 [<0.01; 24.14] 0.765	0.21 [0.01; 4.95] 0.382	-0.04 [-0.11; 0.04] 0.308
Severe, n (%)	0 (0.0)	0 (0.0)	1 (3.8)			
SEC low vs. ETA				0.67 [<0.01; 26.00] 0.800	0.23 [0.01; 5.32] 0.400	-0.04 [-0.11; 0.04] 0.308
SEC high vs. ETA				0.62 [<0.01; 24.14] 0.765	0.21 [0.01; 4.95] 0.382	-0.04 [-0.11; 0.04] 0.308
Abdominal pain upper, n (%)	1 (2.6)	3 (7.1)	3 (11.5)			
SEC low vs. ETA				0.21 [<0.01; 2.75] 0.344	0.22 [0.02; 2.02] 0.293	-0.09 [-0.22; 0.04] 0.184
SEC high vs. ETA				0.59 [0.07; 4.81] 0.835	0.62 [0.13; 2.84] 0.668	-0.04 [-0.19; 0.10] 0.554
Mild, n (%)	1 (2.6)	2 (4.8)	2 (7.7)			
SEC low vs. ETA				0.32 [<0.01; 6.49] 0.699	0.33 [0.03; 3.49] 0.559	-0.05 [-0.17; 0.06] 0.377
SEC high vs. ETA				0.60 [0.04; 8.85] 0.992	0.62 [0.09; 4.13] 0.633	-0.03 [-0.15; 0.09] 0.635
Moderate, n (%)	0 (0.0)	1 (2.4)	1 (3.8)			
SEC low vs. ETA				0.67 [<0.01; 26.00] 0.800	0.23 [0.01; 5.32] 0.400	-0.04 [-0.11; 0.04] 0.308
SEC high vs. ETA				0.61 [<0.01; 49.76] 1.000	0.62 [0.04; 9.48] 1.000	-0.01 [-0.10; 0.07] 0.742
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Nausea, n (%)	3 (7.7)	2 (4.8)	3 (11.5)			
SEC low vs. ETA				0.64 [0.08; 5.22] 0.911	0.67 [0.15; 3.05] 0.676	-0.04 [-0.19; 0.11] 0.612
SEC high vs. ETA				0.39 [0.03; 3.66] 0.563	0.41 [0.07; 2.31] 0.363	-0.07 [-0.21; 0.07] 0.338
Mild, n (%)	1 (2.6)	2 (4.8)	2 (7.7)			
SEC low vs. ETA				0.32 [<0.01; 6.49] 0.699	0.33 [0.03; 3.49] 0.559	-0.05 [-0.17; 0.06] 0.377
SEC high vs. ETA				0.60 [0.04; 8.85] 0.992	0.62 [0.09; 4.13] 0.633	-0.03 [-0.15; 0.09] 0.635
Moderate, n (%)	2 (5.1)	0 (0.0)	1 (3.8)			
SEC low vs. ETA				1.35 [0.07; 82.87] 1.000	1.33 [0.13; 13.96] 1.000	0.01 [-0.09; 0.11] 0.804
SEC high vs. ETA				0.62 [<0.01; 24.14] 0.765	0.21 [0.01; 4.95] 0.382	-0.04 [-0.11; 0.04] 0.308
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Skin and subcutaneous tissue disorders, n (%)	13 (33.3)	14 (33.3)	8 (30.8)			
SEC low vs. ETA				1.12 [0.34; 3.82] 1.000	1.08 [0.52; 2.24] 1.000	0.03 [-0.21; 0.26] 0.828
SEC high vs. ETA				1.12 [0.35; 3.76] 1.000	1.08 [0.53; 2.22] 1.000	0.03 [-0.20; 0.25] 0.825
Mild, n (%)	12 (30.8)	10 (23.8)	6 (23.1)			
SEC low vs. ETA				1.47 [0.42; 5.65] 0.698	1.33 [0.57; 3.10] 0.579	0.08 [-0.14; 0.29] 0.488
SEC high vs. ETA				1.04 [0.29; 4.06] 1.000	1.03 [0.43; 2.50] 1.000	0.01 [-0.20; 0.21] 0.945

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Moderate, n (%)	3 (7.7)	6 (14.3)	1 (3.8)			
SEC low vs. ETA				2.06 [0.16; 113.67] 0.945	2.00 [0.22; 18.20] 0.644	0.04 [-0.07; 0.15] 0.499
SEC high vs. ETA				4.10 [0.45; 199.18] 0.337	3.71 [0.47; 29.14] 0.238	0.10 [-0.02; 0.23] 0.113
Severe, n (%)	0 (0.0)	0 (0.0)	1 (3.8)			
SEC low vs. ETA				0.67 [<0.01; 26.00] 0.800	0.23 [0.01; 5.32] 0.400	-0.04 [-0.11; 0.04] 0.308
SEC high vs. ETA				0.62 [<0.01; 24.14] 0.765	0.21 [0.01; 4.95] 0.382	-0.04 [-0.11; 0.04] 0.308
Respiratory, thoracic and mediastinal disorders, n (%)	5 (12.8)	12 (28.6)	4 (15.4)			
SEC low vs. ETA				0.81 [0.16; 4.56] 1.000	0.83 [0.25; 2.82] 1.000	-0.03 [-0.20; 0.15] 0.773
SEC high vs. ETA				2.18 [0.56; 10.52] 0.342	1.86 [0.67; 5.15] 0.253	0.13 [-0.06; 0.33] 0.184
Mild, n (%)	4 (10.3)	12 (28.6)	4 (15.4)			
SEC low vs. ETA				0.63 [0.11; 3.77] 0.804	0.67 [0.18; 2.43] 0.703	-0.05 [-0.22; 0.12] 0.550
SEC high vs. ETA				2.18 [0.56; 10.52] 0.342	1.86 [0.67; 5.15] 0.253	0.13 [-0.06; 0.33] 0.184
Moderate, n (%)	0 (0.0)	1 (2.4)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				0.62 [0.02; >999.99] 1.000	1.88 [0.08; 44.59] 1.000	0.02 [-0.02; 0.07] 0.311
Severe, n (%)	1 (2.6)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				0.67 [0.02; >999.99] 1.000	2.03 [0.09; 47.88] 1.000	0.03 [-0.02; 0.08] 0.311
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Oropharyngeal pain, n (%)	0 (0.0)	5 (11.9)	1 (3.8)			
SEC low vs. ETA				0.67 [<0.01; 26.00] 0.800	0.23 [0.01; 5.32] 0.400	-0.04 [-0.11; 0.04] 0.308
SEC high vs. ETA				3.33 [0.34; 166.07] 0.500	3.10 [0.38; 25.04] 0.395	0.08 [-0.04; 0.20] 0.198
Mild, n (%)	0 (0.0)	5 (11.9)	1 (3.8)			
SEC low vs. ETA				0.67 [<0.01; 26.00] 0.800	0.23 [0.01; 5.32] 0.400	-0.04 [-0.11; 0.04] 0.308
SEC high vs. ETA				3.33 [0.34; 166.07] 0.500	3.10 [0.38; 25.04] 0.395	0.08 [-0.04; 0.20] 0.198
Moderate, n (%)	0 (0.0)	1 (2.4)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				0.62 [0.02; >999.99] 1.000	1.88 [0.08; 44.59] 1.000	0.02 [-0.02; 0.07] 0.311
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
General disorders and administration site conditions, n (%)	7 (17.9)	9 (21.4)	6 (23.1)			
SEC low vs. ETA				0.73 [0.18; 3.05] 0.840	0.78 [0.29; 2.05] 0.754	-0.05 [-0.25; 0.15] 0.618
SEC high vs. ETA				0.91 [0.24; 3.61] 1.000	0.93 [0.37; 2.31] 1.000	-0.02 [-0.22; 0.19] 0.874
Mild, n (%)	7 (17.9)	7 (16.7)	5 (19.2)			
SEC low vs. ETA				0.92 [0.22; 4.19] 1.000	0.93 [0.33; 2.63] 1.000	-0.01 [-0.21; 0.18] 0.897
SEC high vs. ETA				0.84 [0.20; 3.82] 1.000	0.87 [0.31; 2.45] 1.000	-0.03 [-0.21; 0.16] 0.790

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Moderate, n (%)	0 (0.0)	2 (4.8)	1 (3.8)			
SEC low vs. ETA				0.67 [<0.01; 26.00] 0.800	0.23 [0.01; 5.32] 0.400	-0.04 [-0.11; 0.04] 0.308
SEC high vs. ETA				1.25 [0.06; 76.66] 1.000	1.24 [0.12; 12.98] 1.000	0.01 [-0.09; 0.11] 0.855
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Nervous system disorders, n (%)	6 (15.4)	7 (16.7)	3 (11.5)			
SEC low vs. ETA				1.39 [0.26; 9.45] 0.957	1.33 [0.37; 4.86] 0.731	0.04 [-0.13; 0.21] 0.652
SEC high vs. ETA				1.52 [0.31; 10.07] 0.836	1.44 [0.41; 5.10] 0.730	0.05 [-0.12; 0.22] 0.547
Mild, n (%)	5 (12.8)	7 (16.7)	2 (7.7)			
SEC low vs. ETA				1.75 [0.26; 19.83] 0.825	1.67 [0.35; 7.95] 0.693	0.05 [-0.10; 0.20] 0.493
SEC high vs. ETA				2.37 [0.40; 25.33] 0.498	2.17 [0.49; 9.65] 0.465	0.09 [-0.06; 0.24] 0.248
Moderate, n (%)	1 (2.6)	0 (0.0)	2 (7.7)			
SEC low vs. ETA				0.32 [<0.01; 6.49] 0.699	0.33 [0.03; 3.49] 0.559	-0.05 [-0.17; 0.06] 0.377
SEC high vs. ETA				0.25 [<0.01; 3.25] 0.285	0.13 [0.01; 2.52] 0.143	-0.08 [-0.18; 0.03] 0.141
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Headache, n (%)	5 (12.8)	7 (16.7)	3 (11.5)			
SEC low vs. ETA				1.13 [0.20; 7.96] 1.000	1.11 [0.29; 4.25] 1.000	0.01 [-0.15; 0.17] 0.876
SEC high vs. ETA				1.52 [0.31; 10.07] 0.836	1.44 [0.41; 5.10] 0.730	0.05 [-0.12; 0.22] 0.547

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Mild, n (%)	5 (12.8)	7 (16.7)	2 (7.7)			
SEC low vs. ETA				1.75 [0.26; 19.83] 0.825	1.67 [0.35; 7.95] 0.693	0.05 [-0.10; 0.20] 0.493
SEC high vs. ETA				2.37 [0.40; 25.33] 0.498	2.17 [0.49; 9.65] 0.465	0.09 [-0.06; 0.24] 0.248
Moderate, n (%)	0 (0.0)	0 (0.0)	1 (3.8)			
SEC low vs. ETA				0.67 [<0.01; 26.00] 0.800	0.23 [0.01; 5.32] 0.400	-0.04 [-0.11; 0.04] 0.308
SEC high vs. ETA				0.62 [<0.01; 24.14] 0.765	0.21 [0.01; 4.95] 0.382	-0.04 [-0.11; 0.04] 0.308
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Injury, poisoning and procedural complications, n (%)	3 (7.7)	5 (11.9)	1 (3.8)			
SEC low vs. ETA				2.06 [0.16; 113.67] 0.945	2.00 [0.22; 18.20] 0.644	0.04 [-0.07; 0.15] 0.499
SEC high vs. ETA				3.33 [0.34; 166.07] 0.500	3.10 [0.38; 25.04] 0.395	0.08 [-0.04; 0.20] 0.198
Mild, n (%)	3 (7.7)	5 (11.9)	0 (0.0)			
SEC low vs. ETA				2.67 [0.28; >999.99] 0.418	4.73 [0.25; 87.85] 0.269	0.08 [-0.01; 0.16] 0.071
SEC high vs. ETA				4.53 [0.59; >999.99] 0.163	6.91 [0.40; 119.98] 0.148	0.12 [0.02; 0.22] 0.017
Moderate, n (%)	0 (0.0)	1 (2.4)	1 (3.8)			
SEC low vs. ETA				0.67 [<0.01; 26.00] 0.800	0.23 [0.01; 5.32] 0.400	-0.04 [-0.11; 0.04] 0.308
SEC high vs. ETA				0.61 [<0.01; 49.76] 1.000	0.62 [0.04; 9.48] 1.000	-0.01 [-0.10; 0.07] 0.742
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Investigations, n (%)	4 (10.3)	3 (7.1)	5 (19.2)			
SEC low vs. ETA				0.49 [0.09; 2.54] 0.505	0.53 [0.16; 1.80] 0.465	-0.09 [-0.27; 0.09] 0.326
SEC high vs. ETA				0.33 [0.05; 1.88] 0.266	0.37 [0.10; 1.43] 0.244	-0.12 [-0.29; 0.05] 0.164
Mild, n (%)	4 (10.3)	1 (2.4)	3 (11.5)			
SEC low vs. ETA				0.88 [0.13; 6.55] 1.000	0.89 [0.22; 3.65] 1.000	-0.01 [-0.17; 0.14] 0.872
SEC high vs. ETA				0.19 [<0.01; 2.54] 0.305	0.21 [0.02; 1.88] 0.152	-0.09 [-0.22; 0.04] 0.171
Moderate, n (%)	2 (5.1)	2 (4.8)	3 (11.5)			
SEC low vs. ETA				0.42 [0.03; 3.96] 0.624	0.44 [0.08; 2.48] 0.382	-0.06 [-0.21; 0.08] 0.373
SEC high vs. ETA				0.39 [0.03; 3.66] 0.563	0.41 [0.07; 2.31] 0.363	-0.07 [-0.21; 0.07] 0.338
Severe, n (%)	0 (0.0)	1 (2.4)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				0.62 [0.02; >999.99] 1.000	1.88 [0.08; 44.59] 1.000	0.02 [-0.02; 0.07] 0.311
Reproductive system and breast disorders, n (%)	3 (7.7)	5 (11.9)	3 (11.5)			
SEC low vs. ETA				0.64 [0.08; 5.22] 0.911	0.67 [0.15; 3.05] 0.676	-0.04 [-0.19; 0.11] 0.612
SEC high vs. ETA				1.04 [0.18; 7.30] 1.000	1.03 [0.27; 3.96] 1.000	0.00 [-0.15; 0.16] 0.964
Mild, n (%)	3 (7.7)	5 (11.9)	3 (11.5)			
SEC low vs. ETA				0.64 [0.08; 5.22] 0.911	0.67 [0.15; 3.05] 0.676	-0.04 [-0.19; 0.11] 0.612
SEC high vs. ETA				1.04 [0.18; 7.30] 1.000	1.03 [0.27; 3.96] 1.000	0.00 [-0.15; 0.16] 0.964

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Moderate, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Blood and lymphatic system disorders, n (%)	4 (10.3)	3 (7.1)	1 (3.8)			
SEC low vs. ETA				2.82 [0.26; 146.24] 0.657	2.67 [0.32; 22.54] 0.640	0.06 [-0.06; 0.18] 0.297
SEC high vs. ETA				1.91 [0.14; 104.93] 1.000	1.86 [0.20; 16.92] 1.000	0.03 [-0.07; 0.14] 0.547
Mild, n (%)	2 (5.1)	3 (7.1)	0 (0.0)			
SEC low vs. ETA				1.64 [0.13; >999.99] 0.713	3.38 [0.17; 67.58] 0.512	0.05 [-0.02; 0.12] 0.147
SEC high vs. ETA				2.47 [0.26; >999.99] 0.458	4.40 [0.24; 81.81] 0.281	0.07 [-0.01; 0.15] 0.072
Moderate, n (%)	2 (5.1)	0 (0.0)	1 (3.8)			
SEC low vs. ETA				1.35 [0.07; 82.87] 1.000	1.33 [0.13; 13.96] 1.000	0.01 [-0.09; 0.11] 0.804
SEC high vs. ETA				0.62 [<0.01; 24.14] 0.765	0.21 [0.01; 4.95] 0.382	-0.04 [-0.11; 0.04] 0.308
Severe, n (%)	0 (0.0)	1 (2.4)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				0.62 [0.02; >999.99] 1.000	1.88 [0.08; 44.59] 1.000	0.02 [-0.02; 0.07] 0.311
Musculoskeletal and connective tissue disorders, n (%)	1 (2.6)	4 (9.5)	4 (15.4)			
SEC low vs. ETA				0.15 [<0.01; 1.63] 0.157	0.17 [0.02; 1.41] 0.148	-0.13 [-0.28; 0.02] 0.088
SEC high vs. ETA				0.58 [0.10; 3.47] 0.719	0.62 [0.17; 2.26] 0.470	-0.06 [-0.22; 0.11] 0.485

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Mild, n (%)	1 (2.6)	3 (7.1)	3 (11.5)			
SEC low vs. ETA				0.21 [<0.01; 2.75] 0.344	0.22 [0.02; 2.02] 0.293	-0.09 [-0.22; 0.04] 0.184
SEC high vs. ETA				0.59 [0.07; 4.81] 0.835	0.62 [0.13; 2.84] 0.668	-0.04 [-0.19; 0.10] 0.554
Moderate, n (%)	0 (0.0)	1 (2.4)	1 (3.8)			
SEC low vs. ETA				0.67 [<0.01; 26.00] 0.800	0.23 [0.01; 5.32] 0.400	-0.04 [-0.11; 0.04] 0.308
SEC high vs. ETA				0.61 [<0.01; 49.76] 1.000	0.62 [0.04; 9.48] 1.000	-0.01 [-0.10; 0.07] 0.742
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR (with CI and p-value) from exact logistic regression model with treatment as predictor.
RR and RD calculated directly (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups.

S.1.3 Serious Adverse Events by SOC, PT and Severity, Binary Analysis (SAF)

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	39	42	26			
Any SAE, n (%)	3 (7.7)	4 (9.5)	5 (19.2)			
SEC low vs. ETA				0.36 [0.05; 2.04] 0.317	0.40 [0.10; 1.53] 0.250	-0.12 [-0.29; 0.06] 0.191
SEC high vs. ETA				0.45 [0.08; 2.33] 0.432	0.50 [0.15; 1.68] 0.287	-0.10 [-0.27; 0.08] 0.279
Mild, n (%)	1 (2.6)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				0.67 [0.02; >999.99] 1.000	2.03 [0.09; 47.88] 1.000	0.03 [-0.02; 0.08] 0.311
SEC high vs. ETA				N.E.	N.E.	N.E.
Moderate, n (%)	1 (2.6)	1 (2.4)	3 (11.5)			
SEC low vs. ETA				0.21 [<0.01; 2.75] 0.344	0.22 [0.02; 2.02] 0.293	-0.09 [-0.22; 0.04] 0.184
SEC high vs. ETA				0.19 [<0.01; 2.54] 0.305	0.21 [0.02; 1.88] 0.152	-0.09 [-0.22; 0.04] 0.171
Severe, n (%)	1 (2.6)	3 (7.1)	3 (11.5)			
SEC low vs. ETA				0.21 [<0.01; 2.75] 0.344	0.22 [0.02; 2.02] 0.293	-0.09 [-0.22; 0.04] 0.184
SEC high vs. ETA				0.59 [0.07; 4.81] 0.835	0.62 [0.13; 2.84] 0.668	-0.04 [-0.19; 0.10] 0.554
Gastrointestinal disorders, n (%)	0 (0.0)	0 (0.0)	3 (11.5)			
SEC low vs. ETA				0.16 [<0.01; 1.56] 0.119	0.10 [0.01; 1.79] 0.060	-0.12 [-0.24; 0.01] 0.066
SEC high vs. ETA				0.15 [<0.01; 1.45] 0.104	0.09 [0.00; 1.67] 0.052	-0.12 [-0.24; 0.01] 0.066
Mild, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Moderate, n (%)	0 (0.0)	0 (0.0)	2 (7.7)			
SEC low vs. ETA				0.27 [<0.01; 3.51] 0.313	0.14 [0.01; 2.70] 0.156	-0.08 [-0.18; 0.03] 0.141
SEC high vs. ETA				0.25 [<0.01; 3.25] 0.285	0.13 [0.01; 2.52] 0.143	-0.08 [-0.18; 0.03] 0.141
Severe, n (%)	0 (0.0)	0 (0.0)	1 (3.8)			
SEC low vs. ETA				0.67 [<0.01; 26.00] 0.800	0.23 [0.01; 5.32] 0.400	-0.04 [-0.11; 0.04] 0.308
SEC high vs. ETA				0.62 [<0.01; 24.14] 0.765	0.21 [0.01; 4.95] 0.382	-0.04 [-0.11; 0.04] 0.308

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR (with CI and p-value) from exact logistic regression model with treatment as predictor.
RR and RD calculated directly (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups.

S1.4 Any AE Leading to Study Discontinuation

There are no data meeting the display criteria for this table.

S1.4 Any AE Leading to Study Discontinuation

S1.5 Any AE Leading to Study Drug Discontinuation by SOC and PT, Frequencies (SAF)

	Treatment Groups		
	SEC low (N=39)	**SEC high (N=42)**	**ETA (N=26)**
N'	39	42	26
Investigations, n (%)	0 (0.0)	0 (0.0)	1 (3.8)
Hepatic enzyme increased, n (%)	0 (0.0)	0 (0.0)	1 (3.8)
Psychiatric disorders, n (%)	1 (2.6)	0 (0.0)	0 (0.0)
Behaviour disorder, n (%)	1 (2.6)	0 (0.0)	0 (0.0)
Major depression, n (%)	1 (2.6)	0 (0.0)	0 (0.0)
Mental disorder, n (%)	1 (2.6)	0 (0.0)	0 (0.0)
Suicidal ideation, n (%)	1 (2.6)	0 (0.0)	0 (0.0)
N': Number of patients in the analysis n (%): Number and percentage of patients with event			

S.1.6 Adverse Events of Special Interest by Severity, Binary Analysis (SAF)

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	39	42	26			
Infections and infestations (SOC), n (%)	27 (69.2)	28 (66.7)	19 (73.1)			
SEC low vs. ETA				0.83 [0.23; 2.81] 0.962	0.95 [0.69; 1.30] 0.787	-0.04 [-0.26; 0.19] 0.736
SEC high vs. ETA				0.74 [0.21; 2.42] 0.781	0.91 [0.66; 1.25] 0.788	-0.06 [-0.29; 0.16] 0.572
Mild, n (%)	23 (59.0)	26 (61.9)	17 (65.4)			
SEC low vs. ETA				0.76 [0.24; 2.38] 0.798	0.90 [0.61; 1.32] 0.795	-0.06 [-0.30; 0.18] 0.600
SEC high vs. ETA				0.86 [0.27; 2.66] 0.980	0.95 [0.66; 1.37] 0.802	-0.03 [-0.27; 0.20] 0.771
Moderate, n (%)	12 (30.8)	14 (33.3)	8 (30.8)			
SEC low vs. ETA				1.00 [0.30; 3.43] 1.000	1.00 [0.48; 2.11] 1.000	0.00 [-0.23; 0.23] 1.000
SEC high vs. ETA				1.12 [0.35; 3.76] 1.000	1.08 [0.53; 2.22] 1.000	0.03 [-0.20; 0.25] 0.825
Severe, n (%)	3 (7.7)	3 (7.1)	1 (3.8)			
SEC low vs. ETA				2.06 [0.16; 113.67] 0.945	2.00 [0.22; 18.20] 0.644	0.04 [-0.07; 0.15] 0.499
SEC high vs. ETA				1.91 [0.14; 104.93] 1.000	1.86 [0.20; 16.92] 1.000	0.03 [-0.07; 0.14] 0.547
Serious, n (%)	1 (2.6)	2 (4.8)	0 (0.0)			
SEC low vs. ETA				0.67 [0.02; >999.99] 1.000	2.03 [0.09; 47.88] 1.000	0.03 [-0.02; 0.08] 0.311
SEC high vs. ETA				1.52 [0.12; >999.99] 0.756	3.14 [0.16; 62.94] 0.521	0.05 [-0.02; 0.11] 0.147

S.1.6 Adverse Events of Special Interest by Severity, Binary Analysis (SAF)

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Hypersensitivity (SMQ) (narrow), n (%)	5 (12.8)	8 (19.0)	3 (11.5)			
SEC low vs. ETA				1.13 [0.20; 7.96] 1.000	1.11 [0.29; 4.25] 1.000	0.01 [-0.15; 0.17] 0.876
SEC high vs. ETA				1.79 [0.38; 11.57] 0.645	1.65 [0.48; 5.67] 0.512	0.08 [-0.10; 0.25] 0.389
Mild, n (%)	5 (12.8)	4 (9.5)	3 (11.5)			
SEC low vs. ETA				1.13 [0.20; 7.96] 1.000	1.11 [0.29; 4.25] 1.000	0.01 [-0.15; 0.17] 0.876
SEC high vs. ETA				0.81 [0.12; 6.03] 1.000	0.83 [0.20; 3.40] 1.000	-0.02 [-0.17; 0.13] 0.794
Moderate, n (%)	0 (0.0)	4 (9.5)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				3.47 [0.42; >999.99] 0.275	5.65 [0.32; 100.86] 0.290	0.10 [0.01; 0.18] 0.035
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Serious, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Neutropenia (NMQ) (narrow), n (%)	2 (5.1)	1 (2.4)	1 (3.8)			
SEC low vs. ETA				1.35 [0.07; 82.87] 1.000	1.33 [0.13; 13.96] 1.000	0.01 [-0.09; 0.11] 0.804
SEC high vs. ETA				0.61 [<0.01; 49.76] 1.000	0.62 [0.04; 9.48] 1.000	-0.01 [-0.10; 0.07] 0.742
Mild, n (%)	1 (2.6)	1 (2.4)	0 (0.0)			
SEC low vs. ETA				0.67 [0.02; >999.99] 1.000	2.03 [0.09; 47.88] 1.000	0.03 [-0.02; 0.08] 0.311
SEC high vs. ETA				0.62 [0.02; >999.99] 1.000	1.88 [0.08; 44.59] 1.000	0.02 [-0.02; 0.07] 0.311

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Moderate, n (%)	1 (2.6)	0 (0.0)	1 (3.8)			
SEC low vs. ETA				0.66 [<0.01; 53.69] 1.000	0.67 [0.04; 10.19] 1.000	-0.01 [-0.10; 0.08] 0.778
SEC high vs. ETA				0.62 [<0.01; 24.14] 0.765	0.21 [0.01; 4.95] 0.382	-0.04 [-0.11; 0.04] 0.308
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Serious, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Drug specific antibody present (PT), n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Mild, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Moderate, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Serious, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Hepatitis viral infections (HLT), n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Mild, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Moderate, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Serious, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Inflammatory bowel disease (NMQ) (narrow), n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Mild, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Moderate, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Serious, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
MACE (MI, Stroke, Cardiovascular death) (NMQ), n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Mild, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Moderate, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Serious, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ), n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Mild, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Moderate, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Serious, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Vaccination related complications (HLT), n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Mild, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Moderate, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Serious, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR (with CI and p-value) from exact logistic regression model with treatment as predictor.
RR and RD calculated directly (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups.

Die Diskrepanz in der Häufigkeit der Ereignisse in der SOC Infections and Investigations im Vergleich zu S.1.2 erklärt sich folgendermaßen: In S.1.2. (UE nach SOC und PT) wird die Primary SOC verwendet wird, während in S.1.6. auch Events zur SOC Infections and infestations zugeordnet werden, die zwar auch zu dieser SOC gehören, aber primär einer anderen SOC zugeordnet sind. Konkret handelt es sich dabei um das AE ‚Virus warts' in der Gruppe SEC high (PT: Skin papilloma, Primary SOC: Neoplasms benign, malignant and unspecified, Secondary SOCs: Skin and subcutaneous tissue disorders / Infections and infestations).

S.1.7 Tanner Stage, Binary Analysis (SAF)

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Pubertal at Baseline						
N'	39	42	26			
n (%)	34 (87.2)	29 (69.0)	22 (84.6)			
SEC low vs. ETA				1.23 [0.22; 6.44] 1.000	1.03 [0.84; 1.26] 1.000	0.03 [-0.15; 0.20] 0.773
SEC high vs. ETA				0.41 [0.09; 1.58] 0.247	0.82 [0.63; 1.06] 0.249	-0.16 [-0.35; 0.04] 0.121
Pubertal at Week 52						
N'	37	40	23			
n (%)	34 (91.9)	30 (75.0)	21 (91.3)			
SEC low vs. ETA				1.08 [0.08; 10.24] 1.000	1.01 [0.86; 1.18] 1.000	0.01 [-0.14; 0.15] 0.937
SEC high vs. ETA				0.29 [0.03; 1.58] 0.205	0.82 [0.66; 1.02] 0.183	-0.16 [-0.34; 0.01] 0.071

N': Number of patients with available response value
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR (with CI and p-value) from exact logistic regression model with treatment as predictor.
RR and RD calculated directly (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups.

S.2.1 Adverse Events, Binary Analysis by Age (SAF)

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	39	42	26			
N' Age < 12 years	9	9	6			
N' Age ≥ 12 years	30	33	20			
Any AE						
Interaction test:	p=0.723					
Age < 12 years, n (%)	8 (88.9)	7 (77.8)	5 (83.3)			
SEC low vs. ETA				1.55 [0.02; 141.06] 1.000	1.07 [0.70; 1.63] 1.000	0.06 [-0.31; 0.42] 0.764
SEC high vs. ETA				0.72 [<0.01; 17.65] 1.000	0.93 [0.57; 1.54] 1.000	-0.06 [-0.46; 0.35] 0.787
Age ≥ 12 years, n (%)	24 (80.0)	26 (78.8)	19 (95.0)			
SEC low vs. ETA				0.22 [<0.01; 2.02] 0.279	0.84 [0.69; 1.03] 0.219	-0.15 [-0.32; 0.02] 0.088
SEC high vs. ETA				0.20 [<0.01; 1.78] 0.224	0.83 [0.68; 1.02] 0.234	-0.16 [-0.33; 0.01] 0.060
Any SAE						
Interaction test:	p=1.000					
Age < 12 years, n (%)	0 (0.0)	1 (11.1)	1 (16.7)			
SEC low vs. ETA				0.67 [<0.01; 26.00] 0.800	0.23 [0.01; 4.93] 0.400	-0.17 [-0.46; 0.13] 0.273
SEC high vs. ETA				0.65 [<0.01; 58.78] 1.000	0.67 [0.05; 8.73] 1.000	-0.06 [-0.42; 0.31] 0.764
Age ≥ 12 years, n (%)	3 (10.0)	3 (9.1)	4 (20.0)			
SEC low vs. ETA				0.45 [0.06; 3.05] 0.554	0.50 [0.13; 2.00] 0.416	-0.10 [-0.31; 0.11] 0.340
SEC high vs. ETA				0.41 [0.05; 2.73] 0.467	0.45 [0.11; 1.83] 0.405	-0.11 [-0.31; 0.09] 0.287

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Any severe AE						
Interaction test:	p=0.698					
Age < 12 years, n (%)	0 (0.0)	1 (11.1)	1 (16.7)			
SEC low vs. ETA				0.67 [<0.01; 26.00] 0.800	0.23 [0.01; 4.93] 0.400	-0.17 [-0.46; 0.13] 0.273
SEC high vs. ETA				0.65 [<0.01; 58.78] 1.000	0.67 [0.05; 8.73] 1.000	-0.06 [-0.42; 0.31] 0.764
Age ≥ 12 years, n (%)	3 (10.0)	2 (6.1)	3 (15.0)			
SEC low vs. ETA				0.64 [0.08; 5.31] 0.911	0.67 [0.15; 2.98] 0.672	-0.05 [-0.24; 0.14] 0.606
SEC high vs. ETA				0.37 [0.03; 3.59] 0.542	0.40 [0.07; 2.21] 0.354	-0.09 [-0.27; 0.09] 0.321
Any AE leading to study discontinuation						
Interaction test:	N.E.					
Age < 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Age ≥ 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Any AE leading to study drug discontinuation						
Interaction test:	N.E.					
Age < 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Age ≥ 12 years, n (%)	1 (3.3)	0 (0.0)	1 (5.0)			
SEC low vs. ETA				0.66 [<0.01; 54.11] 1.000	0.67 [0.04; 10.05] 1.000	-0.02 [-0.13; 0.10] 0.777
SEC high vs. ETA				0.61 [<0.01; 23.64] 0.755	0.21 [0.01; 4.82] 0.377	-0.05 [-0.15; 0.05] 0.305

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.
Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.2.2 Adverse Events by SOC and PT, Binary Analysis by Age (SAF)

There are no data meeting the display criteria for this table.

S.2.3 Serious Adverse Events by SOC and PT, Binary Analysis by Age (SAF)

There are no data meeting the display criteria for this table.

S.2.3 Serious Adverse Events by SOC and PT, Binary Analysis by Age (SAF)

S.2.4 Severe Adverse Events by SOC and PT, Binary Analysis by Age (SAF)

There are no data meeting the display criteria for this table.

S.2.5 Adverse Events of Special Interest, Binary Analysis by Age (SAF)

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	39	42	26			
N' Age < 12 years	9	9	6			
N' Age ≥ 12 years	30	33	20			
Infections and infestations (SOC)						
Interaction test:	p=0.273					
Age < 12 years, n (%)	5 (55.6)	7 (77.8)	3 (50.0)			
SEC low vs. ETA				1.23 [0.10; 15.38] 1.000	1.11 [0.41; 2.99] 1.000	0.06 [-0.46; 0.57] 0.833
SEC high vs. ETA				3.20 [0.23; 59.08] 0.573	1.56 [0.65; 3.72] 0.329	0.28 [-0.21; 0.76] 0.260
Age ≥ 12 years, n (%)	22 (73.3)	21 (63.6)	16 (80.0)			
SEC low vs. ETA				0.69 [0.13; 3.16] 0.849	0.92 [0.67; 1.25] 0.740	-0.07 [-0.30; 0.17] 0.580
SEC high vs. ETA				0.44 [0.09; 1.84] 0.344	0.80 [0.57; 1.12] 0.237	-0.16 [-0.40; 0.08] 0.182
Hypersensitivity (SMQ) (narrow)						
Interaction test:	p=1.000					
Age < 12 years, n (%)	1 (11.1)	1 (11.1)	1 (16.7)			
SEC low vs. ETA				0.65 [<0.01; 58.78] 1.000	0.67 [0.05; 8.73] 1.000	-0.06 [-0.42; 0.31] 0.764
SEC high vs. ETA				0.65 [<0.01; 58.78] 1.000	0.67 [0.05; 8.73] 1.000	-0.06 [-0.42; 0.31] 0.764
Age ≥ 12 years, n (%)	4 (13.3)	7 (21.2)	2 (10.0)			
SEC low vs. ETA				1.38 [0.18; 16.74] 1.000	1.33 [0.27; 6.61] 1.000	0.03 [-0.15; 0.21] 0.715
SEC high vs. ETA				2.39 [0.39; 26.14] 0.509	2.12 [0.49; 9.23] 0.456	0.11 [-0.08; 0.30] 0.252

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Neutropenia (NMQ) (narrow)						
Interaction test:	p=0.230					
Age < 12 years, n (%)	2 (22.2)	1 (11.1)	0 (0.0)			
SEC low vs. ETA				1.74 [0.12; >999.99] 0.686	3.50 [0.20; 62.27] 0.486	0.22 [-0.05; 0.49] 0.109
SEC high vs. ETA				0.67 [0.02; >999.99] 1.000	2.10 [0.10; 44.41] 1.000	0.11 [-0.09; 0.32] 0.289
Age ≥ 12 years, n (%)	0 (0.0)	0 (0.0)	1 (5.0)			
SEC low vs. ETA				0.67 [<0.01; 26.00] 0.800	0.23 [0.01; 5.28] 0.400	-0.05 [-0.15; 0.05] 0.305
SEC high vs. ETA				0.61 [<0.01; 23.64] 0.755	0.21 [0.01; 4.82] 0.377	-0.05 [-0.15; 0.05] 0.305
Drug specific antibody present (PT)						
Interaction test:	N.E.					
Age < 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Age ≥ 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Hepatitis viral infections (HLT)						
Interaction test:	N.E.					
Age < 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Age ≥ 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Inflammatory bowel disease (NMQ) (narrow)						
Interaction test:	N.E.					
Age < 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Age ≥ 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
MACE (MI, Stroke, Cardiovascular death) (NMQ)						
Interaction test:	N.E.					
Age < 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Age ≥ 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ)						
Interaction test:	N.E.					
Age < 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Age ≥ 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Vaccination related complications (HLT)						
Interaction test:	N.E.					
Age < 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Age ≥ 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.
Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.2.6 Tanner Stage, Binary Analysis by Age (SAF)

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Pubertal at Baseline						
Interaction Test	**p=0.700**					
Age < 12 years, N / N'	**9 / 9**	**9 / 9**	**6 / 6**			
n (%)	4 (44.4)	1 (11.1)	3 (50.0)			
SEC low vs. ETA				0.81 [0.07; 9.91] 1.000	0.89 [0.30; 2.63] 1.000	-0.06 [-0.57; 0.46] 0.833
SEC high vs. ETA				0.15 [<0.01; 2.64] 0.286	0.22 [0.03; 1.66] 0.235	-0.39 [-0.84; 0.06] 0.090
Age ≥ 12 years, N / N'	**30 / 30**	**33 / 33**	**20 / 20**			
n (%)	30 (100.0)	28 (84.8)	19 (95.0)			
SEC low vs. ETA				1.50 [0.04; N.E.] 0.800	1.05 [0.95; 1.16] 0.400	0.05 [-0.05; 0.15] 0.305
SEC high vs. ETA				0.30 [<0.01; 3.00] 0.510	0.89 [0.75; 1.06] 0.390	-0.10 [-0.26; 0.05] 0.200
Pubertal at Week 52						
Interaction Test	**p=1.000**					
Age < 12 years, N / N'	**9 / 9**	**9 / 9**	**6 / 4**			
n (%)	6 (66.7)	1 (11.1)	2 (50.0)			
SEC low vs. ETA				1.89 [0.09; 39.99] 1.000	1.33 [0.45; 3.94] 1.000	0.17 [-0.41; 0.75] 0.572
SEC high vs. ETA				0.15 [<0.01; 4.27] 0.406	0.22 [0.03; 1.80] 0.203	-0.39 [-0.92; 0.14] 0.151
Age ≥ 12 years, N / N'	**30 / 28**	**33 / 31**	**20 / 19**			
n (%)	28 (100.0)	29 (93.5)	19 (100.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				0.66 [N.E.; 8.72] 0.759	0.94 [0.85; 1.03] 0.519	-0.06 [-0.15; 0.02] 0.144

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup.

Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.3.1 Adverse Events, Binary Analysis by Gender (SAF)

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	39	42	26			
N' Male	14	22	10			
N' Female	25	20	16			
Any AE						
Interaction test:	p=0.004					
Male, n (%)	14 (100.0)	14 (63.6)	9 (90.0)			
SEC low vs. ETA				1.40 [0.04; >999.99] 0.833	1.11 [0.90; 1.37] 0.417	0.10 [-0.09; 0.29] 0.292
SEC high vs. ETA				0.20 [<0.01; 1.99] 0.263	0.71 [0.48; 1.03] 0.210	-0.26 [-0.54; 0.01] 0.059
Female, n (%)	18 (72.0)	19 (95.0)	15 (93.8)			
SEC low vs. ETA				0.18 [<0.01; 1.64] 0.184	0.77 [0.58; 1.01] 0.120	-0.22 [-0.43; -0.01] 0.045
SEC high vs. ETA				1.26 [0.02; 104.59] 1.000	1.01 [0.86; 1.19] 1.000	0.01 [-0.14; 0.16] 0.872
Any SAE						
Interaction test:	p=0.291					
Male, n (%)	0 (0.0)	2 (9.1)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				1.13 [0.08; >999.99] 0.931	2.39 [0.13; 45.70] 1.000	0.09 [-0.03; 0.21] 0.138
Female, n (%)	3 (12.0)	2 (10.0)	5 (31.3)			
SEC low vs. ETA				0.31 [0.04; 1.93] 0.267	0.38 [0.11; 1.39] 0.225	-0.19 [-0.45; 0.07] 0.147
SEC high vs. ETA				0.25 [0.02; 1.89] 0.240	0.32 [0.07; 1.44] 0.204	-0.21 [-0.47; 0.05] 0.112

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Any severe AE						
Interaction test:	p=0.367					
Male, n (%)	2 (14.3)	1 (4.5)	1 (10.0)			
SEC low vs. ETA				1.48 [0.07; 98.19] 1.000	1.43 [0.15; 13.68] 1.000	0.04 [-0.22; 0.30] 0.748
SEC high vs. ETA				0.44 [<0.01; 37.35] 1.000	0.45 [0.03; 6.56] 0.534	-0.05 [-0.26; 0.15] 0.603
Female, n (%)	1 (4.0)	2 (10.0)	3 (18.8)			
SEC low vs. ETA				0.19 [<0.01; 2.62] 0.312	0.21 [0.02; 1.88] 0.281	-0.15 [-0.35; 0.06] 0.161
SEC high vs. ETA				0.49 [0.04; 4.94] 0.781	0.53 [0.10; 2.82] 0.637	-0.09 [-0.32; 0.14] 0.460
Any AE leading to study discontinuation						
Interaction test:	N.E.					
Male, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Female, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Any AE leading to study drug discontinuation						
Interaction test:	p=1.000					
Male, n (%)	0 (0.0)	0 (0.0)	1 (10.0)			
SEC low vs. ETA				0.71 [<0.01; 27.86] 0.833	0.24 [0.01; 5.45] 0.417	-0.10 [-0.29; 0.09] 0.292
SEC high vs. ETA				0.45 [<0.01; 17.73] 0.625	0.16 [0.01; 3.61] 0.313	-0.10 [-0.29; 0.09] 0.292

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Female, n (%)	1 (4.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				0.64 [0.02; >999.99] 1.000	1.96 [0.08; 45.40] 1.000	0.04 [-0.04; 0.12] 0.307
SEC high vs. ETA				N.E.	N.E.	N.E.

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.
Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.3.2 Adverse Events by SOC and PT, Binary Analysis by Gender (SAF)

There are no data meeting the display criteria for this table.

S.3.3 Serious Adverse Events by SOC and PT, Binary Analysis by Gender (SAF)

There are no data meeting the display criteria for this table.

S.3.3 Serious Adverse Events by SOC and PT, Binary Analysis by Gender (SAF)

S.3.4 Severe Adverse Events by SOC and PT, Binary Analysis by Gender (SAF)

There are no data meeting the display criteria for this table.

S.3.5 Adverse Events of Special Interest, Binary Analysis by Gender (SAF)

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	39	42	26			
N' Male	14	22	10			
N' Female	25	20	16			
Infections and infestations (SOC)						
Interaction test:	p=0.027					
Male, n (%)	13 (92.9)	13 (59.1)	9 (90.0)			
SEC low vs. ETA				1.42 [0.02; 121.98] 1.000	1.03 [0.80; 1.33] 1.000	0.03 [-0.20; 0.26] 0.807
SEC high vs. ETA				0.17 [<0.01; 1.62] 0.174	0.66 [0.44; 0.98] 0.114	-0.31 [-0.59; -0.03] 0.029
Female, n (%)	14 (56.0)	15 (75.0)	10 (62.5)			
SEC low vs. ETA				0.77 [0.17; 3.26] 0.934	0.90 [0.54; 1.50] 0.753	-0.06 [-0.37; 0.24] 0.678
SEC high vs. ETA				1.77 [0.34; 9.64] 0.654	1.20 [0.76; 1.89] 0.483	0.13 [-0.18; 0.43] 0.420
Hypersensitivity (SMQ) (narrow)						
Interaction test:	p=1.000					
Male, n (%)	1 (7.1)	2 (9.1)	0 (0.0)			
SEC low vs. ETA				0.71 [0.02; >999.99] 1.000	2.20 [0.10; 49.06] 1.000	0.07 [-0.06; 0.21] 0.299
SEC high vs. ETA				1.13 [0.08; >999.99] 0.931	2.39 [0.13; 45.70] 1.000	0.09 [-0.03; 0.21] 0.138
Female, n (%)	4 (16.0)	6 (30.0)	3 (18.8)			
SEC low vs. ETA				0.83 [0.12; 6.59] 1.000	0.85 [0.22; 3.32] 1.000	-0.03 [-0.27; 0.21] 0.822
SEC high vs. ETA				1.83 [0.31; 13.66] 0.705	1.60 [0.47; 5.42] 0.700	0.11 [-0.16; 0.39] 0.427

S.3.5 Adverse Events of Special Interest, Binary Analysis by Gender (SAF)

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Neutropenia (NMQ) (narrow)						
Interaction test:	N.E.					
Male, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Female, n (%)	2 (8.0)	1 (5.0)	1 (6.3)			
SEC low vs. ETA				1.30 [0.06; 82.01] 1.000	1.28 [0.13; 12.99] 1.000	0.02 [-0.14; 0.18] 0.830
SEC high vs. ETA				0.79 [<0.01; 66.06] 1.000	0.80 [0.05; 11.82] 1.000	-0.01 [-0.16; 0.14] 0.872
Drug specific antibody present (PT)						
Interaction test:	N.E.					
Male, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Female, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Hepatitis viral infections (HLT)						
Interaction test:	N.E.					
Male, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Female, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Inflammatory bowel disease (NMQ) (narrow)						
Interaction test:	N.E.					
Male, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Female, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
MACE (MI, Stroke, Cardiovascular death) (NMQ)						
Interaction test:	N.E.					
Male, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Female, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ)						
Interaction test:	N.E.					
Male, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Female, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Vaccination related complications (HLT)						
Interaction test:	N.E.					
Male, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Female, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.
Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.3.6 Tanner Stage, Binary Analysis by Gender (SAF)

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Pubertal at Baseline						
Interaction Test	**p=0.359**					
Male, N / N'	**14 / 14**	**22 / 22**	**10 / 10**			
n (%)	13 (92.9)	13 (59.1)	8 (80.0)			
SEC low vs. ETA				3.09 [0.14; 206.19] 0.741	1.16 [0.82; 1.63] 0.550	0.13 [-0.15; 0.41] 0.372
SEC high vs. ETA				0.37 [0.03; 2.54] 0.458	0.74 [0.46; 1.18] 0.425	-0.21 [-0.53; 0.11] 0.203
Female, N / N'	**25 / 25**	**20 / 20**	**16 / 16**			
n (%)	21 (84.0)	16 (80.0)	14 (87.5)			
SEC low vs. ETA				0.76 [0.06; 6.13] 1.000	0.96 [0.75; 1.24] 1.000	-0.04 [-0.25; 0.18] 0.751
SEC high vs. ETA				0.58 [0.05; 4.79] 0.891	0.91 [0.69; 1.22] 0.672	-0.07 [-0.31; 0.16] 0.538
Pubertal at Week 52						
Interaction Test	**p=0.523**					
Male, N / N'	**14 / 13**	**22 / 21**	**10 / 8**			
n (%)	13 (100.0)	15 (71.4)	7 (87.5)			
SEC low vs. ETA				1.62 [0.04; N.E.] 0.762	1.14 [0.88; 1.49] 0.381	0.13 [-0.10; 0.35] 0.285
SEC high vs. ETA				0.37 [<0.01; 4.07] 0.705	0.82 [0.56; 1.19] 0.635	-0.16 [-0.46; 0.14] 0.293
Female, N / N'	**25 / 24**	**20 / 19**	**16 / 15**			
n (%)	21 (87.5)	15 (78.9)	14 (93.3)			
SEC low vs. ETA				0.51 [<0.01; 7.09] 0.997	0.94 [0.77; 1.15] 1.000	-0.06 [-0.24; 0.12] 0.532
SEC high vs. ETA				0.28 [<0.01; 3.27] 0.501	0.85 [0.65; 1.11] 0.355	-0.14 [-0.37; 0.08] 0.205

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup.

Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.4.1 Adverse Events, Binary Analysis by Disease Severity (SAF)

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	39	42	26			
N' Baseline PASI ≤ Median	20	19	13			
N' Baseline PASI > Median	19	23	13			
Any AE						
Interaction test:	p=0.318					
Baseline PASI ≤ Median, n (%)	19 (95.0)	15 (78.9)	12 (92.3)			
SEC low vs. ETA				1.56 [0.02; 130.73] 1.000	1.03 [0.85; 1.24] 1.000	0.03 [-0.15; 0.20] 0.761
SEC high vs. ETA				0.32 [<0.01; 3.86] 0.616	0.86 [0.65; 1.13] 0.625	-0.13 [-0.37; 0.10] 0.262
Baseline PASI > Median, n (%)	13 (68.4)	18 (78.3)	12 (92.3)			
SEC low vs. ETA				0.19 [<0.01; 1.93] 0.240	0.74 [0.53; 1.04] 0.195	-0.24 [-0.49; 0.02] 0.066
SEC high vs. ETA				0.31 [<0.01; 3.29] 0.553	0.85 [0.65; 1.11] 0.385	-0.14 [-0.36; 0.08] 0.215
Any SAE						
Interaction test:	p=1.000					
Baseline PASI ≤ Median, n (%)	2 (10.0)	2 (10.5)	2 (15.4)			
SEC low vs. ETA				0.62 [0.04; 9.71] 1.000	0.65 [0.10; 4.06] 1.000	-0.05 [-0.29; 0.18] 0.655
SEC high vs. ETA				0.66 [0.04; 10.30] 1.000	0.68 [0.11; 4.26] 1.000	-0.05 [-0.29; 0.19] 0.691
Baseline PASI > Median, n (%)	1 (5.3)	2 (8.7)	3 (23.1)			
SEC low vs. ETA				0.20 [<0.01; 2.80] 0.342	0.23 [0.03; 1.96] 0.279	-0.18 [-0.43; 0.07] 0.163
SEC high vs. ETA				0.33 [0.02; 3.35] 0.478	0.38 [0.07; 1.97] 0.328	-0.14 [-0.40; 0.11] 0.272

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Any severe AE						
Interaction test:	p=0.014					
Baseline PASI ≤ Median, n (%)	3 (15.0)	2 (10.5)	0 (0.0)			
SEC low vs. ETA				2.71 [0.27; >999.99] 0.418	4.67 [0.26; 83.55] 0.261	0.15 [-0.01; 0.31] 0.060
SEC high vs. ETA				1.71 [0.13; >999.99] 0.690	3.50 [0.18; 67.45] 0.502	0.11 [-0.03; 0.24] 0.135
Baseline PASI > Median, n (%)	0 (0.0)	1 (4.3)	4 (30.8)			
SEC low vs. ETA				0.10 [<0.01; 0.91] 0.040	0.08 [0.00; 1.33] 0.020	-0.31 [-0.56; -0.06] 0.016
SEC high vs. ETA				0.11 [<0.01; 1.30] 0.094	0.14 [0.02; 1.13] 0.047	-0.26 [-0.53; 0.00] 0.050
Any AE leading to study discontinuation						
Interaction test:	N.E.					
Baseline PASI ≤ Median, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Baseline PASI > Median, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Any AE leading to study drug discontinuation						
Interaction test:	p=0.487					
Baseline PASI ≤ Median, n (%)	0 (0.0)	0 (0.0)	1 (7.7)			
SEC low vs. ETA				0.65 [<0.01; 25.35] 0.788	0.22 [0.01; 5.08] 0.394	-0.08 [-0.22; 0.07] 0.298
SEC high vs. ETA				0.68 [<0.01; 26.68] 0.813	0.23 [0.01; 5.32] 0.406	-0.08 [-0.22; 0.07] 0.298

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Baseline PASI > Median, n (%)	1 (5.3)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				0.68 [0.02; >999.99] 1.000	2.10 [0.09; 47.89] 1.000	0.05 [-0.05; 0.15] 0.304
SEC high vs. ETA				N.E.	N.E.	N.E.

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.
Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.4.2 Adverse Events by SOC and PT, Binary Analysis by Disease Severity (SAF)

There are no data meeting the display criteria for this table.

S.4.3 Serious Adverse Events by SOC and PT, Binary Analysis by Disease Severity (SAF)

There are no data meeting the display criteria for this table.

S.4.3 Serious Adverse Events by SOC and PT, Binary Analysis by Disease Severity (SAF)

S.4.4 Severe Adverse Events by SOC and PT, Binary Analysis by Disease Severity (SAF)

There are no data meeting the display criteria for this table.

S.4.4 Severe Adverse Events by SOC and PT, Binary Analysis by Disease Severity (SAF)

S.4.5 Adverse Events of Special Interest, Binary Analysis by Disease Severity (SAF)

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	39	42	26			
N' Baseline PASI ≤ Median	20	19	13			
N' Baseline PASI > Median	19	23	13			
Infections and infestations (SOC)						
Interaction test:	p=0.123					
Baseline PASI ≤ Median, n (%)	18 (90.0)	13 (68.4)	10 (76.9)			
SEC low vs. ETA				2.62 [0.25; 36.32] 0.589	1.17 [0.84; 1.63] 0.360	0.13 [-0.13; 0.39] 0.332
SEC high vs. ETA				0.66 [0.09; 4.08] 0.910	0.89 [0.58; 1.36] 0.704	-0.09 [-0.40; 0.23] 0.591
Baseline PASI > Median, n (%)	9 (47.4)	15 (65.2)	9 (69.2)			
SEC low vs. ETA				0.41 [0.07; 2.16] 0.390	0.68 [0.38; 1.24] 0.289	-0.22 [-0.56; 0.12] 0.203
SEC high vs. ETA				0.84 [0.14; 4.35] 1.000	0.94 [0.59; 1.51] 1.000	-0.04 [-0.36; 0.28] 0.804
Hypersensitivity (SMQ) (narrow)						
Interaction test:	p=0.587					
Baseline PASI ≤ Median, n (%)	4 (20.0)	5 (26.3)	1 (7.7)			
SEC low vs. ETA				2.91 [0.24; 159.84] 0.661	2.60 [0.33; 20.75] 0.625	0.12 [-0.10; 0.35] 0.289
SEC high vs. ETA				4.12 [0.38; 219.28] 0.394	3.42 [0.45; 25.99] 0.361	0.19 [-0.06; 0.43] 0.137
Baseline PASI > Median, n (%)	1 (5.3)	3 (13.0)	2 (15.4)			
SEC low vs. ETA				0.32 [<0.01; 6.77] 0.713	0.34 [0.03; 3.39] 0.552	-0.10 [-0.32; 0.12] 0.368
SEC high vs. ETA				0.83 [0.08; 11.35] 1.000	0.85 [0.16; 4.44] 1.000	-0.02 [-0.26; 0.22] 0.848

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Neutropenia (NMQ) (narrow)						
Interaction test:	p=1.000					
Baseline PASI ≤ Median, n (%)	1 (5.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				0.65 [0.02; >999.99] 1.000	2.00 [0.09; 45.68] 1.000	0.05 [-0.05; 0.15] 0.305
SEC high vs. ETA				N.E.	N.E.	N.E.
Baseline PASI > Median, n (%)	1 (5.3)	1 (4.3)	1 (7.7)			
SEC low vs. ETA				0.68 [<0.01; 56.65] 1.000	0.68 [0.05; 9.99] 1.000	-0.02 [-0.20; 0.15] 0.787
SEC high vs. ETA				0.56 [<0.01; 46.35] 1.000	0.57 [0.04; 8.30] 1.000	-0.03 [-0.20; 0.13] 0.695
Drug specific antibody present (PT)						
Interaction test:	N.E.					
Baseline PASI ≤ Median, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Baseline PASI > Median, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Hepatitis viral infections (HLT)						
Interaction test:	N.E.					
Baseline PASI ≤ Median, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Baseline PASI > Median, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Inflammatory bowel disease (NMQ) (narrow)						
Interaction test:	N.E.					
Baseline PASI ≤ Median, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Baseline PASI > Median, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
MACE (MI, Stroke, Cardiovascular death) (NMQ)						
Interaction test:	N.E.					
Baseline PASI ≤ Median, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Baseline PASI > Median, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ)						
Interaction test:	N.E.					
Baseline PASI ≤ Median, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Baseline PASI > Median, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Vaccination related complications (HLT)						
Interaction test:	N.E.					
Baseline PASI ≤ Median, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Baseline PASI > Median, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.
Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.4.6 Tanner Stage, Binary Analysis by Disease Severity (SAF)

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Pubertal at Baseline						
Interaction Test	**p=0.226**					
Baseline PASI ≤ Median, N / N'	**20 / 20**	**19 / 19**	**13 / 13**			
n (%)	18 (90.0)	11 (57.9)	12 (92.3)			
SEC low vs. ETA				0.76 [0.01; 16.09] 1.000	0.98 [0.79; 1.21] 1.000	-0.02 [-0.22; 0.17] 0.817
SEC high vs. ETA				0.12 [<0.01; 1.16] 0.077	0.63 [0.41; 0.95] 0.050	-0.34 [-0.61; -0.08] 0.011
Baseline PASI > Median, N / N'	**19 / 19**	**23 / 23**	**13 / 13**			
n (%)	16 (84.2)	18 (78.3)	10 (76.9)			
SEC low vs. ETA				1.58 [0.18; 14.25] 0.939	1.09 [0.77; 1.56] 0.666	0.07 [-0.21; 0.35] 0.612
SEC high vs. ETA				1.08 [0.14; 7.00] 1.000	1.02 [0.70; 1.47] 1.000	0.01 [-0.27; 0.30] 0.927
Pubertal at Week 52						
Interaction Test	**p=0.215**					
Baseline PASI ≤ Median, N / N'	**20 / 19**	**19 / 19**	**13 / 12**			
n (%)	17 (89.5)	13 (68.4)	12 (100.0)			
SEC low vs. ETA				0.63 [N.E.; 8.47] 0.735	0.89 [0.77; 1.04] 0.510	-0.11 [-0.24; 0.03] 0.135
SEC high vs. ETA				0.15 [N.E.; 1.17] 0.074	0.68 [0.50; 0.93] 0.059	-0.32 [-0.52; -0.11] 0.003
Baseline PASI > Median, N / N'	**19 / 18**	**23 / 21**	**13 / 11**			
n (%)	17 (94.4)	17 (81.0)	9 (81.8)			
SEC low vs. ETA				3.60 [0.17; 235.69] 0.632	1.15 [0.85; 1.56] 0.539	0.13 [-0.13; 0.38] 0.325
SEC high vs. ETA				0.95 [0.07; 8.21] 1.000	0.99 [0.70; 1.40] 1.000	-0.01 [-0.29; 0.27] 0.952

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup.

Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.5.1 Adverse Events, Binary Analysis by Region (SAF)

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	39	42	26			
N' Europe	25	34	16			
N' Others	14	8	10			
Any AE						
Interaction test:	p=0.439					
Europe, n (%)	22 (88.0)	28 (82.4)	14 (87.5)			
SEC low vs. ETA				1.05 [0.08; 10.38] 1.000	1.01 [0.80; 1.27] 1.000	0.01 [-0.20; 0.21] 0.962
SEC high vs. ETA				0.67 [0.06; 4.43] 0.989	0.94 [0.74; 1.20] 1.000	-0.05 [-0.26; 0.16] 0.625
Others, n (%)	10 (71.4)	5 (62.5)	10 (100.0)			
SEC low vs. ETA				0.22 [<0.01; 1.97] 0.188	0.71 [0.51; 0.99] 0.114	-0.29 [-0.52; -0.05] 0.018
SEC high vs. ETA				0.16 [<0.01; 1.73] 0.137	0.63 [0.37; 1.07] 0.069	-0.38 [-0.71; -0.04] 0.028
Any SAE						
Interaction test:	p=0.699					
Europe, n (%)	2 (8.0)	3 (8.8)	4 (25.0)			
SEC low vs. ETA				0.27 [0.02; 2.20] 0.295	0.32 [0.07; 1.55] 0.187	-0.17 [-0.41; 0.07] 0.160
SEC high vs. ETA				0.30 [0.04; 2.05] 0.273	0.35 [0.09; 1.39] 0.190	-0.16 [-0.39; 0.07] 0.173
Others, n (%)	1 (7.1)	1 (12.5)	1 (10.0)			
SEC low vs. ETA				0.70 [<0.01; 60.32] 1.000	0.71 [0.05; 10.11] 1.000	-0.03 [-0.26; 0.20] 0.807
SEC high vs. ETA				1.27 [0.01; 111.99] 1.000	1.25 [0.09; 17.02] 1.000	0.03 [-0.27; 0.32] 0.868

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Any severe AE						
Interaction test:	p=0.282					
Europe, n (%)	3 (12.0)	2 (5.9)	2 (12.5)			
SEC low vs. ETA				0.96 [0.10; 12.79] 1.000	0.96 [0.18; 5.13] 1.000	-0.01 [-0.21; 0.20] 0.962
SEC high vs. ETA				0.45 [0.03; 6.72] 0.766	0.47 [0.07; 3.05] 0.584	-0.07 [-0.25; 0.11] 0.472
Others, n (%)	0 (0.0)	1 (12.5)	2 (20.0)			
SEC low vs. ETA				0.27 [<0.01; 3.69] 0.326	0.15 [0.01; 2.76] 0.163	-0.20 [-0.45; 0.05] 0.114
SEC high vs. ETA				0.59 [<0.01; 13.72] 1.000	0.63 [0.07; 5.72] 1.000	-0.08 [-0.41; 0.26] 0.663
Any AE leading to study discontinuation						
Interaction test:	N.E.					
Europe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Others, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Any AE leading to study drug discontinuation						
Interaction test:	p=0.473					
Europe, n (%)	0 (0.0)	0 (0.0)	1 (6.3)			
SEC low vs. ETA				0.64 [<0.01; 24.96] 0.780	0.22 [0.01; 5.04] 0.390	-0.06 [-0.18; 0.06] 0.302
SEC high vs. ETA				0.47 [<0.01; 18.35] 0.640	0.16 [0.01; 3.77] 0.320	-0.06 [-0.18; 0.06] 0.302

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Others, n (%)	1 (7.1)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				0.71 [0.02; >999.99] 1.000	2.20 [0.10; 49.06] 1.000	0.07 [-0.06; 0.21] 0.299
SEC high vs. ETA				N.E.	N.E.	N.E.

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.
Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.5.2 Adverse Events by SOC and PT, Binary Analysis by Region (SAF)

There are no data meeting the display criteria for this table.

S.5.3 Serious Adverse Events by SOC and PT, Binary Analysis by Region (SAF)

There are no data meeting the display criteria for this table.

S.5.3 Serious Adverse Events by SOC and PT, Binary Analysis by Region (SAF)

S.5.4 Severe Adverse Events by SOC and PT, Binary Analysis by Region (SAF)

There are no data meeting the display criteria for this table.

S.5.4 Severe Adverse Events by SOC and PT, Binary Analysis by Region (SAF)

S.5.5 Adverse Events of Special Interest, Binary Analysis by Region (SAF)

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	39	42	26			
N' Europe	25	34	16			
N' Others	14	8	10			
Infections and infestations (SOC)						
Interaction test:	p=0.731					
Europe, n (%)	19 (76.0)	25 (73.5)	12 (75.0)			
SEC low vs. ETA				1.05 [0.18; 5.59] 1.000	1.01 [0.71; 1.45] 1.000	0.01 [-0.26; 0.28] 0.942
SEC high vs. ETA				0.93 [0.17; 4.23] 1.000	0.98 [0.69; 1.39] 1.000	-0.01 [-0.27; 0.24] 0.911
Others, n (%)	8 (57.1)	3 (37.5)	7 (70.0)			
SEC low vs. ETA				0.58 [0.07; 4.15] 0.836	0.82 [0.44; 1.50] 0.678	-0.13 [-0.51; 0.26] 0.512
SEC high vs. ETA				0.28 [0.02; 2.58] 0.368	0.54 [0.20; 1.43] 0.342	-0.33 [-0.76; 0.11] 0.147
Hypersensitivity (SMQ) (narrow)						
Interaction test:	p=0.759					
Europe, n (%)	3 (12.0)	7 (20.6)	1 (6.3)			
SEC low vs. ETA				2.01 [0.15; 114.43] 0.977	1.92 [0.22; 16.89] 1.000	0.06 [-0.12; 0.23] 0.517
SEC high vs. ETA				3.80 [0.42; 186.75] 0.388	3.29 [0.44; 24.57] 0.409	0.14 [-0.04; 0.32] 0.119
Others, n (%)	2 (14.3)	1 (12.5)	2 (20.0)			
SEC low vs. ETA				0.68 [0.04; 11.17] 1.000	0.71 [0.12; 4.25] 1.000	-0.06 [-0.37; 0.25] 0.716
SEC high vs. ETA				0.59 [<0.01; 13.72] 1.000	0.63 [0.07; 5.72] 1.000	-0.08 [-0.41; 0.26] 0.663

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Neutropenia (NMQ) (narrow)						
Interaction test:	N.E.					
Europe, n (%)	2 (8.0)	1 (2.9)	1 (6.3)			
SEC low vs. ETA				1.30 [0.06; 82.01] 1.000	1.28 [0.13; 12.99] 1.000	0.02 [-0.14; 0.18] 0.830
SEC high vs. ETA				0.46 [<0.01; 38.04] 1.000	0.47 [0.03; 7.05] 0.542	-0.03 [-0.16; 0.10] 0.622
Others, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Drug specific antibody present (PT)						
Interaction test:	N.E.					
Europe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Others, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Hepatitis viral infections (HLT)						
Interaction test:	N.E.					
Europe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Others, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Inflammatory bowel disease (NMQ) (narrow)						
Interaction test:	N.E.					
Europe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Others, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
MACE (MI, Stroke, Cardiovascular death) (NMQ)						
Interaction test:	N.E.					
Europe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Others, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ)						
Interaction test:	N.E.					
Europe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Others, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Vaccination related complications (HLT)						
Interaction test:	N.E.					
Europe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Others, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.
Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.5.6 Tanner Stage, Binary Analysis by Region (SAF)

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Pubertal at Baseline						
Interaction Test	**p=0.284**					
Europe, N / N'	**25 / 25**	**34 / 34**	**16 / 16**			
n (%)	22 (88.0)	27 (79.4)	15 (93.8)			
SEC low vs. ETA				0.50 [<0.01; 6.89] 0.977	0.94 [0.77; 1.14] 1.000	-0.06 [-0.23; 0.12] 0.517
SEC high vs. ETA				0.26 [<0.01; 2.38] 0.388	0.85 [0.68; 1.05] 0.409	-0.14 [-0.32; 0.04] 0.119
Others, N / N'	**14 / 14**	**8 / 8**	**10 / 10**			
n (%)	12 (85.7)	2 (25.0)	7 (70.0)			
SEC low vs. ETA				2.47 [0.22; 36.53] 0.664	1.22 [0.77; 1.94] 0.615	0.16 [-0.18; 0.50] 0.362
SEC high vs. ETA				0.16 [0.01; 1.61] 0.153	0.36 [0.10; 1.27] 0.153	-0.45 [-0.86; -0.04] 0.033
Pubertal at Week 52						
Interaction Test	**p=0.060**					
Europe, N / N'	**25 / 25**	**34 / 32**	**16 / 16**			
n (%)	22 (88.0)	27 (84.4)	15 (93.8)			
SEC low vs. ETA				0.50 [<0.01; 6.89] 0.977	0.94 [0.77; 1.14] 1.000	-0.06 [-0.23; 0.12] 0.517
SEC high vs. ETA				0.37 [<0.01; 3.74] 0.673	0.90 [0.74; 1.09] 0.648	-0.09 [-0.27; 0.08] 0.288
Others, N / N'	**14 / 12**	**8 / 8**	**10 / 7**			
n (%)	12 (100.0)	3 (37.5)	6 (85.7)			
SEC low vs. ETA				1.71 [0.04; N.E.] 0.737	1.17 [0.86; 1.58] 0.368	0.14 [-0.12; 0.40] 0.280
SEC high vs. ETA				0.12 [<0.01; 1.77] 0.168	0.44 [0.17; 1.12] 0.119	-0.48 [-0.91; -0.06] 0.026

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup.

Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.6.1 Adverse Events, Binary Analysis by Weight (SAF)

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	39	42	26			
N' Weight < 50 kg	19	19	11			
N' Weight ≥ 50 kg	20	23	15			
Any AE						
Interaction test:	p=1.000					
Weight < 50 kg, n (%)	15 (78.9)	15 (78.9)	10 (90.9)			
SEC low vs. ETA				0.39 [<0.01; 4.71] 0.762	0.87 [0.64; 1.17] 0.626	-0.12 [-0.37; 0.13] 0.348
SEC high vs. ETA				0.39 [<0.01; 4.71] 0.762	0.87 [0.64; 1.17] 0.626	-0.12 [-0.37; 0.13] 0.348
Weight ≥ 50 kg, n (%)	17 (85.0)	18 (78.3)	14 (93.3)			
SEC low vs. ETA				0.41 [<0.01; 5.84] 0.838	0.91 [0.72; 1.14] 0.619	-0.08 [-0.28; 0.12] 0.417
SEC high vs. ETA				0.27 [<0.01; 2.78] 0.439	0.84 [0.65; 1.08] 0.371	-0.15 [-0.36; 0.06] 0.161
Any SAE						
Interaction test:	p=1.000					
Weight < 50 kg, n (%)	1 (5.3)	1 (5.3)	2 (18.2)			
SEC low vs. ETA				0.26 [<0.01; 5.68] 0.596	0.29 [0.03; 2.84] 0.537	-0.13 [-0.38; 0.12] 0.309
SEC high vs. ETA				0.26 [<0.01; 5.68] 0.596	0.29 [0.03; 2.84] 0.537	-0.13 [-0.38; 0.12] 0.309
Weight ≥ 50 kg, n (%)	2 (10.0)	3 (13.0)	3 (20.0)			
SEC low vs. ETA				0.46 [0.03; 4.61] 0.719	0.50 [0.10; 2.63] 0.631	-0.10 [-0.34; 0.14] 0.417
SEC high vs. ETA				0.61 [0.07; 5.30] 0.888	0.65 [0.15; 2.81] 0.663	-0.07 [-0.31; 0.18] 0.578

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Any severe AE						
Interaction test:	p=0.522					
Weight < 50 kg, n (%)	0 (0.0)	1 (5.3)	2 (18.2)			
SEC low vs. ETA				0.22 [<0.01; 2.98] 0.253	0.12 [0.01; 2.29] 0.126	-0.18 [-0.41; 0.05] 0.118
SEC high vs. ETA				0.26 [<0.01; 5.68] 0.596	0.29 [0.03; 2.84] 0.537	-0.13 [-0.38; 0.12] 0.309
Weight ≥ 50 kg, n (%)	3 (15.0)	2 (8.7)	2 (13.3)			
SEC low vs. ETA				1.14 [0.11; 15.57] 1.000	1.13 [0.21; 5.91] 1.000	0.02 [-0.22; 0.25] 0.888
SEC high vs. ETA				0.63 [0.04; 9.64] 1.000	0.65 [0.10; 4.14] 1.000	-0.05 [-0.25; 0.16] 0.661
Any AE leading to study discontinuation						
Interaction test:	N.E.					
Weight < 50 kg, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Weight ≥ 50 kg, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Any AE leading to study drug discontinuation						
Interaction test:	p=1.000					
Weight < 50 kg, n (%)	1 (5.3)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				0.58 [0.01; >999.99] 1.000	1.80 [0.08; 40.75] 1.000	0.05 [-0.05; 0.15] 0.304
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Weight ≥ 50 kg, n (%)	0 (0.0)	0 (0.0)	1 (6.7)			
SEC low vs. ETA				0.75 [<0.01; 29.25] 0.857	0.25 [0.01; 5.83] 0.429	-0.07 [-0.19; 0.06] 0.301
SEC high vs. ETA				0.65 [<0.01; 25.43] 0.789	0.22 [0.01; 5.12] 0.395	-0.07 [-0.19; 0.06] 0.301

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.
Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.6.2 Adverse Events by SOC and PT, Binary Analysis by Weight (SAF)

There are no data meeting the display criteria for this table.

S.6.2 Adverse Events by SOC and PT, Binary Analysis by Weight (SAF)

S.6.3 Serious Adverse Events by SOC and PT, Binary Analysis by Weight (SAF)

There are no data meeting the display criteria for this table.

S.6.3 Serious Adverse Events by SOC and PT, Binary Analysis by Weight (SAF)

S.6.4 Severe Adverse Events by SOC and PT, Binary Analysis by Weight (SAF)

There are no data meeting the display criteria for this table.

S.6.5 Adverse Events of Special Interest, Binary Analysis by Weight (SAF)

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	39	42	26			
N' Weight < 50 kg	19	19	11			
N' Weight ≥ 50 kg	20	23	15			
Infections and infestations (SOC)						
Interaction test:	p=1.000					
Weight < 50 kg, n (%)	12 (63.2)	12 (63.2)	8 (72.7)			
SEC low vs. ETA				0.65 [0.08; 4.06] 0.904	0.87 [0.53; 1.43] 0.702	-0.10 [-0.44; 0.25] 0.582
SEC high vs. ETA				0.65 [0.08; 4.06] 0.904	0.87 [0.53; 1.43] 0.702	-0.10 [-0.44; 0.25] 0.582
Weight ≥ 50 kg, n (%)	15 (75.0)	16 (69.6)	11 (73.3)			
SEC low vs. ETA				1.09 [0.17; 6.45] 1.000	1.02 [0.69; 1.52] 1.000	0.02 [-0.28; 0.31] 0.911
SEC high vs. ETA				0.84 [0.14; 4.31] 1.000	0.95 [0.63; 1.43] 1.000	-0.04 [-0.33; 0.25] 0.801
Hypersensitivity (SMQ) (narrow)						
Interaction test:	p=1.000					
Weight < 50 kg, n (%)	2 (10.5)	4 (21.1)	1 (9.1)			
SEC low vs. ETA				1.17 [0.05; 76.26] 1.000	1.16 [0.12; 11.35] 1.000	0.01 [-0.20; 0.23] 0.898
SEC high vs. ETA				2.59 [0.21; 144.24] 0.762	2.32 [0.29; 18.20] 0.626	0.12 [-0.13; 0.37] 0.348
Weight ≥ 50 kg, n (%)	3 (15.0)	4 (17.4)	2 (13.3)			
SEC low vs. ETA				1.14 [0.11; 15.57] 1.000	1.13 [0.21; 5.91] 1.000	0.02 [-0.22; 0.25] 0.888
SEC high vs. ETA				1.36 [0.17; 17.10] 1.000	1.30 [0.27; 6.26] 1.000	0.04 [-0.19; 0.27] 0.731

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Neutropenia (NMQ) (narrow)						
Interaction test:	p=0.537					
Weight < 50 kg, n (%)	2 (10.5)	1 (5.3)	0 (0.0)			
SEC low vs. ETA				1.44 [0.11; >999.99] 0.786	3.00 [0.16; 57.37] 0.520	0.11 [-0.03; 0.24] 0.135
SEC high vs. ETA				0.58 [0.01; >999.99] 1.000	1.80 [0.08; 40.75] 1.000	0.05 [-0.05; 0.15] 0.304
Weight ≥ 50 kg, n (%)	0 (0.0)	0 (0.0)	1 (6.7)			
SEC low vs. ETA				0.75 [<0.01; 29.25] 0.857	0.25 [0.01; 5.83] 0.429	-0.07 [-0.19; 0.06] 0.301
SEC high vs. ETA				0.65 [<0.01; 25.43] 0.789	0.22 [0.01; 5.12] 0.395	-0.07 [-0.19; 0.06] 0.301
Drug specific antibody present (PT)						
Interaction test:	N.E.					
Weight < 50 kg, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Weight ≥ 50 kg, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Hepatitis viral infections (HLT)						
Interaction test:	N.E.					
Weight < 50 kg, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Weight ≥ 50 kg, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Inflammatory bowel disease (NMQ) (narrow)						
Interaction test:	N.E.					
Weight < 50 kg, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Weight ≥ 50 kg, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
MACE (MI, Stroke, Cardiovascular death) (NMQ)						
Interaction test:	N.E.					
Weight < 50 kg, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Weight ≥ 50 kg, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ)						
Interaction test:	N.E.					
Weight < 50 kg, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Weight ≥ 50 kg, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Vaccination related complications (HLT)						
Interaction test:	N.E.					
Weight < 50 kg, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Weight ≥ 50 kg, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.
Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.6.6 Tanner Stage, Binary Analysis by Weight (SAF)

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Pubertal at Baseline						
Interaction Test	**p=0.494**					
Weight < 50 kg, N / N'	**19 / 19**	**19 / 19**	**11 / 11**			
n (%)	14 (73.7)	7 (36.8)	8 (72.7)			
SEC low vs. ETA				1.05 [0.13; 7.24] 1.000	1.01 [0.65; 1.59] 1.000	0.01 [-0.32; 0.34] 0.955
SEC high vs. ETA				0.23 [0.03; 1.38] 0.128	0.51 [0.25; 1.01] 0.128	-0.36 [-0.70; -0.02] 0.039
Weight ≥ 50 kg, N / N'	**20 / 20**	**23 / 23**	**15 / 15**			
n (%)	20 (100.0)	22 (95.7)	14 (93.3)			
SEC low vs. ETA				1.33 [0.03; N.E.] 0.857	1.07 [0.94; 1.23] 0.429	0.07 [-0.06; 0.19] 0.301
SEC high vs. ETA				1.55 [0.02; 128.87] 1.000	1.02 [0.87; 1.20] 1.000	0.02 [-0.13; 0.17] 0.764
Pubertal at Week 52						
Interaction Test	**N.E.**					
Weight < 50 kg, N / N'	**19 / 19**	**19 / 18**	**11 / 9**			
n (%)	16 (84.2)	8 (44.4)	7 (77.8)			
SEC low vs. ETA				1.50 [0.10; 16.45] 1.000	1.08 [0.73; 1.61] 1.000	0.06 [-0.25; 0.38] 0.691
SEC high vs. ETA				0.24 [0.02; 1.77] 0.216	0.57 [0.31; 1.07] 0.217	-0.33 [-0.69; 0.02] 0.066
Weight ≥ 50 kg, N / N'	**20 / 18**	**23 / 22**	**15 / 14**			
n (%)	18 (100.0)	22 (100.0)	14 (100.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup.

Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.7.1 Adverse Events, Binary Analysis by Previous Systemic Therapy (SAF)

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	39	42	26			
N' No previous systemic therapy	8	13	10			
N' Previous systemic therapy	31	29	16			
Any AE						
Interaction test:	p=0.226					
No previous systemic therapy, n (%)	7 (87.5)	11 (84.6)	8 (80.0)			
SEC low vs. ETA				1.70 [0.07; 117.77] 1.000	1.09 [0.73; 1.64] 1.000	0.07 [-0.26; 0.41] 0.663
SEC high vs. ETA				1.36 [0.08; 22.54] 1.000	1.06 [0.72; 1.56] 1.000	0.05 [-0.27; 0.36] 0.775
Previous systemic therapy, n (%)	25 (80.6)	22 (75.9)	16 (100.0)			
SEC low vs. ETA				0.20 [<0.01; 1.55] 0.137	0.81 [0.68; 0.96] 0.082	-0.19 [-0.33; -0.05] 0.006
SEC high vs. ETA				0.15 [<0.01; 1.13] 0.069	0.76 [0.62; 0.93] 0.040	-0.24 [-0.40; -0.09] 0.002
Any SAE						
Interaction test:	p=0.668					
No previous systemic therapy, n (%)	1 (12.5)	1 (7.7)	1 (10.0)			
SEC low vs. ETA				1.27 [0.01; 111.99] 1.000	1.25 [0.09; 17.02] 1.000	0.03 [-0.27; 0.32] 0.868
SEC high vs. ETA				0.76 [<0.01; 65.34] 1.000	0.77 [0.05; 10.85] 1.000	-0.02 [-0.26; 0.21] 0.848
Previous systemic therapy, n (%)	2 (6.5)	3 (10.3)	4 (25.0)			
SEC low vs. ETA				0.21 [0.02; 1.73] 0.184	0.26 [0.05; 1.26] 0.161	-0.19 [-0.41; 0.04] 0.113
SEC high vs. ETA				0.36 [0.04; 2.46] 0.382	0.41 [0.11; 1.62] 0.225	-0.15 [-0.39; 0.09] 0.230

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Any severe AE						
Interaction test:	p=0.178					
No previous systemic therapy, n (%)	2 (25.0)	1 (7.7)	1 (10.0)			
SEC low vs. ETA				2.82 [0.12; 196.28] 0.824	2.50 [0.27; 22.86] 0.559	0.15 [-0.20; 0.50] 0.405
SEC high vs. ETA				0.76 [<0.01; 65.34] 1.000	0.77 [0.05; 10.85] 1.000	-0.02 [-0.26; 0.21] 0.848
Previous systemic therapy, n (%)	1 (3.2)	2 (6.9)	3 (18.8)			
SEC low vs. ETA				0.15 [<0.01; 2.08] 0.215	0.17 [0.02; 1.52] 0.108	-0.16 [-0.36; 0.05] 0.130
SEC high vs. ETA				0.33 [0.02; 3.25] 0.466	0.37 [0.07; 1.98] 0.330	-0.12 [-0.33; 0.09] 0.274
Any AE leading to study discontinuation						
Interaction test:	N.E.					
No previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Any AE leading to study drug discontinuation						
Interaction test:	N.E.					
No previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Previous systemic therapy, n (%)	1 (3.2)	0 (0.0)	1 (6.3)			
SEC low vs. ETA				0.51 [<0.01; 41.84] 1.000	0.52 [0.03; 7.72] 1.000	-0.03 [-0.16; 0.10] 0.658
SEC high vs. ETA				0.55 [<0.01; 21.52] 0.711	0.19 [0.01; 4.39] 0.356	-0.06 [-0.18; 0.06] 0.302

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.
Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.7.2 Adverse Events by SOC and PT, Binary Analysis by Previous Systemic Therapy (SAF)

There are no data meeting the display criteria for this table.

S.7.3 Serious Adverse Events by SOC and PT, Binary Analysis by Previous Systemic Therapy (SAF)

There are no data meeting the display criteria for this table.

S.7.4 Severe Adverse Events by SOC and PT, Binary Analysis by Previous Systemic Therapy (SAF)

There are no data meeting the display criteria for this table.

S.7.5 Adverse Events of Special Interest, Binary Analysis by Previous Systemic Therapy (SAF)

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	39	42	26			
N' No previous systemic therapy	8	13	10			
N' Previous systemic therapy	31	29	16			
Infections and infestations (SOC)						
Interaction test:	p=1.000					
No previous systemic therapy, n (%)	6 (75.0)	10 (76.9)	8 (80.0)			
SEC low vs. ETA				0.76 [0.04; 13.43] 1.000	0.94 [0.57; 1.56] 1.000	-0.05 [-0.44; 0.34] 0.801
SEC high vs. ETA				0.84 [0.06; 9.35] 1.000	0.96 [0.63; 1.48] 1.000	-0.03 [-0.37; 0.31] 0.858
Previous systemic therapy, n (%)	21 (67.7)	18 (62.1)	11 (68.8)			
SEC low vs. ETA				0.96 [0.20; 4.09] 1.000	0.99 [0.65; 1.48] 1.000	-0.01 [-0.29; 0.27] 0.944
SEC high vs. ETA				0.75 [0.16; 3.18] 0.910	0.90 [0.58; 1.40] 0.752	-0.07 [-0.35; 0.22] 0.649
Hypersensitivity (SMQ) (narrow)						
Interaction test:	p=0.205					
No previous systemic therapy, n (%)	3 (37.5)	2 (15.4)	1 (10.0)			
SEC low vs. ETA				4.90 [0.30; 314.24] 0.412	3.75 [0.48; 29.52] 0.275	0.28 [-0.11; 0.66] 0.160
SEC high vs. ETA				1.60 [0.07; 107.11] 1.000	1.54 [0.16; 14.66] 1.000	0.05 [-0.22; 0.32] 0.696
Previous systemic therapy, n (%)	2 (6.5)	6 (20.7)	2 (12.5)			
SEC low vs. ETA				0.49 [0.03; 7.42] 0.841	0.52 [0.08; 3.33] 0.597	-0.06 [-0.24; 0.12] 0.519
SEC high vs. ETA				1.80 [0.27; 20.68] 0.800	1.66 [0.38; 7.27] 0.691	0.08 [-0.14; 0.30] 0.464

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Neutropenia (NMQ) (narrow)						
Interaction test:	p=0.611					
No previous systemic therapy, n (%)	1 (12.5)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				1.25 [0.03; >999.99] 0.889	3.67 [0.17; 79.55] 0.444	0.13 [-0.10; 0.35] 0.285
SEC high vs. ETA				N.E.	N.E.	N.E.
Previous systemic therapy, n (%)	1 (3.2)	1 (3.4)	1 (6.3)			
SEC low vs. ETA				0.51 [<0.01; 41.84] 1.000	0.52 [0.03; 7.72] 1.000	-0.03 [-0.16; 0.10] 0.658
SEC high vs. ETA				0.54 [<0.01; 44.83] 1.000	0.55 [0.04; 8.24] 1.000	-0.03 [-0.16; 0.11] 0.686
Drug specific antibody present (PT)						
Interaction test:	N.E.					
No previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Hepatitis viral infections (HLT)						
Interaction test:	N.E.					
No previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Inflammatory bowel disease (NMQ) (narrow)						
Interaction test:	N.E.					
No previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
MACE (MI, Stroke, Cardiovascular death) (NMQ)						
Interaction test:	N.E.					
No previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ)						
Interaction test:	N.E.					
No previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Vaccination related complications (HLT)						
Interaction test:	N.E.					
No previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.
Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

## S.7.6 Tanner Stage, Binary Analysis by Previous Systemic Therapy (SAF)

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Pubertal at Baseline						
Interaction Test	p=1.000					
No previous systemic therapy, N / N'	**8 / 8**	**13 / 13**	**10 / 10**			
n (%)	6 (75.0)	8 (61.5)	8 (80.0)			
SEC low vs. ETA				0.76 [0.04; 13.43] 1.000	0.94 [0.57; 1.56] 1.000	-0.05 [-0.44; 0.34] 0.801
SEC high vs. ETA				0.42 [0.03; 3.56] 0.626	0.77 [0.45; 1.31] 0.405	-0.18 [-0.55; 0.18] 0.318
Previous systemic therapy, N / N'	**31 / 31**	**29 / 29**	**16 / 16**			
n (%)	28 (90.3)	21 (72.4)	14 (87.5)			
SEC low vs. ETA				1.32 [0.10; 13.02] 1.000	1.03 [0.83; 1.28] 1.000	0.03 [-0.16; 0.22] 0.774
SEC high vs. ETA				0.38 [0.03; 2.34] 0.436	0.83 [0.62; 1.11] 0.292	-0.15 [-0.38; 0.08] 0.198
Pubertal at Week 52						
Interaction Test	p=0.039					
No previous systemic therapy, N / N'	**8 / 7**	**13 / 13**	**10 / 8**			
n (%)	5 (71.4)	11 (84.6)	7 (87.5)			
SEC low vs. ETA				0.38 [<0.01; 9.33] 0.892	0.82 [0.48; 1.40] 0.569	-0.16 [-0.57; 0.24] 0.437
SEC high vs. ETA				0.79 [0.01; 18.11] 1.000	0.97 [0.68; 1.37] 1.000	-0.03 [-0.33; 0.27] 0.851
Previous systemic therapy, N / N'	**31 / 30**	**29 / 27**	**16 / 15**			
n (%)	29 (96.7)	19 (70.4)	14 (93.3)			
SEC low vs. ETA				2.04 [0.02; 168.10] 1.000	1.04 [0.89; 1.20] 1.000	0.03 [-0.11; 0.17] 0.645
SEC high vs. ETA				0.18 [<0.01; 1.57] 0.170	0.75 [0.57; 1.00] 0.123	-0.23 [-0.44; -0.02] 0.035

	Treatment Groups			Comparison		
	SEC low (N=39)	SEC high (N=42)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup.

Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

Figures

Efficacy Analysis

8.1 CDLQI, Boxplot (FAS)

## 8.3 CDLQI, Boxplot by Gender (FAS)

Male

**Boxplots by subgroup are displayed if the interaction test for the subgrouping factor is significant.**

Female

Boxplots by subgroup are displayed if the interaction test for the subgrouping factor is significant.

9.1 CDLQI (Age ≤ 16), Boxplot (FAS)

9.3 CDLQI (Age ≤ 16), Boxplot by Gender (FAS)

Male

Boxplots by subgroup are displayed if the interaction test for the subgrouping factor is significant.

Female

Boxplots by subgroup are displayed if the interaction test for the subgrouping factor is significant.